diff --git "a/PHEE_train_v1.conll" "b/PHEE_train_v1.conll"
new file mode 100644--- /dev/null
+++ "b/PHEE_train_v1.conll"
@@ -0,0 +1,20634 @@
+OBJECTIVE	O
+To	O
+test	O
+the	O
+hypothesis	O
+that	O
+tumor	O
+necrosis	O
+factor	O
+(TNF)-alpha	O
+may	O
+mediate	O
+the	O
+loss	O
+and	O
+the	O
+dedifferentiation	O
+of	O
+subcutaneous	O
+fat	O
+tissue	O
+in	O
+the	O
+insulin-induced	O
+lipoatrophies	B-Adev
+of	O
+a	O
+diabetic	O
+patient	O
+who	O
+presented	O
+extensive	O
+lesions	O
+
+An	O
+evaluation	O
+of	O
+ovarian	O
+structure	O
+and	O
+function	O
+should	O
+be	O
+considered	O
+in	O
+women	O
+of	O
+reproductive	O
+age	O
+being	O
+treated	O
+with	O
+valproate	O
+for	O
+epilepsy	O
+especially	O
+if	O
+they	O
+develop	O
+menstrual	B-Adev
+cycle	I-Adev
+disturbances	I-Adev
+during	O
+treatment	O
+
+Phenobarbital	O
+hepatotoxicity	B-Adev
+in	O
+an	O
+8-month-old	O
+infant	O
+
+The	O
+authors	O
+report	O
+a	O
+case	O
+of	O
+Balint	B-Adev
+syndrome	I-Adev
+with	I-Adev
+irreversible	I-Adev
+posterior	I-Adev
+leukoencephalopathy	I-Adev
+on	I-Adev
+MRI	I-Adev
+following	O
+intrathecal	O
+methotrexate	O
+and	O
+cytarabine	O
+
+According	O
+to	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+flecainide	O
+was	O
+the	O
+probable	O
+cause	O
+of	O
+the	O
+patient's	O
+delirium	B-Adev
+	O
+the	O
+Horn	O
+Drug	O
+Interaction	O
+Probability	O
+Scale	O
+indicates	O
+a	O
+possible	O
+pharmacokinetic	O
+drug	O
+interaction	O
+between	O
+flecainide	O
+and	O
+paroxetine	O
+
+Contact	B-Adev
+dermatitis	I-Adev
+due	O
+to	O
+budesonide	O
+report	O
+of	O
+five	O
+cases	O
+and	O
+review	O
+of	O
+the	O
+Japanese	O
+literature	O
+
+Prolongation	B-Adev
+of	I-Adev
+the	I-Adev
+QT	I-Adev
+interval	I-Adev
+observed	O
+in	O
+a	O
+Japanese	O
+patient	O
+with	O
+vivax	O
+malaria	O
+following	O
+treatment	O
+with	O
+halofantrine	O
+
+We	O
+report	O
+three	O
+cases	O
+of	O
+severe	B-Adev
+hepatotoxicity	I-Adev
+related	O
+to	O
+benzarone	O
+a	O
+benzofuran	O
+derivative	O
+
+Four	O
+patients	O
+who	O
+manifested	O
+symptoms	O
+of	O
+the	O
+antiepileptic	O
+drug	O
+(AED)	O
+hypersensitivity	B-Adev
+syndrome	I-Adev
+during	O
+therapy	O
+with	O
+carbamazepine	O
+are	O
+reported	O
+
+Minocycline	O
+as	O
+a	O
+cause	O
+of	O
+drug-induced	O
+autoimmune	B-Adev
+hepatitis	I-Adev
+	O
+
+Secondary	B-Adev
+acute	I-Adev
+myeloid	I-Adev
+leukemia	I-Adev
+after	O
+etoposide	O
+therapy	O
+for	O
+haemophagocytic	O
+lymphohistiocytosis	O
+
+Allergic	B-Adev
+contact	I-Adev
+angioedema	I-Adev
+to	O
+benzoyl	O
+peroxide	O
+
+A	O
+60-year-old	O
+white	O
+man	O
+with	O
+chronic	O
+bronchitis	O
+was	O
+noted	O
+to	O
+develop	O
+acute	B-Adev
+respiratory	I-Adev
+failure	I-Adev
+and	I-Adev
+metabolic	I-Adev
+acidosis	I-Adev
+four	O
+days	O
+after	O
+being	O
+started	O
+on	O
+methazolamide	O
+(Neptazane)	O
+for	O
+an	O
+ophthalmologic	O
+problem	O
+
+L-DOPA-induced	O
+excessive	O
+daytime	B-Adev
+sleepiness	I-Adev
+in	O
+PD	O
+a	O
+placebo-controlled	O
+case	O
+with	O
+MSLT	O
+assessment	O
+
+CONCLUSIONS	O
+It	O
+is	O
+probable	O
+that	O
+foscarnet	O
+contributed	O
+to	O
+the	O
+electrolyte	B-Adev
+disorders	I-Adev
+and	I-Adev
+symptomatology	I-Adev
+in	O
+this	O
+patient	O
+
+Acute	B-Adev
+drug	I-Adev
+induced	I-Adev
+hepatitis	I-Adev
+due	O
+to	O
+erlotinib	O
+
+We	O
+observed	O
+3	O
+diabetic	O
+patients	O
+with	O
+intolerable	B-Adev
+dizziness	I-Adev
+followed	I-Adev
+by	I-Adev
+nausea	I-Adev
+and	I-Adev
+vomiting	I-Adev
+immediately	O
+after	O
+an	O
+initial	O
+administration	O
+of	O
+the	O
+alpha-glucosidase	O
+inhibitor	O
+voglibose	O
+
+Although	O
+risk	O
+factors	O
+for	O
+MTX-induced	O
+pulmonary	B-Adev
+toxicity	I-Adev
+are	O
+poorly	O
+understood	O
+the	O
+presence	O
+in	O
+3	O
+out	O
+of	O
+5	O
+of	O
+our	O
+patients	O
+of	O
+pre-existing	O
+lung	O
+disease	O
+represented	O
+by	O
+diffuse	O
+interstitial	O
+changes	O
+on	O
+chest	O
+X-ray	O
+and	O
+mild	O
+bronchial	O
+asthma	O
+in	O
+two	O
+RA	O
+patients	O
+and	O
+by	O
+pulmonary	O
+silicosis	O
+in	O
+the	O
+patient	O
+with	O
+PsA	O
+may	O
+account	O
+for	O
+a	O
+predisposition	O
+to	O
+the	O
+development	O
+of	O
+MTX	O
+pneumonitis	O
+
+Acute	O
+esmolol	O
+toxicity	B-Adev
+may	O
+be	O
+self-limiting	O
+because	O
+of	O
+its	O
+extremely	O
+short	O
+half-life	O
+
+The	O
+association	O
+with	O
+prolonged	O
+unopposed	O
+estrogen-like	O
+stimulation	O
+with	O
+tamoxifen	O
+as	O
+a	O
+possible	O
+factor	O
+in	O
+the	O
+development	B-Adev
+of	I-Adev
+ovarian	I-Adev
+endometrioid	I-Adev
+carcinoma	I-Adev
+is	O
+discussed	O
+
+The	O
+other	O
+woman	O
+had	O
+rheumatoid	O
+arthritis	O
+and	O
+developed	O
+acute	B-Adev
+tubular	I-Adev
+necrosis	I-Adev
+after	O
+treatment	O
+with	O
+gentamicin	O
+and	O
+cefoxitin	O
+
+One	O
+patient	O
+who	O
+received	O
+clindamycin	O
+had	O
+liver	O
+biopsy	O
+findings	O
+of	O
+marked	B-Adev
+cholestasis	I-Adev
+portal	I-Adev
+inflammation	I-Adev
+bile	I-Adev
+duct	I-Adev
+injury	I-Adev
+and	I-Adev
+bile	I-Adev
+duct	I-Adev
+paucity	I-Adev
+(ductopenia)	I-Adev
+	O
+
+A	O
+MEDLINE	O
+search	O
+(1966-January	O
+2009)	O
+revealed	O
+one	O
+in	O
+vivo	O
+pharmacokinetic	O
+study	O
+on	O
+the	O
+interaction	O
+between	O
+flecainide	O
+a	O
+CYP2D6	O
+substrate	O
+and	O
+paroxetine	O
+a	O
+CYP2D6	O
+inhibitor	O
+as	O
+well	O
+as	O
+3	O
+case	O
+reports	O
+of	O
+flecainide-induced	O
+delirium	B-Adev
+	O
+
+As	O
+these	O
+cases	O
+revealed	O
+close	O
+monitoring	O
+of	O
+blood	O
+chemistry	O
+is	O
+mandatory	O
+after	O
+starting	O
+spironolactone	O
+and	O
+patients	O
+should	O
+be	O
+advised	O
+to	O
+stop	O
+spironolactone	O
+immediately	O
+if	O
+diarrhoea	B-Adev
+develops	O
+
+When	O
+these	O
+cells	O
+are	O
+exposed	O
+to	O
+nicotinic	O
+acid	O
+an	O
+[['exaggerated	B-Adev
+immune	I-Adev
+response']	I-Adev
+['pain	I-Adev
+redness	I-Adev
+and	I-Adev
+swelling	I-Adev
+at	I-Adev
+the	I-Adev
+injection	I-Adev
+sit']]	I-Adev
+aggerated	O
+immune	O
+response	O
+is	O
+produced	O
+that	O
+may	O
+lead	O
+to	O
+pain	O
+redness	O
+and	O
+swelling	O
+at	O
+the	O
+injection	O
+site	O
+
+A	O
+case	O
+of	O
+heatstroke	B-Adev
+is	O
+reported	O
+in	O
+a	O
+32-year-old	O
+man	O
+diagnosed	O
+with	O
+schizophrenia	O
+and	O
+on	O
+clozapine	O
+monotherapy	O
+
+Paraplegia	B-Adev
+following	O
+intrathecal	O
+cytosine	O
+arabinoside	O
+
+Cimetidine-induced	O
+fever	B-Adev
+	O
+
+This	O
+case	O
+report	O
+illustrates	O
+the	O
+neurotoxicity	B-Adev
+unique	I-Adev
+to	O
+HDARAC	O
+
+Agranulocytosis	B-Adev
+associated	O
+with	O
+ticlopidine	O
+a	O
+possible	O
+benefit	O
+with	O
+filgastim	O
+
+Since	O
+SS	O
+is	O
+a	O
+clinical	O
+diagnosis	O
+heightened	O
+clinician	O
+awareness	O
+of	O
+the	O
+possibility	O
+of	O
+SS	O
+among	O
+patients	O
+receiving	O
+SSRI	O
+or	O
+mirtazapine	O
+in	O
+combination	O
+with	O
+opioids	O
+may	O
+lead	O
+to	O
+earlier	O
+detection	O
+and	O
+avoidance	O
+of	O
+potentially	B-Adev
+lethal	I-Adev
+consequences	I-Adev
+	O
+
+The	O
+mechanism	O
+by	O
+which	O
+sunitinib	O
+induces	O
+gynaecomastia	B-Adev
+is	O
+thought	O
+to	O
+be	O
+associated	O
+with	O
+an	O
+unknown	O
+direct	O
+action	O
+on	O
+breast	O
+hormonal	O
+receptors	O
+
+Some	O
+patients	O
+develop	O
+hypersensitivity	B-Adev
+rash	I-Adev
+in	O
+response	O
+to	O
+HCQ	O
+
+To	O
+report	O
+a	O
+case	O
+of	O
+serotonin	B-Adev
+toxicity	I-Adev
+	O
+presenting	O
+in	O
+the	O
+postoperative	O
+period	O
+caused	O
+by	O
+an	O
+interaction	O
+between	O
+paroxetine	O
+(a	O
+selective	O
+serotonin	O
+reuptake	O
+inhibitor	O
+SSRI)	O
+and	O
+fentanyl	O
+(a	O
+phenylpiperidine	O
+opioid)	O
+
+However	O
+to	O
+our	O
+knowledge	O
+in	O
+newborns	O
+there	O
+have	O
+been	O
+no	O
+reported	O
+cases	O
+to	O
+date	O
+of	O
+thrombocytosis	B-Adev
+induced	O
+by	O
+enoxaparin	O
+
+The	O
+case	O
+presented	O
+here	O
+documents	O
+adverse	B-Adev
+cardiac	I-Adev
+effects	I-Adev
+in	O
+a	O
+28-year-old	O
+man	O
+who	O
+intentionally	O
+ingested	O
+24	O
+mg	O
+of	O
+risperidone--4	O
+times	O
+the	O
+recommended	O
+dose	O
+
+Anaphylaxis	B-Adev
+to	O
+cisplatin	O
+following	O
+nine	O
+previous	O
+uncomplicated	O
+cycles	O
+
+To	O
+the	O
+best	O
+of	O
+the	O
+authors'	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+Propecia-associated	O
+cataract	B-Adev
+	O
+
+Serotonin	B-Adev
+syndrome	I-Adev
+caused	O
+by	O
+interaction	O
+between	O
+citalopram	O
+and	O
+fentanyl	O
+
+We	O
+report	O
+on	O
+three	O
+observations	O
+of	O
+parkinsonian	O
+patients	O
+with	O
+levo-dopa-induced	O
+diphasic	B-Adev
+dyskinesias	I-Adev
+	O
+who	O
+received	O
+subcutaneous	O
+apomorphine	O
+to	O
+reduce	O
+the	O
+duration	O
+of	O
+abnormal	O
+movements	O
+
+We	O
+report	O
+on	O
+three	O
+observations	O
+of	O
+parkinsonian	O
+patients	O
+with	O
+levo-dopa-induced	O
+diphasic	O
+dyskinesias	O
+who	O
+received	O
+subcutaneous	O
+apomorphine	O
+to	O
+reduce	O
+the	O
+duration	O
+of	O
+abnormal	O
+movements	O
+
+This	O
+report	O
+presents	O
+a	O
+case	O
+of	O
+acute	B-Adev
+lung	I-Adev
+injury	I-Adev
+developing	O
+within	O
+hours	O
+after	O
+administration	O
+of	O
+mefloquine	O
+for	O
+a	O
+low-level	O
+Plasmodium	O
+falciparum	O
+malaria	O
+which	O
+was	O
+persistent	O
+despite	O
+halofantrine	O
+therapy	O
+
+Warfarin-associated	O
+bleeding	B-Adev
+generally	O
+is	O
+considered	O
+deleterious	O
+however	O
+in	O
+our	O
+patient	O
+it	O
+unmasked	O
+an	O
+early	O
+stage	O
+of	O
+colon	O
+cancer	O
+and	O
+thus	O
+may	O
+have	O
+saved	O
+the	O
+patient's	O
+life	O
+
+The	O
+clinical	O
+use	O
+of	O
+itraconazole	O
+in	O
+patients	O
+receiving	O
+multiple	O
+doses	O
+of	O
+oxycodone	O
+for	O
+pain	O
+relief	O
+may	O
+increase	O
+the	O
+risk	O
+of	O
+opioid-associated	B-Adev
+adverse	I-Adev
+effects	I-Adev
+	O
+
+Three	O
+cases	O
+of	O
+gold-related	O
+neuropathy	B-Adev
+are	O
+reported	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+man	O
+treated	O
+with	O
+mesalazine	O
+for	O
+Crohn's	O
+disease	O
+who	O
+developed	O
+drug-induced	B-Adev
+pericarditis	I-Adev
+	O
+
+We	O
+report	O
+the	O
+occurrence	O
+of	O
+spontaneous	B-Adev
+intracranial	I-Adev
+bleeding	I-Adev
+in	O
+an	O
+human	O
+immunodeficiency	O
+virus	O
+(HIV)-infected	O
+adolescent	O
+with	O
+hemophilia	O
+A	O
+who	O
+was	O
+receiving	O
+amprenavir	O
+(APV)	O
+
+Under	O
+the	O
+suspicion	O
+of	O
+amiodarone-induced	O
+acute	B-Adev
+pancreatitis	I-Adev
+	O
+amiodarone	O
+was	O
+substituted	O
+by	O
+propafenone	O
+
+Evidence	O
+is	O
+shown	O
+in	O
+this	O
+report	O
+that	O
+adenosine	O
+was	O
+associated	O
+with	O
+dangerous	B-Adev
+worsening	I-Adev
+of	I-Adev
+arrhythmia	I-Adev
+in	O
+patients	O
+with	O
+atrial	O
+flutter	O
+
+Salicylate	O
+hepato	B-Adev
+toxicity	I-Adev
+in	O
+rheumatic	O
+fever	O
+
+A	O
+case	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+that	O
+developed	O
+during	O
+concurrent	O
+linezolid	O
+and	O
+fluoxetine	O
+is	O
+presented	O
+
+Herein	O
+we	O
+report	O
+four	O
+patients	O
+who	O
+underwent	O
+liver	O
+transplantation	O
+and	O
+developed	O
+neutropenia	B-Adev
+while	O
+receiving	O
+MMF	O
+
+A	O
+study	O
+of	O
+in	O
+vitro	O
+reactivity	O
+to	O
+L-T4	O
+as	O
+assessed	O
+by	O
+peripheral	O
+blood	O
+lymphocyte	O
+transformation	O
+was	O
+carried	O
+out	O
+in	O
+a	O
+patient	O
+with	O
+Hashimoto's	O
+disease	O
+who	O
+developed	O
+leukopenia	B-Adev
+during	O
+treatment	O
+with	O
+L-T4	O
+
+Methemoglobinemia	B-Adev
+is	O
+another	O
+common	O
+finding	O
+among	O
+patients	O
+receiving	O
+dapsone	O
+therapy	O
+but	O
+rarely	O
+does	O
+it	O
+result	O
+in	O
+prominent	O
+symptoms	O
+other	O
+than	O
+transient	O
+pallor	O
+
+During	O
+the	O
+first	O
+treatment	O
+dysarthria	B-Adev
+and	I-Adev
+ataxia	I-Adev
+were	O
+seen	O
+after	O
+completion	O
+of	O
+the	O
+patient's	O
+eighth	O
+and	O
+final	O
+dose	O
+of	O
+HDARAC	O
+
+Four	O
+weeks	O
+earlier	O
+she	O
+had	O
+developed	O
+hepatopathy	B-Adev
+during	O
+a	O
+regimen	O
+of	O
+carbamazepine	O
+lynestrenol	O
+and	O
+sodium	O
+valproate	O
+
+We	O
+consider	O
+asterixis	B-Adev
+to	O
+be	O
+an	O
+easily	O
+overlooked	O
+sign	O
+of	O
+neurotoxicity	O
+which	O
+may	O
+occur	O
+even	O
+at	O
+low	O
+or	O
+moderate	O
+dosage	O
+levels	O
+if	O
+certain	O
+drugs	O
+as	O
+lithium	O
+or	O
+clozapine	O
+are	O
+used	O
+in	O
+combination	O
+with	O
+CBZ	O
+
+We	O
+report	O
+here	O
+a	O
+rare	O
+case	O
+of	O
+pleuropericarditis	B-Adev
+due	O
+to	O
+methotrexate	O
+
+A	O
+case	O
+of	O
+phenytoin-induced	O
+hepatitis	B-Adev
+with	I-Adev
+mononucleosis	I-Adev
+is	O
+reported	O
+and	O
+syndromes	O
+associated	O
+with	O
+phenytoin	O
+hypersensitivity	O
+reactions	O
+are	O
+discussed	O
+
+We	O
+also	O
+discuss	O
+whether	O
+screening	O
+for	O
+DPD	O
+deficiency	O
+is	O
+warranted	O
+to	O
+identify	O
+patients	O
+at	O
+risk	O
+for	O
+severe	B-Adev
+toxicities	I-Adev
+from	O
+5-FU	O
+treatment	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+reversible	B-Adev
+encephalopathy	I-Adev
+syndrome	I-Adev
+in	O
+a	O
+16-year-old	O
+girl	O
+with	O
+acute	O
+myelogenous	O
+leukemia	O
+(AML)	O
+who	O
+is	O
+undergoing	O
+during	O
+consolidation	O
+chemotherapy	O
+composed	O
+of	O
+BH-AC	O
+(N4-behenoyl-1-beta-D-arabinofuranosyl	O
+cytosine)	O
+and	O
+idarubicin	O
+
+Concurrent	O
+use	O
+of	O
+vismodegib	O
+and	O
+warfarin	O
+was	O
+deemed	O
+the	O
+probable	O
+cause	O
+of	O
+acute	B-Adev
+INR	I-Adev
+elevation	I-Adev
+in	O
+this	O
+case	O
+suggesting	O
+the	O
+need	O
+for	O
+close	O
+monitoring	O
+of	O
+INR	O
+values	O
+in	O
+patients	O
+receiving	O
+this	O
+combination	O
+of	O
+drugs	O
+
+Captopril	O
+is	O
+an	O
+angiotensin-converting	O
+enzyme	O
+(ACE)	O
+inhibitor	O
+and	O
+their	O
+cutaneous	B-Adev
+side-effects	I-Adev
+are	O
+documented	O
+but	O
+little	O
+has	O
+been	O
+published	O
+concerning	O
+the	O
+usefulness	O
+of	O
+patch	O
+test	O
+when	O
+they	O
+occur	O
+
+High-dose	O
+methylprednisolone	O
+in	O
+a	O
+pregnant	O
+woman	O
+with	O
+Crohn's	O
+disease	O
+and	O
+adrenal	B-Adev
+suppression	I-Adev
+in	I-Adev
+her	I-Adev
+newborn	I-Adev
+	O
+
+Cardiac	B-Adev
+hypersensitivity	I-Adev
+and	I-Adev
+myopericarditis	I-Adev
+have	O
+been	O
+reported	O
+during	O
+long-term	O
+treatment	O
+with	O
+mesalazine	O
+
+It	O
+is	O
+concluded	O
+that	O
+'	O
+cerebral	B-Adev
+atrophy	I-Adev
+'	O
+on	O
+CT	O
+scans	O
+may	O
+represent	O
+an	O
+accumulative	O
+effect	O
+of	O
+ACTH	O
+and	O
+that	O
+ACTH	O
+should	O
+be	O
+given	O
+with	O
+the	O
+utmost	O
+discretion	O
+and	O
+in	O
+as	O
+low	O
+a	O
+dose	O
+as	O
+possible	O
+
+Two	O
+cases	O
+of	O
+polymorphic	B-Adev
+ventricular	I-Adev
+tachycardia	I-Adev
+induced	O
+by	O
+the	O
+administration	O
+of	O
+verapamil	O
+against	O
+paroxysmal	O
+supraventricular	O
+tachycardia	O
+
+Fatal	B-Adev
+acute	I-Adev
+encephalomyelitis	I-Adev
+after	O
+a	O
+single	O
+dose	O
+of	O
+intrathecal	O
+methotrexate	O
+
+The	O
+authors	O
+report	O
+one	O
+case	O
+of	O
+incomplete	B-Adev
+posterior	I-Adev
+hyaloid	I-Adev
+detachment	I-Adev
+(PHD)	I-Adev
+following	O
+intravitreal	O
+pegaptanib	O
+to	O
+treat	O
+DME	O
+
+Pulmonary	B-Adev
+edema	I-Adev
+as	O
+a	O
+delayed	O
+complication	O
+of	O
+ritodrine	O
+therapy	O
+
+Carbamazepine	B-Adev
+toxicity	I-Adev
+following	O
+Oxybutynin	O
+and	O
+Dantrolene	O
+administration	O
+a	O
+case	O
+report	O
+
+Multiple	B-Adev
+seizures	I-Adev
+after	O
+bupropion	O
+overdose	O
+in	O
+a	O
+small	O
+child	O
+
+Sorafenib	O
+a	O
+multitargeted	O
+kinase	O
+inhibitor	O
+used	O
+for	O
+the	O
+treatment	O
+of	O
+unresectable	O
+hepatocellular	O
+carcinoma	O
+and	O
+advanced	O
+renal	O
+cell	O
+carcinomas	O
+received	O
+FDA	O
+approval	O
+in	O
+2005	O
+
+Triiodothyronine-induced	O
+thyrotoxicosis	B-Adev
+in	O
+ophthalmic	O
+Graves	O
+disease	O
+
+Bleomycin	O
+induced	O
+hyperpigmentation	B-Adev
+with	I-Adev
+yolk	I-Adev
+sac	I-Adev
+tumor	I-Adev
+	O
+
+PURPOSE	O
+To	O
+describe	O
+bilateral	B-Adev
+corneal	I-Adev
+endothelial	I-Adev
+dysfunction	I-Adev
+in	O
+a	O
+patient	O
+with	O
+Parkinson	O
+disease	O
+who	O
+was	O
+treated	O
+with	O
+long-term	O
+amantadine	O
+
+A	O
+case	O
+of	O
+severe	O
+acute	B-Adev
+hepatitis	I-Adev
+caused	O
+by	O
+cyproterone	O
+acetate	O
+in	O
+a	O
+71	O
+year	O
+old	O
+man	O
+with	O
+prostatic	O
+carcinoma	O
+is	O
+reported	O
+with	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+on	O
+hepatic	O
+reactions	O
+to	O
+this	O
+drug	O
+
+Insulin-dependent	B-Adev
+diabetes	I-Adev
+mellitus	I-Adev
+associated	O
+with	O
+danazol	O
+
+CONCLUSIONS	O
+Topical	O
+brimonidine	O
+may	O
+be	O
+associated	O
+with	O
+central	B-Adev
+nervous	I-Adev
+system	I-Adev
+depression	I-Adev
+in	O
+infants	O
+
+Flecainide-associated	O
+pneumonitis	B-Adev
+with	I-Adev
+acute	I-Adev
+respiratory	I-Adev
+failure	I-Adev
+in	O
+a	O
+patient	O
+with	O
+the	O
+LEOPARD	O
+syndrome	O
+
+Seizure	B-Adev
+with	I-Adev
+hyponatremia	I-Adev
+in	O
+a	O
+child	O
+prescribed	O
+desmopressin	O
+for	O
+nocturnal	O
+enuresis	O
+
+Risks	O
+and	O
+benefits	O
+of	O
+co-treatment	O
+should	O
+be	O
+carefully	O
+considered	O
+and	O
+therapeutic	O
+alternatives	O
+to	O
+NSAIDs	O
+should	O
+be	O
+recommended	O
+to	O
+patients	O
+with	O
+central	O
+DI	O
+in	O
+order	O
+to	O
+improve	O
+DDAVP	O
+safety	O
+
+She	O
+had	O
+been	O
+treated	O
+by	O
+Carbamazepine	O
+1000	O
+mg/day	O
+for	O
+neuropathic	O
+pain	O
+for	O
+2	O
+years	O
+without	O
+clinical	O
+or	O
+laboratory	O
+signs	O
+of	O
+toxicity	O
+
+The	O
+chemotherapeutics	O
+including	O
+vincristine	O
+actinomycin	O
+D	O
+and	O
+epirubicin	O
+in	O
+case	O
+1	O
+and	O
+vincristine	O
+and	O
+actinomycin	O
+D	O
+in	O
+case	O
+2	O
+were	O
+given	O
+before	O
+the	O
+hepatotoxicity	B-Adev
+developed	I-Adev
+	O
+
+The	O
+chemotherapeutics	O
+including	O
+vincristine	O
+actinomycin	O
+D	O
+and	O
+epirubicin	O
+in	O
+case	O
+1	O
+and	O
+vincristine	O
+and	O
+actinomycin	O
+D	O
+in	O
+case	O
+2	O
+were	O
+given	O
+before	O
+the	O
+hepatotoxicity	B-Adev
+developed	I-Adev
+	O
+
+After	O
+a	O
+second	O
+dose	O
+of	O
+metoclopramide	O
+these	O
+symptoms	O
+recurred	O
+and	O
+were	O
+associated	O
+with	O
+confusion	B-Adev
+agitation	I-Adev
+fever	I-Adev
+diaphoresis	I-Adev
+tachypnea	I-Adev
+tachycardia	I-Adev
+and	I-Adev
+hypertension	I-Adev
+	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+tuberculous	B-Adev
+uveitis	I-Adev
+due	O
+to	O
+etanercept	O
+
+Acute	B-Adev
+hyperphosphatemia	I-Adev
+caused	O
+by	O
+sodium	O
+phosphate	O
+enema	O
+in	O
+a	O
+patient	O
+with	O
+liver	O
+dysfunction	O
+and	O
+chronic	O
+renal	O
+failure	O
+
+We	O
+discuss	O
+the	O
+association	O
+between	O
+carbamazepine	O
+and	O
+hyponatremia	B-Adev
+and	O
+the	O
+causes	O
+of	O
+hyponatremia	O
+after	O
+cardiopulmonary	O
+bypass	O
+
+Use	O
+of	O
+the	O
+Naranjo	O
+adverse	O
+drug	O
+reaction	O
+probability	O
+algorithm	O
+indicated	O
+a	O
+probable	O
+relationship	O
+between	O
+serotonin	B-Adev
+syndrome	I-Adev
+and	O
+treatment	O
+with	O
+lithium	O
+and	O
+venlafaxine	O
+
+The	O
+exact	O
+mechanism	O
+of	O
+IVIG-associated	O
+acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+remains	O
+unclear	O
+
+We	O
+report	O
+on	O
+7	O
+patients	O
+(2	O
+women	O
+5	O
+men)	O
+with	O
+chronic	O
+renal	O
+failure	O
+who	O
+developed	O
+under	O
+a	O
+high	O
+dosage	O
+of	O
+the	O
+new	O
+diuretic	O
+muzolimine	O
+(range	O
+240	O
+to	O
+1440	O
+mg	O
+per	O
+day)	O
+fatal	B-Adev
+neuromyeloencephalopathy	I-Adev
+	O
+
+Two	O
+renal	O
+transplant	O
+patients	O
+developed	O
+anemia	B-Adev
+during	O
+treatment	O
+of	O
+hypertension	O
+with	O
+enalapril	O
+medication	O
+
+Sotalol-induced	O
+bradycardia	O
+reversed	O
+by	O
+glucagon	O
+
+Sotalol-induced	O
+bradycardia	B-Adev
+reversed	O
+by	O
+glucagon	O
+
+The	O
+development	O
+of	O
+cutaneous	B-Adev
+ecchymosis	I-Adev
+associated	O
+with	O
+a	O
+sudden	O
+fall	O
+in	O
+hemoglobin	O
+after	O
+the	O
+administration	O
+of	O
+alteplase	O
+should	O
+strongly	O
+suggest	O
+the	O
+possibility	O
+of	O
+diffuse	O
+subfascial	O
+hematoma	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+papillary	B-Adev
+necrosis	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+with	O
+indinavir	O
+
+Generalized	B-Adev
+maculopapular	I-Adev
+and	I-Adev
+papular	I-Adev
+purpuric	I-Adev
+eruptions	I-Adev
+are	O
+perhaps	O
+the	O
+most	O
+common	O
+thionamide-induced	O
+reactions	O
+
+Imidazoline	O
+intoxication	B-Adev
+due	O
+to	O
+overdose	O
+or	O
+accidental	O
+ingestion	O
+but	O
+also	O
+after	O
+normal	O
+therapeutic	O
+usage	O
+is	O
+frequent	O
+in	O
+children	O
+
+A	O
+50-year-old	O
+diabetic	O
+and	O
+hypertensive	O
+male	O
+patient	O
+is	O
+reported	O
+who	O
+had	O
+ticlopidine-induced	O
+marrow	B-Adev
+aplasia	I-Adev
+partially	O
+responsive	O
+to	O
+colony-stimulating	O
+factors	O
+and	O
+corticosteroids	O
+but	O
+experienced	O
+complete	O
+recovery	O
+with	O
+cyclosporine	O
+
+A	O
+50-year-old	O
+diabetic	O
+and	O
+hypertensive	O
+male	O
+patient	O
+is	O
+reported	O
+who	O
+had	O
+ticlopidine-induced	O
+marrow	O
+aplasia	O
+partially	O
+responsive	O
+to	O
+colony-stimulating	O
+factors	O
+and	O
+corticosteroids	O
+but	O
+experienced	O
+complete	O
+recovery	O
+with	O
+cyclosporine	O
+
+A	O
+patient	O
+with	O
+intracranial	O
+osteosarcoma	O
+that	O
+arose	O
+16	O
+years	O
+after	O
+radiation	O
+therapy	O
+for	O
+hereditary	O
+retinoblastoma	O
+developed	O
+fatal	O
+cerebral	B-Adev
+edema	I-Adev
+and	I-Adev
+brainstem	I-Adev
+herniation	I-Adev
+after	O
+she	O
+received	O
+a	O
+single	O
+dose	O
+of	O
+intravenous	O
+methotrexate	O
+
+Neutropenia	B-Adev
+is	O
+an	O
+infrequent	O
+complication	O
+following	O
+administration	O
+of	O
+the	O
+angiotensin-converting	O
+enzyme	O
+(ACE)	O
+inhibitor	O
+captopril	O
+
+INTRODUCTION	O
+We	O
+describe	O
+the	O
+neurointensive	O
+care	O
+(NIC)	O
+management	O
+of	O
+a	O
+patient	O
+with	O
+severe	B-Adev
+cerebral	I-Adev
+swelling	I-Adev
+and	I-Adev
+raised	I-Adev
+intracranial	I-Adev
+pressure	I-Adev
+(ICP)	I-Adev
+after	O
+severe	O
+sodium	O
+valproic	O
+acid	O
+(VPA)	O
+intoxication	O
+
+Lithium	O
+therapy	O
+was	O
+discontinued	O
+because	O
+of	O
+poor	O
+compliance	O
+to	O
+the	O
+medication	O
+and	O
+intolerable	O
+polyuria	B-Adev
+	O
+
+Both	O
+PAN	O
+and	O
+methotrexate	O
+have	O
+been	O
+independently	O
+demonstrated	O
+to	O
+cause	O
+sensorineural	B-Adev
+hearing	I-Adev
+loss	I-Adev
+	O
+
+CONCLUSION	O
+A	O
+26-year-old	O
+man	O
+with	O
+bipolar	O
+disorder	O
+developed	O
+hyperammonemia	B-Adev
+three	O
+weeks	O
+after	O
+initiating	O
+carbamazepine	O
+therapy	O
+
+We	O
+report	O
+two	O
+adults	O
+who	O
+received	O
+gabapentin	O
+(GBP)	O
+and	O
+subsequently	O
+developed	O
+behavioural	B-Adev
+side	I-Adev
+effects	I-Adev
+	O
+
+Atrial	B-Adev
+fibrillation	I-Adev
+was	O
+induced	O
+by	O
+diltiazem	O
+in	O
+two	O
+patients	O
+and	O
+verapamil	O
+induced	O
+syncope	O
+in	O
+one	O
+patient	O
+
+Atrial	O
+fibrillation	O
+was	O
+induced	O
+by	O
+diltiazem	O
+in	O
+two	O
+patients	O
+and	O
+verapamil	O
+induced	O
+syncope	B-Adev
+in	O
+one	O
+patient	O
+
+We	O
+can	O
+conclude	O
+that	O
+in	O
+this	O
+case	O
+as	O
+in	O
+many	O
+others	O
+akathisia	B-Adev
+as	O
+a	O
+possible	O
+adverse	O
+effect	O
+of	O
+psychopharmacs	O
+was	O
+very	O
+hard	O
+to	O
+identify	O
+
+Although	O
+HAART	O
+is	O
+very	O
+important	O
+in	O
+the	O
+treatment	O
+of	O
+HIV	O
+its	O
+side	O
+effects	O
+are	O
+responsible	O
+for	O
+patients'	O
+non-adherence	B-Adev
+to	I-Adev
+medications	I-Adev
+	O
+
+A	O
+case	O
+of	O
+acute	B-Adev
+subdural	I-Adev
+haematoma	I-Adev
+originating	O
+spontaneously	O
+from	O
+an	O
+angiomatous	O
+meningioma	O
+in	O
+a	O
+patient	O
+receiving	O
+prophylactic	O
+aspirin	O
+therapy	O
+is	O
+presented	O
+
+Long	O
+known	O
+to	O
+psychiatrists	O
+monoamine	O
+oxidase	O
+inhibitors	O
+(MAOIs)	O
+and	O
+complications	O
+of	O
+their	O
+use	O
+may	O
+be	O
+unfamiliar	O
+to	O
+medical	O
+and	O
+surgical	O
+practitioners	O
+who	O
+may	O
+thus	O
+unwittingly	O
+precipitate	O
+a	O
+hypertensive	B-Adev
+crisis	I-Adev
+or	I-Adev
+serotonin	I-Adev
+syndrome	I-Adev
+	O
+
+According	O
+to	O
+the	O
+Naranjo	O
+adverse	O
+drug	O
+reaction	O
+probability	O
+scale	O
+the	O
+likelihood	O
+that	O
+temozolomide	O
+was	O
+responsible	O
+for	O
+the	O
+adverse	O
+drug	O
+reaction	O
+of	O
+fever	B-Adev
+was	O
+probable	O
+(score	O
+of	O
+6)	O
+
+OBJECTIVE	O
+To	O
+describe	O
+the	O
+development	O
+of	O
+valproate-related	O
+reproductive	B-Adev
+endocrine	I-Adev
+disorders	I-Adev
+in	O
+women	O
+with	O
+epilepsy	O
+
+Alprazolam-induced	O
+mania	B-Adev
+	O
+two	O
+clinical	O
+cases	O
+
+Bronchiolitis	B-Adev
+obliterans	I-Adev
+organising	I-Adev
+pneumonia	I-Adev
+associated	O
+with	O
+the	O
+use	O
+of	O
+nitrofurantoin	O
+
+To	O
+our	O
+knowledge	O
+this	O
+recurrence	O
+of	O
+amiodarone	O
+pulmonary	B-Adev
+toxicity	I-Adev
+has	O
+not	O
+been	O
+reported	O
+previously	O
+
+A	O
+patient	O
+treated	O
+with	O
+itraconazole	O
+(ITCZ)	O
+under	O
+the	O
+diagnosis	O
+of	O
+Aspergillus	O
+flavus-induced	O
+chronic	O
+hypertrophic	O
+pachymeningitis	O
+is	O
+presented	O
+
+Severe	B-Adev
+autoimmune	I-Adev
+hemolytic	I-Adev
+anemia	I-Adev
+following	O
+rituximab	O
+therapy	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+lymphoproliferative	O
+disorder	O
+
+The	O
+renal	O
+consequences	O
+of	O
+indinavir-associated	O
+nephrotoxicity	B-Adev
+are	O
+uncertain	O
+
+BACKGROUND	O
+reports	O
+on	O
+delated	B-Adev
+cutaneous	I-Adev
+reactions	I-Adev
+to	O
+captopril	O
+have	O
+been	O
+seldom	O
+reported	O
+
+Bismuth	O
+subsalicylate	O
+30	O
+mL	O
+every	O
+4	O
+hours	O
+was	O
+prescribed	O
+for	O
+diarrhea	O
+
+A	O
+drug	O
+interaction	O
+between	O
+the	O
+alpha(2)-adrenergic	O
+agonist	O
+medetomidine	O
+and	O
+lignocaine	O
+is	O
+suspected	O
+and	O
+highlights	O
+the	O
+potential	O
+for	O
+seizures	B-Adev
+following	O
+the	O
+subcutaneous	O
+administration	O
+of	O
+relatively	O
+large	O
+doses	O
+of	O
+lignocaine	O
+under	O
+medetomidine	O
+sedation	O
+
+Oesophageal	B-Adev
+ulceration	I-Adev
+due	O
+to	O
+emepronium	O
+bromide	O
+
+Development	O
+of	O
+sarcoidosis	B-Adev
+during	O
+interferon	O
+alpha	O
+2b	O
+and	O
+ribavirin	O
+combination	O
+therapy	O
+for	O
+chronic	O
+hepatitis	O
+C--a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+CONCLUSION	O
+The	O
+findings	O
+in	O
+these	O
+two	O
+patients	O
+suggest	O
+that	O
+colchicine	O
+may	O
+delay	B-Adev
+corneal	I-Adev
+wound	I-Adev
+healing	I-Adev
+	O
+
+Gemcitabine-associated	O
+hemolytic-uremic	B-Adev
+syndrome	I-Adev
+	O
+
+Case	O
+study	O
+adverse	B-Adev
+response	I-Adev
+to	O
+clonidine	O
+
+In	O
+this	O
+report	O
+a	O
+patient	O
+who	O
+had	O
+undergone	O
+a	O
+renal	O
+transplantation	O
+as	O
+a	O
+result	O
+of	O
+malignant	O
+hypertension	O
+and	O
+who	O
+was	O
+on	O
+immunosuppressive	O
+therapy	O
+consisting	O
+of	O
+cyclosporin	O
+prednisone	O
+and	O
+azathioprine	O
+developed	O
+thrombosis	B-Adev
+of	I-Adev
+the	I-Adev
+central	I-Adev
+retinal	I-Adev
+vein	I-Adev
+5	O
+years	O
+following	O
+the	O
+transplantation	O
+
+In	O
+each	O
+of	O
+the	O
+three	O
+reported	O
+patients	O
+alteration	B-Adev
+of	I-Adev
+eyelid	I-Adev
+appearance	I-Adev
+with	I-Adev
+deepening	I-Adev
+of	I-Adev
+the	I-Adev
+lid	I-Adev
+sulcus	I-Adev
+was	O
+evident	O
+as	O
+the	O
+result	O
+of	O
+topical	O
+bimatoprost	O
+therapy	O
+
+PURPOSE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+traumatic	B-Adev
+flap	I-Adev
+dehiscence	I-Adev
+and	I-Adev
+Enterobacter	I-Adev
+keratitis	I-Adev
+34	O
+months	O
+after	O
+LASIK	O
+
+CONCLUSIONS	O
+The	O
+risk	O
+of	O
+drug-induced	O
+rhabdomyolysis	B-Adev
+due	O
+to	O
+the	O
+potential	O
+interaction	O
+between	O
+lovastatin	O
+and	O
+azithromycin	O
+or	O
+clarithromycin	O
+should	O
+be	O
+considered	O
+before	O
+the	O
+concomitant	O
+use	O
+of	O
+these	O
+agents	O
+
+Ten	O
+years	O
+of	O
+behavioral	O
+data	O
+are	O
+presented	O
+to	O
+support	O
+the	O
+hypothesis	O
+that	O
+phenobarbital	O
+was	O
+exacerbating	O
+maladaptive	B-Adev
+behaviors	I-Adev
+	O
+
+Terbinafine-induced	O
+cholestatic	B-Adev
+liver	I-Adev
+disease	I-Adev
+
+The	O
+proteasome	O
+inhibitor	O
+Bortezomib	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+potent	O
+enhancer	O
+of	O
+TRAIL-induced	O
+apoptosis	O
+in	O
+several	O
+human	O
+cancers	O
+
+METHODS	O
+A	O
+retrospective	O
+report	O
+of	O
+the	O
+first	O
+case	O
+of	O
+gemcitabine-related	O
+HUS	B-Adev
+	O
+in	O
+a	O
+patient	O
+with	O
+metastatic	O
+pancreatic	O
+adenocarcinoma	O
+treated	O
+with	O
+a	O
+variety	O
+of	O
+standard	O
+therapies	O
+in	O
+addition	O
+to	O
+rituximab	O
+is	O
+presented	O
+
+Their	O
+parkinsonism	O
+improved	O
+on	O
+discontinuation	O
+of	O
+metoclopramide	O
+therapy	O
+
+Lichen	B-Adev
+planus	I-Adev
+induced	O
+by	O
+hepatitis	O
+B	O
+vaccination	O
+a	O
+new	O
+case	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+A	O
+total	O
+of	O
+40	O
+healthy	O
+volunteers	O
+were	O
+planned	O
+to	O
+start	O
+with	O
+600	O
+mg	O
+rifampicin	O
+once	O
+daily	O
+from	O
+days	O
+1-5	O
+
+Skin	B-Adev
+necrosis	I-Adev
+secondary	O
+to	O
+low-molecular	O
+weight	O
+heparin	O
+in	O
+a	O
+patient	O
+with	O
+antiphospholipid	O
+antibody	O
+syndrome	O
+
+Exacerbation	O
+of	O
+anthracycline-induced	O
+early	B-Adev
+chronic	I-Adev
+cardiomyopathy	I-Adev
+with	O
+ATRA	O
+role	O
+of	O
+B-type	O
+natriuretic	O
+peptide	O
+as	O
+an	O
+indicator	O
+of	O
+cardiac	O
+dysfunction	O
+
+Fixed	B-Adev
+drug	I-Adev
+eruption	I-Adev
+in	I-Adev
+hands	I-Adev
+caused	O
+by	O
+omeprazole	O
+
+FK506	O
+which	O
+began	O
+to	O
+be	O
+administered	O
+12	O
+days	O
+earlier	O
+rose	O
+to	O
+a	O
+level	O
+of	O
+44	O
+ng/mL	O
+(normal	O
+range	O
+10-20	O
+ng/mL)	O
+1	O
+day	O
+before	O
+neurologic	B-Adev
+abnormalities	I-Adev
+began	I-Adev
+	O
+
+Sweet's	B-Adev
+syndrome	I-Adev
+is	I-Adev
+an	I-Adev
+acute	I-Adev
+febrile	I-Adev
+neutrophilic	I-Adev
+dermatosis	I-Adev
+that	O
+is	O
+a	O
+known	O
+complication	O
+of	O
+the	O
+administration	O
+of	O
+filgrastim	O
+a	O
+drug	O
+that	O
+causes	O
+increased	O
+neutrophil	O
+proliferation	O
+and	O
+differentiation	O
+
+Although	O
+it	O
+would	O
+be	O
+expected	O
+that	O
+like	O
+other	O
+type	O
+IA	O
+toxicities	O
+diphenhydramine-induced	O
+cardiotoxicity	B-Adev
+could	O
+be	O
+responsive	O
+to	O
+hypertonic	O
+sodium	O
+bicarbonate	O
+this	O
+finding	O
+is	O
+largely	O
+unappreciated	O
+
+Although	O
+it	O
+would	O
+be	O
+expected	O
+that	O
+like	O
+other	O
+type	O
+IA	O
+toxicities	O
+diphenhydramine-induced	O
+cardiotoxicity	O
+could	O
+be	O
+responsive	O
+to	O
+hypertonic	O
+sodium	O
+bicarbonate	O
+this	O
+finding	O
+is	O
+largely	O
+unappreciated	O
+
+We	O
+describe	O
+a	O
+patient	O
+who	O
+experienced	O
+chronic	B-Adev
+nausea	I-Adev
+and	I-Adev
+an	I-Adev
+episode	I-Adev
+of	I-Adev
+confusion	I-Adev
+while	O
+treated	O
+with	O
+a	O
+small	O
+stable	O
+dose	O
+of	O
+oral	O
+morphine	O
+in	O
+the	O
+setting	O
+of	O
+mild	O
+renal	O
+insufficiency	O
+
+Bulbar	B-Adev
+and	I-Adev
+pseudobulbar	I-Adev
+palsy	I-Adev
+complicating	O
+therapy	O
+with	O
+high-dose	O
+cytosine	O
+arabinoside	O
+in	O
+children	O
+with	O
+leukemia	O
+
+The	O
+development	B-Adev
+of	I-Adev
+erythroid	I-Adev
+leukemia	I-Adev
+plus	I-Adev
+carcinoma	I-Adev
+in	O
+these	O
+two	O
+men	O
+suggests	O
+mutagenic	O
+change	O
+secondary	O
+to	O
+cyclophosphamide	O
+therapy	O
+
+Administration	O
+of	O
+thiazide	O
+diuretics	O
+also	O
+has	O
+been	O
+the	O
+cause	O
+of	O
+hyponatremia	B-Adev
+	O
+
+Serotonin	B-Adev
+syndrome	I-Adev
+is	O
+a	O
+potentially	O
+lethal	O
+adverse	O
+drug	O
+reaction	O
+that	O
+may	O
+occur	O
+in	O
+patients	O
+taking	O
+proserotoninergic	O
+medications	O
+
+However	O
+there	O
+remain	O
+questions	O
+concerning	O
+whether	O
+these	O
+drugs	O
+especially	O
+methimazole	O
+(MMI)	O
+may	O
+be	O
+associated	O
+with	O
+aplasia	B-Adev
+cutis	I-Adev
+congenita	I-Adev
+(ACC)	O
+and	O
+how	O
+best	O
+to	O
+avoid	O
+impairment	O
+of	O
+fetal	O
+thyroid	O
+function	O
+during	O
+their	O
+use	O
+
+An	O
+18-year-old	O
+man	O
+with	O
+attention-deficit-hyperactivity	O
+disorder	O
+(ADHD)	O
+was	O
+prescribed	O
+varenicline	O
+for	O
+smoking	O
+cessation	O
+
+The	O
+condition	O
+should	O
+be	O
+suspected	O
+in	O
+patients	O
+who	O
+develop	O
+unexplained	B-Adev
+abdominal	I-Adev
+pain	I-Adev
+or	I-Adev
+collapse	I-Adev
+following	O
+vasopressin	O
+treatment	O
+
+The	O
+present	O
+observation	O
+suggests	O
+that	O
+a	O
+batch	O
+of	O
+different	O
+testing	O
+doses	O
+including	O
+lower	O
+testing	O
+doses	O
+may	O
+help	O
+to	O
+differentiate	O
+between	O
+an	B-Adev
+allergic	I-Adev
+type	I-Adev
+of	I-Adev
+contact	I-Adev
+dermatitis	I-Adev
+and	O
+an	O
+irritant	O
+type	O
+of	O
+reaction	O
+after	O
+treatment	O
+with	O
+calcipotriol	O
+
+Acute	B-Adev
+erythroid	I-Adev
+leukemia	I-Adev
+after	O
+cyclophosphamide	O
+therapy	O
+for	O
+multiple	O
+myeloma	O
+report	O
+of	O
+two	O
+cases	O
+
+A	O
+combination	O
+of	O
+behavioural	O
+and	O
+cognitive	O
+adverse	O
+effects	O
+is	O
+illustrated	O
+in	O
+this	O
+case	O
+report	O
+of	O
+a	O
+recurrent	O
+triazolam-induced	O
+eating	B-Adev
+disorder	I-Adev
+	O
+
+5-fluorouracil	O
+(5-FU)-associated	O
+peripheral	B-Adev
+neuropathy	I-Adev
+is	O
+an	O
+uncommon	O
+event	O
+
+Insulin-induced	O
+lipoatrophy	B-Adev
+in	O
+type	O
+I	O
+diabetes	O
+
+This	O
+article	O
+describes	O
+a	O
+patient	O
+with	O
+suspected	O
+ciprofloxacin-induced	O
+interstitial	B-Adev
+nephritis	I-Adev
+	O
+
+We	O
+report	O
+3	O
+cases	O
+of	O
+HIV-1	O
+infected	O
+patients	O
+who	O
+experienced	O
+symptomatic	B-Adev
+angiolipomas	I-Adev
+shortly	O
+after	O
+starting	O
+antiretroviral	O
+therapy	O
+including	O
+the	O
+protease	O
+inhibitor	O
+indinavir	O
+
+Depressive	B-Adev
+symptoms	I-Adev
+disappeared	O
+after	O
+interferon	O
+therapy	O
+was	O
+stopped	O
+
+Coumarin	O
+is	O
+reported	O
+to	O
+elevate	B-Adev
+liver	I-Adev
+function	I-Adev
+tests	I-Adev
+(LFT)	I-Adev
+values	I-Adev
+	O
+
+Decreased	B-Adev
+plasma	I-Adev
+cortisol	I-Adev
+level	I-Adev
+during	O
+alprazolam	O
+treatment	O
+of	O
+panic	O
+disorder	O
+a	O
+case	O
+report	O
+
+Severe	O
+diffuse	B-Adev
+interstitial	I-Adev
+pneumonitis	I-Adev
+induced	O
+by	O
+carmustine	O
+(BCNU)	O
+
+Fever	B-Adev
+pulmonary	I-Adev
+infiltrates	I-Adev
+and	I-Adev
+pleural	I-Adev
+effusion	I-Adev
+following	O
+acyclovir	O
+therapy	O
+for	O
+herpes	O
+zoster	O
+ophthalmicus	O
+
+We	O
+propose	O
+a	O
+mechanism	O
+of	O
+vancomycin-induced	O
+mast	B-Adev
+cell	I-Adev
+degranulation	I-Adev
+and	I-Adev
+subsequent	I-Adev
+release	I-Adev
+of	I-Adev
+eosinophil	I-Adev
+chemotactic	I-Adev
+factor	I-Adev
+as	I-Adev
+a	I-Adev
+cause	I-Adev
+of	I-Adev
+CSFE	I-Adev
+	O
+
+Within	O
+3	O
+weeks	O
+of	O
+beginning	O
+continuous	O
+daily	O
+isoniazid	O
+and	O
+rifampin	O
+therapy	O
+for	O
+pulmonary	O
+tuberculosis	O
+a	O
+patient	O
+developed	O
+acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+	O
+
+We	O
+report	O
+four	O
+cases	O
+of	O
+severe	O
+corneal	B-Adev
+ulceration	I-Adev
+in	O
+methamphetamine	O
+abusers	O
+
+Diagnosis	O
+practolol	O
+induced	O
+sclerosing	B-Adev
+peritonitis	I-Adev
+	O
+
+We	O
+report	O
+the	O
+first	O
+biopsy	O
+confirmed	O
+occurrence	O
+of	O
+acute	B-Adev
+interstitial	I-Adev
+nephritis	I-Adev
+in	O
+a	O
+patient	O
+receiving	O
+treatment	O
+with	O
+Sunitinib	O
+for	O
+metastatic	O
+renal	O
+cell	O
+cancer	O
+
+Multiple	B-Adev
+pulmonary	I-Adev
+nodules	I-Adev
+	O
+an	O
+unusual	O
+presentation	O
+of	O
+fludarabine	O
+pulmonary	O
+toxicity	O
+case	O
+report	O
+and	O
+review	O
+of	O
+literature	O
+
+Clozapine-induced	O
+tardive	B-Adev
+dyskinesia	I-Adev
+in	O
+schizophrenic	O
+patients	O
+taking	O
+clozapine	O
+as	O
+a	O
+first-line	O
+antipsychotic	O
+drug	O
+
+Recently	O
+her	O
+serum	O
+theophylline	B-Adev
+levels	I-Adev
+had	I-Adev
+increased	I-Adev
+to	I-Adev
+the	I-Adev
+toxic	I-Adev
+range	I-Adev
+(133.2	O
+micromol/L	O
+[24	O
+microg/mL])	O
+shortly	O
+after	O
+the	O
+addition	O
+of	O
+zafirlukast	O
+(Accolate	O
+Zeneca	O
+Pharmaceuticals	O
+Wilmington	O
+Del)	O
+to	O
+her	O
+regimen	O
+
+Withdrawal	B-Adev
+emergent	I-Adev
+syndrome	I-Adev
+in	O
+an	O
+infant	O
+associated	O
+with	O
+maternal	O
+haloperidol	O
+therapy	O
+
+Diphenylhydantoin	O
+apparently	O
+adversely	B-Adev
+affected	I-Adev
+both	I-Adev
+the	I-Adev
+clinical	I-Adev
+and	I-Adev
+biochemical	I-Adev
+parameters	I-Adev
+of	I-Adev
+the	I-Adev
+acute	I-Adev
+intermittent	I-Adev
+porphyria	I-Adev
+	O
+
+Successful	O
+recovery	O
+from	O
+interstitial	B-Adev
+pneumonitis	I-Adev
+	O
+induced	O
+by	O
+bicalutamide	O
+and	O
+leuprorelin	O
+acetate	O
+given	O
+as	O
+treatment	O
+for	O
+prostate	O
+cancer	O
+
+Gold-induced	O
+pneumonitis	B-Adev
+	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+significant	B-Adev
+hepatic	I-Adev
+and	I-Adev
+renal	I-Adev
+failure	I-Adev
+with	O
+the	O
+use	O
+of	O
+argatroban	O
+in	O
+a	O
+patient	O
+with	O
+heparin-induced	O
+thrombocytopenia	O
+(HIT)	O
+requiring	O
+continuous	O
+veno-veno	O
+hemodialysis	O
+(CVVHD)	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+significant	O
+hepatic	O
+and	O
+renal	O
+failure	O
+with	O
+the	O
+use	O
+of	O
+argatroban	O
+in	O
+a	O
+patient	O
+with	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+(HIT)	O
+requiring	O
+continuous	O
+veno-veno	O
+hemodialysis	O
+(CVVHD)	O
+
+Visceral	B-Adev
+leishmaniasis	I-Adev
+and	I-Adev
+macrophagic	I-Adev
+activation	I-Adev
+syndrome	I-Adev
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+under	O
+treatment	O
+with	O
+adalimumab	O
+
+He	O
+was	O
+diagnosed	O
+with	O
+possible	B-Adev
+serotonin	I-Adev
+syndrome	I-Adev
+	O
+his	O
+symptoms	O
+resolved	O
+after	O
+clomipramine	O
+was	O
+stopped	O
+but	O
+before	O
+clozapine	O
+was	O
+restarted	O
+eight	O
+days	O
+later	O
+
+Disseminated	B-Adev
+intravascular	I-Adev
+coagulation	I-Adev
+associated	I-Adev
+with	I-Adev
+acute	I-Adev
+hemoglobinemia	I-Adev
+or	I-Adev
+hemoglobinuria	I-Adev
+following	O
+Rh(0)(D)	O
+immune	O
+globulin	O
+intravenous	O
+administration	O
+for	O
+immune	O
+thrombocytopenic	O
+purpura	O
+
+Two	O
+patients	O
+had	O
+ampicillin-associated	O
+seizures	B-Adev
+	O
+
+A	O
+patient	O
+developed	O
+restless	B-Adev
+legs	I-Adev
+symptoms	I-Adev
+paralleling	O
+the	O
+course	O
+of	O
+interferon-alpha	O
+(IFN	O
+alpha)	O
+therapy	O
+for	O
+chronic	O
+hepatitis	O
+C	O
+
+While	O
+many	O
+can	O
+benefit	O
+from	O
+coadministration	O
+of	O
+serotonergic	O
+antidepressants	O
+and	O
+opioids	O
+it	O
+appears	O
+that	O
+some	O
+individuals	O
+are	O
+at	O
+increased	O
+risk	O
+for	O
+SS	B-Adev
+	O
+
+Stomatitis	O
+diarrhea	B-Adev
+	O
+dermatitis	O
+and	O
+myelosuppression	O
+are	O
+the	O
+main	O
+toxicities	O
+of	O
+5-FU	O
+
+After	O
+treatment	O
+with	O
+cimetidine	O
+there	O
+was	O
+a	B-Adev
+rapid	I-Adev
+deterioration	I-Adev
+with	I-Adev
+decreased	I-Adev
+oxygen	I-Adev
+saturation	I-Adev
+and	I-Adev
+arterial	I-Adev
+PO2	I-Adev
+values	I-Adev
+	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+advanced	O
+ovarian	O
+carcinoma	O
+who	O
+developed	O
+difficulty	B-Adev
+walking	I-Adev
+because	I-Adev
+of	I-Adev
+marked	I-Adev
+pain	I-Adev
+in	I-Adev
+the	I-Adev
+lower	I-Adev
+extremities	I-Adev
+and	I-Adev
+loss	I-Adev
+of	I-Adev
+proprioception	I-Adev
+25	O
+days	O
+after	O
+treatment	O
+with	O
+weekly	O
+taxol	O
+(80	O
+mg/m(2)x3)	O
+
+Agranulocytosis	B-Adev
+and	I-Adev
+granulocytopenia	I-Adev
+associated	O
+with	O
+quetiapine	O
+
+The	O
+multiple	B-Adev
+comedones	I-Adev
+and	I-Adev
+ruptured	I-Adev
+epidermoid	I-Adev
+cysts	I-Adev
+are	O
+newly	O
+reported	O
+adverse	O
+effects	O
+of	O
+imiquimod	O
+therapy	O
+
+We	O
+conclude	O
+that	O
+neurosurgeons	O
+and	O
+neurologists	O
+should	O
+be	O
+aware	O
+of	O
+calcium	O
+antagonist--related	O
+ileus	B-Adev
+in	O
+patients	O
+treated	O
+with	O
+nimodipine	O
+
+Hyperpigmentation	B-Adev
+during	O
+interferon-alpha	O
+therapy	O
+for	O
+chronic	O
+hepatitis	O
+C	O
+virus	O
+infection	O
+
+Chlorambucil-induced	O
+chromosome	B-Adev
+damage	I-Adev
+to	O
+human	O
+lymphocytes	O
+is	O
+dose-dependent	O
+and	O
+cumulative	O
+
+Carbamazepine	O
+hypersensitivity	B-Adev
+syndrome	I-Adev
+is	O
+a	O
+rare	O
+life-threatening	O
+condition	O
+
+Case	O
+report	O
+dapsone	O
+hypersensitivity	B-Adev
+syndrome	I-Adev
+associated	O
+with	O
+treatment	O
+of	O
+the	O
+bite	O
+of	O
+a	O
+brown	O
+recluse	O
+spider	O
+
+Acute	B-Adev
+asymptomatic	I-Adev
+hepatitis	I-Adev
+in	O
+a	O
+healthy	O
+normal	O
+volunteer	O
+exposed	O
+to	O
+2	O
+oral	O
+doses	O
+of	O
+amodiaquine	O
+and	O
+artesunate	O
+
+The	O
+authors	O
+report	O
+a	O
+case	O
+of	O
+focal	B-Adev
+myocardial	I-Adev
+necrosis	I-Adev
+presenting	I-Adev
+clinically	I-Adev
+as	I-Adev
+an	I-Adev
+acute	I-Adev
+myocardial	I-Adev
+infarction	I-Adev
+during	O
+the	O
+administration	O
+of	O
+the	O
+antineoplastic	O
+drug	O
+amsacrine	O
+in	O
+a	O
+patient	O
+without	O
+coronary	O
+artery	O
+disease	O
+
+Baclofen	O
+and	O
+oxazepam	O
+were	O
+prescribed	O
+secondary	O
+to	O
+right-sided	O
+hemiparesis	O
+contractures	O
+
+DISCUSSION	O
+A	O
+review	O
+of	O
+the	O
+cases	O
+of	O
+SS	B-Adev
+with	O
+implication	O
+of	O
+mirtazapine	O
+as	O
+the	O
+cause	O
+was	O
+performed	O
+
+A	O
+small	O
+number	O
+of	O
+oxaliplatin-related	O
+hemolytic	B-Adev
+and/or	I-Adev
+thrombocytopenic	I-Adev
+reactions	I-Adev
+have	O
+been	O
+reported	O
+
+CASE	O
+SUMMARY	O
+A	O
+39-year-old	O
+white	O
+Jewish	O
+schizophrenic	O
+man	O
+treated	O
+with	O
+olanzapine	O
+developed	O
+an	B-Adev
+elevated	I-Adev
+serum	I-Adev
+CK	I-Adev
+concentration	I-Adev
+with	O
+a	O
+peak	O
+concentration	O
+of	O
+4000	O
+IU/L	O
+(normal	O
+<	O
+230)	O
+
+Severe	B-Adev
+water	I-Adev
+intoxication	I-Adev
+secondary	O
+to	O
+the	O
+concomitant	O
+intake	O
+of	O
+non-steroidal	O
+anti-inflammatory	O
+drugs	O
+and	O
+desmopressin	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+An	O
+apparent	O
+link	O
+is	O
+described	O
+between	O
+the	O
+use	O
+of	O
+MMF	O
+with	O
+prednisone	O
+to	O
+treat	O
+pemphigus	O
+vulgaris	O
+and	O
+the	O
+development	O
+of	O
+red	B-Adev
+blood	I-Adev
+cell	I-Adev
+anemia	I-Adev
+	O
+
+Other	O
+potential	O
+causes	O
+of	O
+renal	O
+failure	O
+were	O
+not	O
+present	O
+in	O
+our	O
+patient	O
+and	O
+his	O
+renal	O
+function	O
+gradually	O
+recovered	O
+with	O
+the	O
+cessation	O
+of	O
+suramin	O
+treatment	O
+
+Massive	O
+CBZ	O
+OD	O
+may	O
+produce	O
+a	O
+reversible	B-Adev
+encephalopathy	I-Adev
+that	I-Adev
+includes	I-Adev
+cortical	I-Adev
+hyperexcitability	I-Adev
+a	I-Adev
+profound	I-Adev
+burst-suppression	I-Adev
+EEG	I-Adev
+pattern	I-Adev
+and	I-Adev
+cranial	I-Adev
+nerve	I-Adev
+areflexia	I-Adev
+	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+a	O
+fluoxetine-related	O
+death	B-Adev
+in	O
+a	O
+child	O
+with	O
+a	O
+confirmed	O
+genetic	O
+polymorphism	O
+of	O
+the	O
+CYP2D6	O
+gene	O
+that	O
+results	O
+in	O
+impaired	O
+drug	O
+metabolism	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+reversible	B-Adev
+DKA	I-Adev
+and	I-Adev
+new-onset	I-Adev
+DM	I-Adev
+that	O
+developed	O
+in	O
+a	O
+demented	O
+patient	O
+who	O
+was	O
+treated	O
+with	O
+quetiapine	O
+for	O
+14	O
+days	O
+
+We	O
+describe	O
+3	O
+cases	O
+of	O
+diphenhydramine-induced	O
+cardiac	B-Adev
+toxicity	I-Adev
+that	O
+were	O
+responsive	O
+to	O
+bicarbonate	O
+
+We	O
+describe	O
+3	O
+cases	O
+of	O
+diphenhydramine-induced	O
+cardiac	O
+toxicity	O
+that	O
+were	O
+responsive	O
+to	O
+bicarbonate	O
+
+The	O
+patient's	O
+arthritis	B-Adev
+flared	I-Adev
+after	O
+the	O
+second	O
+infusion	O
+of	O
+infliximab	O
+which	O
+was	O
+discontinued	O
+
+CONCLUSION	O
+Marked	B-Adev
+visual	I-Adev
+field	I-Adev
+constriction	I-Adev
+appears	O
+to	O
+be	O
+associated	O
+with	O
+vigabatrin	O
+therapy	O
+
+Possible	O
+serotonin	B-Adev
+syndrome	I-Adev
+associated	I-Adev
+with	I-Adev
+clomipramine	I-Adev
+after	O
+withdrawal	O
+of	O
+clozapine	O
+
+A	O
+14-year-old	O
+female	O
+developed	O
+systemic	B-Adev
+lupus	I-Adev
+erythematosus	I-Adev
+(SLE)-like	I-Adev
+symptoms	I-Adev
+rash	I-Adev
+fever	I-Adev
+leukopenia	I-Adev
+and	I-Adev
+positive	I-Adev
+anti-nuclear	I-Adev
+antibody	I-Adev
+(ANA)	I-Adev
+two	O
+weeks	O
+after	O
+administration	O
+of	O
+carbamazepine	O
+(CBZ	O
+Tegretol)	O
+used	O
+against	O
+benign	O
+Rolandic	O
+epilepsy	O
+
+There	O
+was	O
+a	O
+clear	O
+relationship	O
+between	O
+restarting	O
+the	O
+Accutane	O
+and	O
+recurrence	B-Adev
+of	I-Adev
+the	I-Adev
+transient	I-Adev
+myopia	I-Adev
+	O
+
+Graves'	B-Adev
+hyperthyroidism	I-Adev
+following	I-Adev
+transient	I-Adev
+thyrotoxicosis	I-Adev
+during	O
+interferon	O
+therapy	O
+for	O
+chronic	O
+hepatitis	O
+type	O
+C	O
+
+Masculinization	B-Adev
+of	I-Adev
+a	I-Adev
+female	I-Adev
+fetus	I-Adev
+occurred	O
+in	O
+5	O
+of	O
+39	O
+(12.8%)	O
+exposed	O
+to	O
+norethisterone	O
+all	O
+were	O
+cases	O
+of	O
+clitoral	O
+hypertrophy	O
+not	O
+requiring	O
+surgical	O
+treatment	O
+
+She	O
+continued	O
+taking	O
+verapamil	O
+for	O
+6	O
+months	O
+then	O
+on	O
+her	O
+own	O
+stopped	O
+all	O
+medications	O
+including	O
+the	O
+sustained-release	O
+verapamil	O
+and	O
+her	O
+asthma	O
+symptoms	O
+disappeared	O
+
+Two	O
+patients	O
+with	O
+ovarian	O
+cancer	O
+who	O
+had	O
+received	O
+multiple	O
+courses	O
+of	O
+cisplatin	O
+without	O
+complications	O
+experienced	O
+hypersensitivity	O
+reactions	O
+to	O
+cisplatin	O
+one	O
+involving	O
+intrahepatic	O
+artery	O
+infusion	O
+manifested	B-Adev
+general	I-Adev
+erythema	I-Adev
+dyspnea	I-Adev
+and	I-Adev
+hypotension	I-Adev
+	O
+the	O
+other	O
+involving	O
+intravenous	O
+infusion	O
+manifested	O
+abdominal	O
+pain	O
+general	O
+erythema	O
+and	O
+fever	O
+
+Two	O
+patients	O
+with	O
+ovarian	O
+cancer	O
+who	O
+had	O
+received	O
+multiple	O
+courses	O
+of	O
+cisplatin	O
+without	O
+complications	O
+experienced	O
+hypersensitivity	O
+reactions	O
+to	O
+cisplatin	O
+one	O
+involving	O
+intrahepatic	O
+artery	O
+infusion	O
+manifested	O
+general	O
+erythema	O
+dyspnea	O
+and	O
+hypotension	O
+the	O
+other	O
+involving	O
+intravenous	O
+infusion	O
+manifested	B-Adev
+abdominal	I-Adev
+pain	I-Adev
+general	I-Adev
+erythema	I-Adev
+and	I-Adev
+fever	I-Adev
+	O
+
+CONCLUSION	O
+There	O
+are	O
+only	O
+a	O
+few	O
+confirmed	O
+cases	O
+of	O
+gemcitabine-associated	O
+HUS	B-Adev
+despite	O
+the	O
+widespread	O
+use	O
+of	O
+the	O
+drug	O
+
+In	O
+these	O
+patients	O
+long-acting	O
+octreotide	O
+may	O
+trigger	O
+serious	B-Adev
+hypoglycemia	I-Adev
+	O
+
+Usefulness	O
+of	O
+antiplatelet	O
+drugs	O
+in	O
+the	O
+management	O
+of	O
+heparin-associated	O
+thrombocytopenia	B-Adev
+and	I-Adev
+thrombosis	I-Adev
+	O
+
+Usefulness	O
+of	O
+antiplatelet	O
+drugs	O
+in	O
+the	O
+management	O
+of	O
+heparin-associated	O
+thrombocytopenia	O
+and	O
+thrombosis	O
+
+An	O
+intertrigo-like	B-Adev
+eruption	I-Adev
+from	O
+pegylated	O
+liposomal	O
+doxorubicin	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+NEH	B-Adev
+masquerading	I-Adev
+as	I-Adev
+cutaneous	I-Adev
+vasculitis	I-Adev
+in	O
+a	O
+woman	O
+receiving	O
+cyclophosphamide	O
+for	O
+lupus	O
+nephritis	O
+
+The	O
+diagnosis	O
+of	O
+hypothermia	O
+was	O
+delayed	O
+until	O
+it	O
+was	O
+apparent	O
+for	O
+several	O
+days	O
+but	O
+resolved	O
+with	O
+the	O
+discontinuation	O
+of	O
+risperidone	O
+and	O
+continuation	O
+of	O
+clozapine	O
+
+Unaccountable	B-Adev
+severe	I-Adev
+hypercalcemia	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+for	O
+hypoparathyroidism	O
+with	O
+dihydrotachysterol	O
+
+Anaphylaxis	B-Adev
+to	O
+calcitonin	O
+
+However	O
+he	O
+developed	O
+acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+hyperkalemia	I-Adev
+and	I-Adev
+hyperuricemia	I-Adev
+30	O
+d	O
+after	O
+receiving	O
+the	O
+sorafenib	O
+treatment	O
+
+Mycobacterium	O
+marinum	O
+infection	O
+complicating	O
+Crohn's	O
+disease	O
+treated	O
+with	O
+infliximab	O
+
+Current	O
+immunosuppressive	O
+therapies	O
+are	O
+effective	O
+but	O
+can	O
+be	O
+associated	O
+with	O
+significant	B-Adev
+adverse	I-Adev
+reactions	I-Adev
+
+This	O
+report	O
+describes	O
+the	O
+first	O
+association	O
+(exclusive	O
+of	O
+drug	O
+overdose)	O
+of	O
+symptomatic	B-Adev
+torsades	I-Adev
+de	I-Adev
+pointes	I-Adev
+occurring	O
+with	O
+the	O
+use	O
+of	O
+terfenadine	O
+in	O
+a	O
+patient	O
+who	O
+was	O
+taking	O
+the	O
+recommended	O
+prescribed	O
+dose	O
+of	O
+this	O
+drug	O
+in	O
+addition	O
+to	O
+cefaclor	O
+ketoconazole	O
+and	O
+medroxyprogesterone	O
+
+Tamoxifen	O
+is	O
+suggested	O
+to	O
+be	O
+carcinogenic	B-Adev
+both	I-Adev
+through	I-Adev
+direct	I-Adev
+genotoxic	I-Adev
+and	I-Adev
+epigenetic	I-Adev
+mechanisms	I-Adev
+	O
+
+DISCUSSION	O
+Colchicine	O
+the	O
+most	O
+important	O
+drug	O
+in	O
+treatment	O
+of	O
+FMF	O
+can	O
+cause	O
+myopathy	B-Adev
+in	O
+patients	O
+with	O
+impaired	O
+renal	O
+and	O
+hepatic	O
+function	O
+
+In	O
+the	O
+presented	O
+case	O
+fluvoxamine-induced	O
+akathisia	O
+in	O
+an	O
+OCD	O
+patient	O
+was	O
+partially	O
+resistant	O
+to	O
+the	O
+anticholinergic	O
+agent	O
+biperiden	O
+and	O
+was	O
+successfully	O
+treated	O
+with	O
+the	O
+5-HT2A/5-HT2C	O
+antagonist	O
+mianserin	O
+
+SUBSEQUENT	O
+COURSE	O
+The	O
+nephrosis	O
+resolved	O
+almost	O
+completely	O
+once	O
+the	O
+interferon	O
+was	O
+stopped	O
+and	O
+after	O
+immunosuppressive	O
+treatment	O
+
+In	O
+two	O
+patients	O
+apomorphine	O
+remained	O
+effective	O
+in	O
+the	O
+morning	O
+but	O
+increased	O
+the	O
+intensity	B-Adev
+of	I-Adev
+the	I-Adev
+dyskinesias	I-Adev
+in	I-Adev
+the	I-Adev
+afternoon	I-Adev
+	O
+
+Transient	B-Adev
+asymptomatic	I-Adev
+bradycardia	I-Adev
+in	O
+patients	O
+on	O
+infusional	O
+5-fluorouracil	O
+
+In	O
+2006	O
+he	O
+was	O
+diagnosed	O
+with	O
+deep	O
+vein	O
+thrombosis	O
+and	O
+pulmonary	O
+embolism	O
+and	O
+was	O
+started	O
+on	O
+warfarin	O
+
+Scleritis	B-Adev
+complicating	O
+zoledronic	O
+acid	O
+infusion	O
+
+A	O
+22-year-old	O
+black	O
+man	O
+developed	O
+fever	B-Adev
+chills	I-Adev
+fatigue	I-Adev
+night	I-Adev
+sweats	I-Adev
+tender	I-Adev
+lymphadenopathy	I-Adev
+and	I-Adev
+a	I-Adev
+generalized	I-Adev
+pruritic	I-Adev
+macular	I-Adev
+eruption	I-Adev
+3	O
+weeks	O
+after	O
+starting	O
+minocycline	O
+therapy	O
+for	O
+acne	O
+
+Ticlopidine-induced	O
+aplastic	B-Adev
+anemia	I-Adev
+	O
+two	O
+new	O
+case	O
+reports	O
+review	O
+and	O
+meta-analysis	O
+of	O
+55	O
+additional	O
+cases	O
+
+This	O
+is	O
+the	O
+second	O
+report	O
+of	O
+acute	B-Adev
+lung	I-Adev
+injury	I-Adev
+and	I-Adev
+diffuse	I-Adev
+alveolar	I-Adev
+damage	I-Adev
+caused	O
+by	O
+mefloquine	O
+
+A	O
+case	O
+of	O
+Erythema	B-Adev
+Multiforme	I-Adev
+Bullosum	I-Adev
+in	O
+patient	O
+of	O
+lepromatous	O
+leprosy	O
+with	O
+pulmonary	O
+tuberculosis	O
+due	O
+to	O
+Rifampicin	O
+is	O
+described	O
+
+Life-threatening	B-Adev
+alterations	I-Adev
+in	I-Adev
+heart	I-Adev
+rate	I-Adev
+after	O
+the	O
+use	O
+of	O
+adenosine	O
+in	O
+atrial	O
+flutter	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+pancytopenia	B-Adev
+in	O
+a	O
+23-year-old	O
+man	O
+with	O
+Crohn's	O
+disease	O
+who	O
+was	O
+treated	O
+with	O
+5-aminosalicylic	O
+acid	O
+(Pentasa	O
+Nisshin	O
+Tokyo	O
+Japan)	O
+3.0	O
+g/day	O
+
+The	B-Adev
+ampicillin	I-Adev
+rash	I-Adev
+occurring	O
+in	O
+cases	O
+of	O
+infectious	O
+mononucleosis	O
+is	O
+well	O
+documented	O
+
+The	O
+major	O
+side	O
+effect	O
+of	O
+infliximab	O
+is	O
+infection	B-Adev
+	O
+
+An	O
+asymptomatic	O
+HIV-infected	O
+woman	O
+experienced	O
+right-sided	B-Adev
+renal	I-Adev
+colicky	I-Adev
+pain	I-Adev
+during	O
+treatment	O
+with	O
+indinavir	O
+
+The	O
+case	O
+resembles	O
+two	O
+previously	O
+reported	O
+cases	O
+of	O
+optic	B-Adev
+neuropathy	I-Adev
+which	O
+occurred	O
+in	O
+patients	O
+with	O
+Wilson's	O
+disease	O
+who	O
+were	O
+receiving	O
+penicillamine	O
+
+Cutaneous	B-Adev
+ulceration	I-Adev
+	O
+an	O
+unusual	O
+complication	O
+of	O
+intravenous	O
+pentamidine	O
+therapy	O
+
+Pulmonary	B-Adev
+hemorrhage	I-Adev
+is	O
+an	O
+uncommon	O
+feature	O
+in	O
+the	O
+HUS	O
+and	O
+seems	O
+to	O
+appear	O
+especially	O
+in	O
+the	O
+HUS	O
+associated	O
+with	O
+MMC	O
+therapy	O
+
+Immunosuppression	O
+elicited	O
+by	O
+the	O
+extensive	O
+administration	O
+of	O
+prednisolone	O
+was	O
+suspected	O
+for	O
+the	O
+initiation	O
+of	O
+the	O
+generalized	O
+mite	B-Adev
+infestation	I-Adev
+	O
+
+The	B-Adev
+episode	I-Adev
+appeared	I-Adev
+to	I-Adev
+have	I-Adev
+been	I-Adev
+precipitated	I-Adev
+by	I-Adev
+toxicity	I-Adev
+due	O
+to	O
+ingestion	O
+of	O
+a	O
+large	O
+amount	O
+of	O
+phenytoin	O
+
+Cardiopulmonary	B-Adev
+arrest	I-Adev
+following	O
+intravenous	O
+phenytoin	O
+loading	O
+
+Although	O
+taxol	O
+has	O
+shown	O
+significant	O
+activity	O
+in	O
+advanced	O
+ovarian	O
+cancer	O
+peripheral	B-Adev
+neuropathy	I-Adev
+is	O
+likely	O
+to	O
+become	O
+the	O
+major	O
+dose-limiting	O
+toxicity	O
+
+Syringotropic	B-Adev
+hypersensitivity	I-Adev
+reaction	I-Adev
+associated	O
+with	O
+infliximab	O
+and	O
+leflunomide	O
+combination	O
+therapy	O
+in	O
+a	O
+child	O
+with	O
+psoriatic	O
+arthritis	O
+
+Corticosteroid	O
+therapy	O
+was	O
+continued	O
+for	O
+8	O
+months	O
+since	O
+there	O
+was	O
+still	O
+improvement	O
+of	O
+pulmonary	O
+function	O
+studies	O
+
+OBJECTIVE	O
+To	O
+describe	O
+a	O
+case	O
+of	O
+sertraline-induced	O
+rhabdomyolysis	B-Adev
+in	O
+an	O
+elderly	O
+patient	O
+with	O
+dementia	O
+and	O
+comorbidities	O
+
+Beyond	O
+the	O
+predictable	O
+pharmacokinetic	O
+drug-drug	O
+interaction	O
+requiring	O
+a	O
+significant	O
+warfarin	O
+dose	O
+reduction	O
+the	O
+iodine-rich	O
+amiodarone	O
+affects	O
+the	O
+thyroid	O
+gland	O
+causing	O
+overt	B-Adev
+hypothyroidism	I-Adev
+or	I-Adev
+thyrotoxicosis	I-Adev
+in	O
+14%-18%	O
+of	O
+cases	O
+
+Toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+associated	O
+with	O
+interleukin-2	O
+
+The	O
+pulmonary	B-Adev
+toxicity	I-Adev
+of	O
+gold	O
+salts	O
+is	O
+an	O
+uncommon	O
+cause	O
+of	O
+life-threatening	O
+respiratory	O
+failure	O
+
+With	O
+its	O
+characteristics	O
+tizanidine	O
+has	O
+the	O
+potential	O
+to	O
+compromise	B-Adev
+hemodynamic	I-Adev
+stability	I-Adev
+during	O
+concomitant	O
+angiotensin-converting	O
+enzyme	O
+inhibitor	O
+use	O
+
+Premature	B-Adev
+closure	I-Adev
+of	I-Adev
+the	I-Adev
+ductus	I-Adev
+arteriosus	I-Adev
+	O
+variable	O
+response	O
+among	O
+monozygotic	O
+twins	O
+after	O
+in	O
+utero	O
+exposure	O
+to	O
+indomethacin	O
+
+Possible	O
+mechanisms	O
+by	O
+which	O
+clonidine	O
+decreases	O
+spasticity	O
+are	O
+described	O
+probable	O
+mechanisms	O
+of	O
+induced	O
+bradycardia	B-Adev
+are	O
+reviewed	O
+and	O
+specific	O
+treatment	O
+recommendations	O
+for	O
+the	O
+use	O
+of	O
+clonidine	O
+in	O
+spinal	O
+cord	O
+injured	O
+patients	O
+are	O
+presented	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+a	O
+possible	O
+association	O
+between	O
+an	B-Adev
+acute	I-Adev
+cardiovascular	I-Adev
+event	I-Adev
+and	O
+venlafaxine	O
+
+Since	O
+early	O
+symptoms	O
+of	O
+the	O
+toxic	O
+effects	O
+of	O
+theophylline	O
+can	O
+mimic	O
+peptic	O
+ulcer	O
+disease	O
+cimetidine	O
+might	O
+be	O
+prescribed	O
+for	O
+the	O
+gastrointestinal	O
+symptoms	O
+with	O
+subsequent	O
+worsening	O
+of	O
+theophylline	O
+poisoning	O
+
+Acute	B-Adev
+renal	I-Adev
+failure	I-Adev
+in	O
+a	O
+patient	O
+receiving	O
+treatment	O
+with	O
+suramin	O
+
+A	O
+further	O
+case	O
+of	O
+anaphylactoid	B-Adev
+reaction	I-Adev
+to	O
+methylprednisolone	O
+is	O
+reported	O
+
+Pulmonary	B-Adev
+hemorrhage	I-Adev
+as	O
+a	O
+clinical	O
+manifestation	O
+of	O
+hemolytic-uremic	O
+syndrome	O
+associated	O
+with	O
+mitomycin	O
+C	O
+therapy	O
+
+EEG	B-Adev
+abnormalities	I-Adev
+were	O
+observed	O
+in	O
+two	O
+of	O
+the	O
+nine	O
+children	O
+during	O
+chlorambucil	O
+therapy	O
+
+Discontinuation	O
+of	O
+the	O
+itraconazole	O
+caused	O
+resolution	O
+of	O
+the	O
+drug	B-Adev
+eruption	I-Adev
+	O
+
+The	O
+addition	O
+of	O
+intrathecal	O
+methotrexate	O
+to	O
+treatment	O
+protocols	O
+has	O
+increased	O
+survival	O
+rates	O
+in	O
+children	O
+with	O
+acute	O
+lymphoblastic	O
+leukemia	O
+but	O
+is	O
+also	O
+associated	O
+with	O
+varying	B-Adev
+degrees	I-Adev
+of	I-Adev
+neurotoxicity	I-Adev
+	O
+
+We	O
+conclude	O
+that	O
+the	O
+presence	O
+of	O
+this	O
+metabolic	O
+defect	O
+combined	O
+with	O
+topical	O
+5-FU	O
+(a	O
+drug	O
+demonstrating	O
+a	O
+narrow	O
+therapeutic	O
+index)	O
+results	O
+in	O
+the	O
+unusual	B-Adev
+presentation	I-Adev
+of	I-Adev
+life-threatening	I-Adev
+toxicity	I-Adev
+after	O
+treatment	O
+with	O
+a	O
+topical	O
+drug	O
+
+Six	O
+patients	O
+with	O
+rheumatoid	O
+arthritis	O
+developed	O
+a	O
+syndrome	B-Adev
+resembling	I-Adev
+lupus	I-Adev
+erythematosus	I-Adev
+while	O
+being	O
+treated	O
+with	O
+penicillamine	O
+
+This	O
+case	O
+highlights	O
+the	O
+need	O
+to	O
+monitor	O
+liver	O
+enzymes	O
+in	O
+patients	O
+treated	O
+with	O
+6-TG	O
+and	O
+identifies	O
+the	O
+need	O
+for	O
+additional	O
+research	O
+focused	O
+on	O
+the	O
+mechanism	O
+of	O
+thiopurine-induced	O
+hepatic	B-Adev
+injury	I-Adev
+	O
+
+During	O
+clarithromycin	O
+coadministration	O
+four	O
+out	O
+of	O
+the	O
+seven	O
+patients	O
+developed	O
+moderate-to-severe	B-Adev
+toxic	I-Adev
+symptoms	I-Adev
+of	I-Adev
+carbamazepine	I-Adev
+such	I-Adev
+as	I-Adev
+drowsiness	I-Adev
+dizziness	I-Adev
+and	I-Adev
+ataxia	I-Adev
+	O
+which	O
+resolved	O
+within	O
+5	O
+days	O
+after	O
+clarithromycin	O
+discontinuation	O
+
+During	O
+clarithromycin	O
+coadministration	O
+four	O
+out	O
+of	O
+the	O
+seven	O
+patients	O
+developed	O
+moderate-to-severe	O
+toxic	O
+symptoms	O
+of	O
+carbamazepine	O
+such	O
+as	O
+drowsiness	O
+dizziness	O
+and	O
+ataxia	O
+which	O
+resolved	O
+within	O
+5	O
+days	O
+after	O
+clarithromycin	O
+discontinuation	O
+
+5-Fluorouracil	O
+(5-FU)	O
+is	O
+an	O
+analogue	O
+of	O
+pyrimidine	O
+nucleosides	O
+that	O
+is	O
+widely	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+head	O
+and	O
+neck	O
+breast	O
+ovarian	O
+and	O
+colon	O
+cancer	O
+
+Fulminant	B-Adev
+fatal	I-Adev
+cardiotoxicity	I-Adev
+following	O
+cyclophosphamide	O
+therapy	O
+
+The	O
+reaction	B-Adev
+in	O
+our	O
+patient	O
+appeared	O
+after	O
+tizanidine	O
+initiation	O
+and	O
+improved	O
+after	O
+both	O
+lisinopril	O
+and	O
+tizanidine	O
+were	O
+discontinued	O
+
+The	O
+reaction	O
+in	O
+our	O
+patient	O
+appeared	O
+after	O
+tizanidine	O
+initiation	O
+and	O
+improved	O
+after	O
+both	O
+lisinopril	O
+and	O
+tizanidine	O
+were	O
+discontinued	O
+
+We	O
+describe	O
+the	O
+exceptional	O
+development	O
+of	O
+AML	B-Adev
+and	O
+lung	O
+cancer	O
+in	O
+a	O
+patient	O
+with	O
+previously	O
+diagnosed	O
+CLL	O
+in	O
+minimal	O
+residual	O
+disease	O
+status	O
+after	O
+fludarabine	O
+treatment	O
+followed	O
+by	O
+autologous	O
+peripheral	O
+blood	O
+stem-cell	O
+transplantation	O
+
+Valproate-induced	O
+hyperammonemia	O
+as	O
+a	O
+cause	O
+of	O
+altered	B-Adev
+mental	I-Adev
+status	I-Adev
+	O
+
+We	O
+report	O
+5	O
+cases	O
+of	O
+acute	B-Adev
+reversible	I-Adev
+renal	I-Adev
+failure	I-Adev
+coinciding	O
+with	O
+the	O
+onset	O
+of	O
+treatment	O
+with	O
+captopril	O
+in	O
+patients	O
+with	O
+severe	O
+drug-resistant	O
+hypertension	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+contact	B-Adev
+dermatitis	I-Adev
+due	O
+to	O
+sodium	O
+bisulfite	O
+in	O
+Tathion	O
+eye	O
+drops	O
+
+The	O
+first	O
+patient	O
+is	O
+undergoing	O
+hemodialysis	O
+and	O
+though	O
+responding	O
+to	O
+sunitinib	O
+is	O
+having	O
+significant	B-Adev
+fatigue	I-Adev
+and	I-Adev
+hypertension	I-Adev
+	O
+
+CCBs	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+treatment	O
+of	O
+5-FU	O
+or	O
+capecitabine-induced	O
+headaches	O
+
+Furosemide	O
+spironolactone	O
+allopurinol	O
+and	O
+hydroxyurea	O
+were	O
+considered	O
+possible	O
+causes	O
+of	O
+the	O
+reaction	B-Adev
+and	O
+were	O
+discontinued	O
+
+PATIENTS	O
+One	O
+patient	O
+with	O
+mucositis	B-Adev
+secondary	O
+to	O
+chemotherapy	O
+
+A	O
+patient	O
+with	O
+monocular	O
+open-angle	O
+glaucoma	O
+had	O
+trichiasis	B-Adev
+	O
+a	O
+condition	O
+associated	O
+with	O
+the	O
+use	O
+of	O
+a	O
+prostaglandin	O
+analog	O
+
+A	O
+53-year-old	O
+African	O
+American	O
+male	O
+with	O
+HIV	O
+was	O
+prescribed	O
+warfarin	O
+5	O
+mg/day	O
+for	O
+12	O
+months	O
+after	O
+diagnosis	O
+of	O
+idiopathic	O
+deep	O
+vein	O
+thrombosis	O
+and	O
+bilateral	O
+pulmonary	O
+emboli	O
+(target	O
+INR	O
+2.5	O
+[range	O
+2.0-3.0])	O
+
+After	O
+treatment	O
+with	O
+a	O
+beta-sympathomimetic	O
+drug	O
+(Partusisten)	O
+one	O
+fetus	O
+developed	O
+supraventricular	B-Adev
+tachycardia	I-Adev
+
+Serotonin	B-Adev
+syndrome	I-Adev
+developed	O
+in	O
+a	O
+patient	O
+taking	O
+concurrent	O
+linezolid	O
+and	O
+fluoxetine	O
+
+RESULTS	O
+A	O
+male	O
+and	O
+a	O
+female	O
+patient	O
+with	O
+spasticity	O
+treated	O
+with	O
+intrathecal	O
+baclofen	O
+were	O
+recognized	O
+to	O
+have	O
+sexual	B-Adev
+dysfunction	I-Adev
+side	O
+effects	O
+from	O
+treatment	O
+
+OBJECTIVE	O
+To	O
+describe	O
+a	O
+patient	O
+with	O
+ifosfamide-induced	O
+nonconvulsive	B-Adev
+status	I-Adev
+epilepticus	I-Adev
+	O
+
+Upper	B-Adev
+gastrointestinal	I-Adev
+haemorrhage	I-Adev
+is	O
+a	O
+serious	O
+complication	O
+of	O
+aspirin	O
+and	O
+clopidogrel	O
+(dual)	O
+anti-platelet	O
+therapy	O
+with	O
+a	O
+high	O
+morbidity	O
+and	O
+mortality	O
+
+Flecainide	O
+overdose	O
+can	O
+rapidly	O
+result	O
+in	O
+profound	B-Adev
+cardiovascular	I-Adev
+collapse	I-Adev
+and	I-Adev
+is	I-Adev
+associated	I-Adev
+with	I-Adev
+a	I-Adev
+relatively	I-Adev
+high	I-Adev
+mortality	I-Adev
+	O
+
+Sulfasalazine-induced	O
+lupus	B-Adev
+erythematosus	I-Adev
+	O
+
+Reye	B-Adev
+syndrome	I-Adev
+(RS)	I-Adev
+is	O
+believed	O
+to	O
+occur	O
+infrequently	O
+among	O
+children	O
+receiving	O
+long-term	O
+aspirin	O
+therapy	O
+
+Propecia-associated	O
+bilateral	B-Adev
+cataract	I-Adev
+	O
+
+After	O
+39	O
+hours	O
+on	O
+argatroban	O
+the	O
+infusion	O
+was	O
+stopped	O
+when	O
+minor	B-Adev
+bleeding	I-Adev
+was	I-Adev
+observed	I-Adev
+with	I-Adev
+a	I-Adev
+concurrent	I-Adev
+activated	I-Adev
+partial	I-Adev
+thromboplastin	I-Adev
+time	I-Adev
+(aPTT)	I-Adev
+of	I-Adev
+100	I-Adev
+seconds	I-Adev
+	O
+
+Anaphylactoid	B-Adev
+reaction	I-Adev
+to	O
+methylprednisolone	O
+pulsed	O
+therapy	O
+for	O
+multiple	O
+sclerosis	O
+
+Warfarin-induced	O
+skin	B-Adev
+necrosis	I-Adev
+and	O
+heparin-induced	O
+thrombocytopenia	O
+following	O
+mitral	O
+valve	O
+replacement	O
+for	O
+marantic	O
+endocarditis	O
+
+Warfarin-induced	O
+skin	O
+necrosis	O
+and	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+following	O
+mitral	O
+valve	O
+replacement	O
+for	O
+marantic	O
+endocarditis	O
+
+Surprisingly	O
+we	O
+found	O
+that	O
+three	O
+patients	O
+appeared	O
+to	O
+develop	O
+tardive	B-Adev
+OGC	I-Adev
+while	O
+taking	O
+clozapine	O
+
+We	O
+report	O
+a	O
+fatal	O
+case	O
+of	O
+toxic	B-Adev
+epidermal	I-Adev
+necrolysis	I-Adev
+(TEN)	I-Adev
+resulting	O
+from	O
+a	O
+high	O
+dose	O
+of	O
+cytosine	O
+arabinoside	O
+(ARA-C)	O
+
+On	O
+the	O
+fifth	O
+day	O
+after	O
+administration	O
+of	O
+a	O
+high	O
+dose	O
+of	O
+ARA-C	O
+(2	O
+g/m2	O
+intravenously	O
+every	O
+12	O
+hours)	O
+she	O
+developed	O
+bullous	B-Adev
+lesions	I-Adev
+on	I-Adev
+the	I-Adev
+hands	I-Adev
+and	I-Adev
+soles	I-Adev
+that	I-Adev
+disseminated	I-Adev
+evolving	I-Adev
+to	I-Adev
+necrosis	I-Adev
+sepsis	I-Adev
+and	I-Adev
+death	I-Adev
+on	O
+the	O
+22nd	O
+day	O
+
+We	O
+describe	O
+2	O
+patients	O
+with	O
+cutaneous	O
+lupus	O
+erythematosus	O
+who	O
+developed	O
+severe	B-Adev
+dapsone	I-Adev
+reaction	I-Adev
+after	O
+low	O
+dose	O
+therapy	O
+with	O
+a	O
+fatal	O
+outcome	O
+in	O
+one	O
+
+A	O
+patient	O
+with	O
+ulcerative	O
+colitis	O
+developed	O
+skin	B-Adev
+pigmentation	I-Adev
+and	I-Adev
+diffuse	I-Adev
+pulmonary	I-Adev
+shadowing	I-Adev
+without	I-Adev
+respiratory	I-Adev
+symptomatology	I-Adev
+	O
+while	O
+taking	O
+sulfasalazine	O
+
+This	O
+is	O
+a	O
+case	O
+report	O
+involving	O
+a	O
+patient	O
+who	O
+was	O
+treated	O
+with	O
+topical	O
+5-FU	O
+cream	O
+and	O
+subsequently	O
+developed	O
+a	B-Adev
+severe	I-Adev
+case	I-Adev
+of	I-Adev
+angioedema	I-Adev
+	O
+
+Cessation	O
+of	O
+D-Pen	O
+and	O
+the	O
+start	O
+of	O
+corticosteroid	O
+therapy	O
+were	O
+followed	O
+by	O
+recovery	O
+from	O
+bicytopenia	O
+
+Prevention	O
+of	O
+infection	O
+by	O
+immunization	O
+together	O
+with	O
+early	O
+recognition	O
+and	O
+prompt	O
+antiviral	O
+treatment	O
+are	O
+critical	O
+
+A	O
+case	O
+of	O
+normotensive	B-Adev
+scleroderma	I-Adev
+renal	I-Adev
+crisis	I-Adev
+after	O
+high-dose	O
+methylprednisolone	O
+treatment	O
+
+OBJECTIVES	O
+A	O
+delayed	B-Adev
+stroke-like	I-Adev
+leukoencephalopathy	I-Adev
+has	O
+been	O
+observed	O
+in	O
+patients	O
+receiving	O
+methotrexate	O
+(MTX)	O
+for	O
+childhood	O
+leukemia	O
+
+Duloxetine-induced	O
+hyponatremia	B-Adev
+in	O
+an	O
+elderly	O
+patient	O
+treated	O
+with	O
+thiazide	O
+diuretics	O
+
+The	O
+following	O
+is	O
+a	O
+case	O
+report	O
+analysis	O
+intended	O
+to	O
+draw	O
+attention	O
+to	O
+the	O
+need	O
+for	O
+better	O
+care	O
+coordination	O
+by	O
+describing	O
+the	O
+observed	O
+relationship	O
+of	O
+olanzapine	O
+to	O
+metabolic	B-Adev
+changes	I-Adev
+manifested	I-Adev
+as	I-Adev
+uncontrolled	I-Adev
+diabetes	I-Adev
+mellitus	I-Adev
+and	I-Adev
+weight	I-Adev
+gain	I-Adev
+	O
+
+Arsenic	O
+trioxide	O
+has	O
+recently	O
+been	O
+introduced	O
+as	O
+a	O
+promising	O
+new	O
+agent	O
+to	O
+treat	O
+refractory	O
+acute	O
+promyelocytic	O
+leukemia	O
+(APL)	O
+
+Although	O
+the	B-Adev
+t-AML	I-Adev
+developed	O
+following	O
+oral	O
+etoposide	O
+therapy	O
+the	O
+child	O
+had	O
+previously	O
+received	O
+high-dose	O
+multiagent	O
+chemotherapy	O
+and	O
+rearrangement	O
+of	O
+the	O
+MLL	O
+gene	O
+was	O
+not	O
+demonstrated	O
+
+Heat	B-Adev
+stroke	I-Adev
+in	O
+schizophrenia	O
+during	O
+clozapine	O
+treatment	O
+rapid	O
+recognition	O
+and	O
+management	O
+
+The	O
+same	B-Adev
+symptoms	I-Adev
+recurred	O
+few	O
+days	O
+after	O
+taking	O
+nitrendipine	O
+
+The	O
+authors	O
+report	O
+two	O
+cases	O
+of	O
+acute	B-Adev
+dystonic	I-Adev
+reactions	I-Adev
+(ADRs)	I-Adev
+as	O
+a	O
+side	O
+effect	O
+of	O
+lamivudine	O
+
+Isoniazid-induced	O
+anaphylaxis	B-Adev
+	O
+
+Histopathology	O
+of	O
+the	O
+thyroid	O
+in	O
+amiodarone-induced	O
+hypothyroidism	B-Adev
+	O
+
+Deepening	B-Adev
+of	I-Adev
+lid	I-Adev
+sulcus	I-Adev
+from	O
+topical	O
+bimatoprost	O
+therapy	O
+
+Gastro-oesophageal	B-Adev
+reflux	I-Adev
+associated	O
+with	O
+nifedipine	O
+
+CASE	O
+SUMMARY	O
+A	O
+68-year-old	O
+woman	O
+developed	O
+a	B-Adev
+dry	I-Adev
+irritating	I-Adev
+cough	I-Adev
+within	O
+one	O
+month	O
+of	O
+starting	O
+quinapril	O
+therapy	O
+for	O
+the	O
+treatment	O
+of	O
+essential	O
+hypertension	O
+
+Sertraline-induced	O
+rhabdomyolysis	B-Adev
+in	O
+an	O
+elderly	O
+patient	O
+with	O
+dementia	O
+and	O
+comorbidities	O
+
+After	O
+the	O
+dose	O
+of	O
+methylprednisolone	O
+was	O
+reduced	O
+from	O
+40	O
+mg	O
+to	O
+20	O
+mg	O
+i.v	O
+q6h	O
+and	O
+shifted	O
+to	O
+other	O
+anti-asthma	O
+treatment	O
+by	O
+procaterol	O
+metered	O
+dose	O
+inhaler	O
+via	O
+spacer	O
+the	O
+psychotic	O
+reaction	O
+disappeared	O
+a	O
+few	O
+hours	O
+later	O
+
+Sirolimus	O
+works	O
+differently	O
+from	O
+the	O
+immunosuppressants	O
+currently	O
+available	O
+and	O
+except	O
+for	O
+increased	B-Adev
+lipid	I-Adev
+levels	I-Adev
+	O
+the	O
+adverse	O
+reaction	O
+profile	O
+of	O
+sirolimus	O
+does	O
+not	O
+appear	O
+to	O
+overlap	O
+to	O
+any	O
+great	O
+extent	O
+with	O
+that	O
+associated	O
+with	O
+cyclosporine	O
+or	O
+tacrolimus	O
+
+Patient	O
+was	O
+on	O
+warfarin	O
+for	O
+a	O
+prior	O
+deep	O
+venous	O
+thrombosis	O
+
+Quetiapine-induced	O
+myoclonus	B-Adev
+	O
+
+Dyspnea	B-Adev
+possibly	O
+associated	O
+with	O
+controlled-release	O
+morphine	O
+sulfate	O
+tablets	O
+
+The	O
+incidence	O
+of	O
+ARE	B-Adev
+suddenly	O
+exceeded	O
+10%	O
+of	O
+the	O
+patients	O
+treated	O
+by	O
+melarsoprol	O
+during	O
+August	O
+1992	O
+and	O
+September	O
+1993	O
+
+A	O
+patient	O
+with	O
+disseminated	O
+herpes	O
+zoster	O
+developed	O
+a	O
+syndrome	B-Adev
+of	I-Adev
+inappropriate	I-Adev
+antidiuretic	I-Adev
+hormone	I-Adev
+and	I-Adev
+profound	I-Adev
+hyponatremia	I-Adev
+secondary	O
+to	O
+the	O
+administration	O
+of	O
+adenine	O
+arabinoside	O
+
+One	O
+patient	O
+with	O
+systemic	O
+lupus	O
+erythematosus	O
+developed	O
+erythema	B-Adev
+multiforme	I-Adev
+after	O
+taking	O
+griseofulvin	O
+
+We	O
+report	O
+a	O
+rare	O
+case	O
+of	O
+colonic	B-Adev
+mucosal	I-Adev
+necrosis	I-Adev
+following	O
+Kalimate	O
+(calcium	O
+polystryrene	O
+sulfonate)	O
+an	O
+analogue	O
+of	O
+Kayexalate	O
+without	O
+sorbitol	O
+in	O
+a	O
+34-yr-old	O
+man	O
+
+Bilateral	B-Adev
+anterior	I-Adev
+uveitis	I-Adev
+associated	O
+with	O
+clomiphene	O
+citrate	O
+
+Progressive	B-Adev
+anemia	I-Adev
+following	O
+combination	O
+therapy	O
+with	O
+interferon-alpha	O
+and	O
+interleukin-2	O
+in	O
+a	O
+patient	O
+with	O
+metastatic	O
+renal	O
+cell	O
+carcinoma	O
+
+Metoclopramide-induced	O
+parkinsonism	B-Adev
+	O
+
+A	O
+12	O
+year	O
+old	O
+patient	O
+with	O
+atrial	O
+flutter	O
+is	O
+presented	O
+in	O
+whom	O
+intravenous	O
+adenosine	O
+was	O
+followed	O
+by	O
+acceleration	B-Adev
+of	I-Adev
+the	I-Adev
+heart	I-Adev
+rate	I-Adev
+to	I-Adev
+a	I-Adev
+potentially	I-Adev
+dangerous	I-Adev
+arrhythmia	I-Adev
+	O
+
+Similar	O
+to	O
+reports	O
+in	O
+patients	O
+receiving	O
+gefitinib	O
+those	O
+with	O
+pathologic	O
+findings	O
+of	O
+UIP	O
+on	O
+resected	O
+lung	O
+specimens	O
+or	O
+known	O
+pulmonary	O
+fibrosis	O
+may	O
+be	O
+at	O
+particular	O
+risk	O
+for	O
+erlotinib	B-Adev
+pulmonary	I-Adev
+toxicity	I-Adev
+
+Eleven	O
+days	O
+after	O
+increase	O
+of	O
+the	O
+trimipramine	O
+dosage	O
+to	O
+100	O
+mg/d	O
+she	O
+was	O
+hospitalized	O
+because	O
+of	O
+seizures	B-Adev
+suggesting	I-Adev
+a	I-Adev
+secondary	I-Adev
+generalized	I-Adev
+grand-mal	I-Adev
+episode	I-Adev
+	O
+
+AIM	O
+To	O
+report	O
+a	O
+patient	O
+with	O
+diabetic	O
+rubeosis	O
+who	O
+suffered	O
+from	O
+acute	B-Adev
+retinal	I-Adev
+ischemic	I-Adev
+change	I-Adev
+and	I-Adev
+stroke	I-Adev
+after	O
+intravitreal	O
+injection	O
+of	O
+bevacizumab	O
+
+Stevens-Johnson	B-Adev
+syndrome	I-Adev
+caused	O
+by	O
+the	O
+antiretroviral	O
+drug	O
+nevirapine	O
+
+From	O
+these	O
+data	O
+acute	B-Adev
+generalized	I-Adev
+dystonia	I-Adev
+with	I-Adev
+brainstem	I-Adev
+and	I-Adev
+thalamic	I-Adev
+lesions	I-Adev
+may	O
+occur	O
+in	O
+WD	O
+patients	O
+after	O
+an	O
+initial	O
+d-penicillamine	O
+therapy	O
+
+Although	O
+this	O
+combination	O
+agent	O
+has	O
+been	O
+associated	O
+with	O
+a	O
+hypersensitivity	O
+syndrome	O
+involving	O
+cutaneous	O
+skin	O
+eruptions	O
+pediatric	O
+cases	O
+of	O
+TMP-SMX-induced	O
+hepatotoxicity	B-Adev
+are	O
+rare	O
+
+Drug	O
+resistant	O
+tuberculosis	O
+requires	O
+more	O
+complex	O
+and	O
+longer	O
+treatment	O
+with	O
+alternative	O
+substances	O
+
+Intracranial	B-Adev
+haemorrhage	I-Adev
+from	I-Adev
+a	I-Adev
+meningioma	I-Adev
+in	O
+a	O
+patient	O
+receiving	O
+aspirin	O
+prophylaxis	O
+a	O
+case	O
+report	O
+
+The	O
+objective	O
+of	O
+this	O
+report	O
+is	O
+to	O
+describe	O
+a	O
+case	O
+of	O
+fixed	B-Adev
+drug	I-Adev
+eruption	I-Adev
+that	O
+occurred	O
+during	O
+omeprazole	O
+treatment	O
+
+Case	O
+2	O
+A	O
+43-year-old	O
+male	O
+alcoholic	O
+remained	O
+completely	O
+abstinent	O
+with	O
+cyanamide	O
+treatment	O
+for	O
+5	O
+years	O
+and	O
+complained	O
+of	O
+general	B-Adev
+fatigue	I-Adev
+	O
+
+Delayed	B-Adev
+hypersensitivity	I-Adev
+to	O
+flurbiprofen	O
+
+Propafenone-induced	O
+ataxia	B-Adev
+	O
+report	O
+of	O
+three	O
+cases	O
+
+Delavirdine	O
+and	O
+efavirenz	O
+(but	O
+not	O
+nevirapine)	O
+also	O
+were	O
+strong	O
+inhibitors	O
+of	O
+CYP3A	O
+consistent	O
+with	O
+clinical	B-Adev
+hazards	I-Adev
+of	O
+initial	O
+cotreatment	O
+with	O
+either	O
+of	O
+these	O
+drugs	O
+and	O
+substrates	O
+of	O
+CYP3A	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+UFT-induced	O
+scleroderma-like	B-Adev
+reaction	I-Adev
+	O
+
+Can	O
+roxithromycin	O
+and	O
+betamethasone	O
+induce	O
+acute	B-Adev
+pancreatitis	I-Adev
+?	O
+A	O
+case	O
+report	O
+
+Up	O
+to	O
+four	O
+percent	O
+of	O
+patients	O
+treated	O
+with	O
+imatinib	O
+may	O
+develop	O
+hepatotoxicity	B-Adev
+	O
+which	O
+usually	O
+resolves	O
+with	O
+discontinuation	O
+of	O
+the	O
+drug	O
+
+Schneiderian	B-Adev
+first-rank	I-Adev
+symptoms	I-Adev
+associated	O
+with	O
+fluvoxamine	O
+treatment	O
+a	O
+case	O
+report	O
+
+Peripheral	B-Adev
+and	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+was	O
+usually	O
+seen	O
+after	O
+several	O
+months	O
+of	O
+linezolid	O
+therapy	O
+(median	O
+5	O
+mo)	O
+lactic	O
+acidosis	O
+after	O
+several	O
+weeks	O
+(median	O
+6	O
+wks)	O
+and	O
+serotonin	O
+syndrome	O
+after	O
+several	O
+days	O
+(median	O
+4	O
+days)	O
+
+Muzolimine-induced	O
+severe	O
+neuromyeloencephalopathy	B-Adev
+	O
+report	O
+of	O
+seven	O
+cases	O
+
+We	O
+conclude	O
+peripheral	B-Adev
+neuropathy	I-Adev
+with	O
+5-FU	O
+is	O
+rare	O
+
+Additionally	O
+danazol	O
+produces	O
+hepatocellular	B-Adev
+damage	I-Adev
+in	O
+approximately	O
+10%	O
+of	O
+women	O
+
+CONCLUSIONS	O
+We	O
+report	O
+a	O
+typical	B-Adev
+symptoms	I-Adev
+of	I-Adev
+Charles-Bonnet	I-Adev
+syndrome	I-Adev
+(CBS)	I-Adev
+in	O
+patients	O
+with	O
+severe	O
+AMD	O
+after	O
+intravitreal	O
+Avastin-injections	O
+
+Proconvulsive	B-Adev
+tendency	I-Adev
+of	O
+imipenem/cilastatin	O
+is	O
+one	O
+of	O
+its	O
+well-known	O
+side	O
+effects	O
+
+A	O
+49-year-old	O
+man	O
+with	O
+Crohn's	O
+disease	O
+treated	O
+with	O
+prednisone	O
+and	O
+mesalamine	O
+(5-ASA)	O
+developed	O
+worsening	B-Adev
+respiratory	I-Adev
+distress	I-Adev
+and	I-Adev
+fever	I-Adev
+
+OBJECTIVE	O
+This	O
+case	O
+report	O
+outlines	O
+a	B-Adev
+significant	I-Adev
+type	I-Adev
+of	I-Adev
+morbidity	I-Adev
+due	O
+to	O
+continued	O
+use	O
+of	O
+gabapentin	O
+during	O
+an	O
+episode	O
+of	O
+acute	O
+renal	O
+failure	O
+
+Acute	B-Adev
+delirium	I-Adev
+resulting	O
+from	O
+levofloxacin	O
+therapy	O
+is	O
+an	O
+exceedingly	O
+rare	O
+complication	O
+that	O
+has	O
+been	O
+thought	O
+to	O
+occur	O
+more	O
+commonly	O
+in	O
+elderly	O
+patients	O
+
+Selective	O
+estrogen	O
+receptor	O
+modulator	O
+raloxifene-associated	O
+aggravation	B-Adev
+of	I-Adev
+nonalcoholic	I-Adev
+steatohepatitis	I-Adev
+	O
+
+The	O
+day	O
+after	O
+methotrexate	O
+administration	O
+the	O
+patient	O
+complained	O
+of	O
+severe	B-Adev
+back	I-Adev
+pain	I-Adev
+and	I-Adev
+urinary	I-Adev
+retention	I-Adev
+	O
+
+Pulmonary	B-Adev
+toxicity	I-Adev
+secondary	O
+to	O
+procarbazine	O
+
+In	O
+keeping	O
+with	O
+findings	O
+in	O
+the	O
+literature	O
+the	O
+aortic	B-Adev
+wall	I-Adev
+in	I-Adev
+this	I-Adev
+case	I-Adev
+was	I-Adev
+damaged	I-Adev
+by	O
+secondary	O
+changes	O
+following	O
+irradiation	O
+and	O
+Bleomycin	O
+treatment	O
+
+It	O
+has	O
+been	O
+suggested	O
+that	O
+PPE	B-Adev
+caused	O
+by	O
+cytarabine	O
+does	O
+not	O
+recur	O
+with	O
+subsequent	O
+cytarabine	O
+re-challenge	O
+
+CONCLUSIONS	O
+The	O
+value	O
+of	O
+multihormonal	O
+therapy	O
+in	O
+breast	O
+carcinoma	O
+is	O
+not	O
+established	O
+and	O
+the	O
+addition	O
+of	O
+progestogens	O
+to	O
+tamoxifen	O
+may	O
+not	O
+reduce	O
+of	O
+developing	O
+[['endometrial	B-Adev
+lesions']	I-Adev
+['carcinoma']]	I-Adev
+dometrial	O
+lesions	O
+including	O
+carcinoma	O
+
+Inappropriate	B-Adev
+antidiuretic	I-Adev
+hormone	I-Adev
+following	O
+adenine	O
+arabinoside	O
+administration	O
+
+Ampicillin-associated	O
+seizures	B-Adev
+	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+fibrosing	B-Adev
+alveolitis	I-Adev
+	O
+diagnosed	O
+by	O
+lung	O
+biopsy	O
+in	O
+a	O
+patient	O
+receiving	O
+amiodarone	O
+which	O
+responded	O
+to	O
+corticosteroid	O
+therapy	O
+
+Furosemide-associated	O
+fever	B-Adev
+	O
+
+Thymic	B-Adev
+enlargement	I-Adev
+in	O
+a	O
+patient	O
+with	O
+juvenile	O
+idiopathic	O
+arthritis	O
+during	O
+etanercept	O
+therapy	O
+
+Fatal	O
+methylene	O
+blue	O
+associated	O
+serotonin	B-Adev
+toxicity	I-Adev
+	O
+
+Mannitol-induced	O
+ARF	B-Adev
+responds	O
+promptly	O
+to	O
+hemodialysis	O
+with	O
+rapid	O
+resolution	O
+of	O
+anuria	O
+and	O
+recovery	O
+of	O
+renal	O
+failure	O
+
+We	O
+report	O
+a	O
+rare	O
+case	O
+of	O
+recurrent	B-Adev
+(stuttering)	I-Adev
+priapism	I-Adev
+in	O
+a	O
+patient	O
+with	O
+protein	O
+C	O
+deficiency	O
+while	O
+maintained	O
+on	O
+Warfarin	O
+therapy	O
+
+Angioedema	B-Adev
+and	I-Adev
+maculopapular	I-Adev
+eruptions	I-Adev
+associated	O
+with	O
+carbamazepine	O
+administration	O
+
+Mental	B-Adev
+nerve	I-Adev
+neuropathy	I-Adev
+as	O
+a	O
+result	O
+of	O
+hepatitis	O
+B	O
+vaccination	O
+
+We	O
+describe	O
+a	O
+premenopausal	O
+woman	O
+who	O
+while	O
+having	O
+tamoxifen	O
+due	O
+to	O
+a	O
+diagnosis	O
+of	O
+in	O
+situ	O
+ductal	O
+carcinoma	O
+developed	O
+endometriosis	B-Adev
+requiring	O
+surgery	O
+
+Disseminated	B-Adev
+cellulitic	I-Adev
+cryptococcosis	I-Adev
+in	O
+the	O
+setting	O
+of	O
+prednisone	O
+monotherapy	O
+for	O
+pemphigus	O
+vulgaris	O
+
+We	O
+describe	O
+a	O
+63	O
+year	O
+old	O
+woman	O
+with	O
+a	O
+suppurative	O
+mediastinitis	O
+treated	O
+with	O
+continuous	O
+PI	O
+irrigation	O
+who	O
+developed	O
+an	O
+acute	B-Adev
+oliguric	I-Adev
+renal	I-Adev
+failure	I-Adev
+	O
+
+A	O
+young	O
+woman	O
+with	O
+epilepsy	O
+had	O
+tonic-clonic	B-Adev
+seizures	I-Adev
+during	O
+antineoplastic	O
+therapy	O
+with	O
+adriamycin	O
+and	O
+cisplatin	O
+
+CONCLUSIONS	O
+This	O
+patient's	O
+rhabdomyolysis	B-Adev
+was	O
+probably	O
+induced	O
+by	O
+sertraline	O
+therapy	O
+
+Nephrotic	B-Adev
+syndrome	I-Adev
+in	O
+a	O
+multiple	O
+sclerosis	O
+patient	O
+treated	O
+with	O
+interferon	O
+beta	O
+1a	O
+
+In	O
+our	O
+patient	O
+DIAN	B-Adev
+possibly	O
+was	O
+related	O
+to	O
+cefuroxime	O
+but	O
+the	O
+patient	O
+did	O
+not	O
+experience	O
+associated	O
+allergic	O
+symptoms	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+nonatopic	O
+17-year-old	O
+girl	O
+with	O
+bronchial	O
+asthma	O
+and	O
+aspirin	O
+intolerance	O
+who	O
+developed	O
+a	B-Adev
+dramatic	I-Adev
+anaphylactic	I-Adev
+reaction	I-Adev
+to	O
+oral	O
+prednisone	O
+
+CASE	O
+SUMMARY	O
+A	O
+10-year-old	O
+white	O
+girl	O
+with	O
+bilateral	O
+optic	O
+glioma	O
+developed	O
+a	O
+hypersensitivity	B-Adev
+reaction	I-Adev
+to	O
+carboplatin	O
+after	O
+nine	O
+courses	O
+
+Liver	B-Adev
+function	I-Adev
+should	I-Adev
+be	I-Adev
+carefully	I-Adev
+monitored	I-Adev
+when	O
+rifampicin	O
+and	O
+lopinavir/ritonavir	O
+are	O
+combined	O
+in	O
+patients	O
+
+We	O
+report	O
+three	O
+patients	O
+all	O
+of	O
+whom	O
+had	O
+preexisting	O
+diabetic	O
+dyslipidemia	O
+who	O
+showed	O
+a	O
+profound	O
+reduction	O
+in	O
+plasma	O
+HDL	O
+cholesterol	O
+and	O
+apolipoprotein	O
+AI	O
+levels	O
+soon	O
+after	O
+the	O
+initiation	O
+of	O
+rosiglitazone	O
+therapy	O
+
+This	O
+finding	O
+suggests	O
+that	O
+fluvoxamine	O
+can	O
+precipitate	O
+Schneiderian	B-Adev
+first-rank	I-Adev
+symptoms	I-Adev
+in	O
+some	O
+susceptible	O
+patients	O
+
+Warfarin-associated	O
+thoracic	B-Adev
+aortic	I-Adev
+dissection	I-Adev
+in	O
+an	O
+elderly	O
+woman	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+an	O
+adverse	O
+effect	O
+of	O
+fetal	B-Adev
+renal	I-Adev
+circulation	I-Adev
+by	O
+maternal	O
+ingestion	O
+of	O
+nimesulide	O
+
+Diarrhea-associated	B-Adev
+over-anticoagulation	I-Adev
+in	O
+a	O
+patient	O
+taking	O
+warfarin	O
+therapeutic	O
+role	O
+of	O
+cholestyramine	O
+
+A	O
+72-year-old	O
+white	O
+man	O
+suddenly	O
+developed	O
+combative	B-Adev
+behavior	I-Adev
+refused	I-Adev
+to	I-Adev
+leave	I-Adev
+his	I-Adev
+room	I-Adev
+stopped	I-Adev
+eating	I-Adev
+and	I-Adev
+began	I-Adev
+falling	I-Adev
+to	I-Adev
+the	I-Adev
+floor	I-Adev
+6	O
+weeks	O
+after	O
+being	O
+given	O
+ticlopidine	O
+
+The	O
+case	O
+history	O
+confirms	O
+that	O
+gold	O
+treatment	O
+even	O
+in	O
+the	O
+same	O
+patient	O
+can	O
+give	O
+rise	O
+to	O
+a	O
+wide	B-Adev
+range	I-Adev
+of	I-Adev
+skin	I-Adev
+disturbances	I-Adev
+which	I-Adev
+in	I-Adev
+many	I-Adev
+cases	I-Adev
+do	I-Adev
+not	I-Adev
+break	I-Adev
+out	I-Adev
+until	I-Adev
+long	I-Adev
+after	I-Adev
+the	I-Adev
+drug	I-Adev
+has	I-Adev
+been	I-Adev
+withdrawn	I-Adev
+	O
+
+Lithium	B-Adev
+neurotoxicity	I-Adev
+should	O
+be	O
+considered	O
+in	O
+Creutzfeldt-Jakob	O
+disease	O
+differential	O
+diagnosis	O
+serial	O
+electroencephalograms	O
+being	O
+the	O
+most	O
+valuable	O
+
+The	O
+authors	O
+describe	O
+a	O
+case	O
+of	O
+neuroleptic	B-Adev
+malignant	I-Adev
+syndrome	I-Adev
+that	O
+occurred	O
+in	O
+a	O
+patient	O
+on	O
+amitriptyline	O
+and	O
+lithium	O
+carbonate	O
+
+The	O
+findings	O
+were	O
+judged	O
+to	O
+be	O
+consistent	O
+with	O
+soft-tissue	B-Adev
+injury	I-Adev
+associated	O
+with	O
+intravenous	O
+administration	O
+of	O
+phenytoin	O
+also	O
+termed	O
+purple	O
+glove	O
+syndrome	O
+
+However	O
+as	O
+illustrated	O
+by	O
+these	O
+and	O
+other	O
+cases	O
+reported	O
+to	O
+date	O
+the	O
+onset	O
+of	O
+troglitazone-induced	O
+liver	B-Adev
+injury	I-Adev
+is	I-Adev
+insidious	I-Adev
+and	I-Adev
+temporally	I-Adev
+variable	I-Adev
+	O
+
+Soon	O
+after	O
+its	O
+introduction	O
+in	O
+1952	O
+chlorpromazine	O
+was	O
+noted	O
+to	O
+induce	O
+symptoms	B-Adev
+resembling	I-Adev
+Parkinson's	I-Adev
+disease	I-Adev
+	O
+
+Erythromycin	O
+is	O
+a	O
+macrolide	O
+antibiotic	O
+that	O
+may	O
+i	O
+ncrease	B-Adev
+the	I-Adev
+risk	I-Adev
+of	I-Adev
+lovastatin-induced	I-Adev
+rhabdomyolysis	I-Adev
+	O
+
+A	O
+23-year-old	O
+white	O
+male	O
+patient	O
+was	O
+originally	O
+admitted	O
+to	O
+receive	O
+intravenous	O
+chemotherapy	O
+for	O
+acute	O
+myelogenous	O
+leukemia	O
+
+We	O
+present	O
+two	O
+children	O
+with	O
+acute	O
+lymphocytic	O
+leukemia	O
+who	O
+developed	O
+leukoencephalopathy	B-Adev
+following	O
+administration	O
+of	O
+a	O
+combination	O
+of	O
+intravenous	O
+ara	O
+=	O
+C	O
+and	O
+methotrexate	O
+during	O
+the	O
+consolidation	O
+phase	O
+of	O
+chemotherapy	O
+
+Lethal	O
+anuria	B-Adev
+complicating	O
+high	O
+dose	O
+ifosfamide	O
+chemotherapy	O
+in	O
+a	O
+breast	O
+cancer	O
+patient	O
+with	O
+an	O
+impaired	O
+renal	O
+function	O
+
+CONCLUSIONS	O
+Low	O
+dosages	O
+of	O
+quinacrine	O
+used	O
+for	O
+malaria	O
+prophylaxis	O
+can	O
+be	O
+associated	O
+with	O
+a	B-Adev
+delayed	I-Adev
+severe	I-Adev
+maculopathy	I-Adev
+indistinguishable	O
+from	O
+chloroquine	O
+maculopathy	O
+in	O
+certain	O
+patients	O
+
+CONCLUSIONS	O
+Low	O
+dosages	O
+of	O
+quinacrine	O
+used	O
+for	O
+malaria	O
+prophylaxis	O
+can	O
+be	O
+associated	O
+with	O
+a	O
+delayed	O
+severe	O
+maculopathy	O
+indistinguishable	O
+from	O
+chloroquine	B-Adev
+maculopathy	I-Adev
+in	O
+certain	O
+patients	O
+
+When	O
+pilsicainide	O
+is	O
+prescribed	O
+in	O
+patients	O
+with	O
+coronary	O
+artery	O
+disease	O
+or	O
+renal	O
+dysfunction	O
+close	O
+attention	O
+must	O
+be	O
+paid	O
+to	O
+avoid	O
+life-threatening	B-Adev
+arrhythmias	I-Adev
+due	O
+to	O
+high	O
+plasma	O
+concentrations	O
+of	O
+the	O
+drug	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+severe	B-Adev
+aplastic	I-Adev
+anemia	I-Adev
+(AA)	I-Adev
+that	O
+was	O
+probably	O
+induced	O
+by	O
+lenalidomide	O
+
+We	O
+present	O
+a	O
+case	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+typhoid	O
+fever	O
+who	O
+experienced	O
+a	O
+hypersensitivity	B-Adev
+reaction	I-Adev
+subsequent	O
+to	O
+the	O
+infusion	O
+of	O
+chloramphenicol	O
+sodium	O
+succinate	O
+
+This	O
+confirmed	O
+the	O
+history	O
+of	O
+captopril-related	O
+asthma	B-Adev
+	O
+
+Four	O
+cases	O
+of	O
+adverse	B-Adev
+experiences	I-Adev
+with	O
+clonidine	O
+are	O
+described	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+reversible	B-Adev
+nonthrombocytopenic	I-Adev
+palpable	I-Adev
+purpura	I-Adev
+associated	O
+with	O
+metoclopramide	O
+
+Three	O
+patients	O
+received	O
+respectively	O
+190	O
+mg	O
+175	O
+mg	O
+and	O
+196	O
+mg	O
+of	O
+methotrexate	O
+and	O
+developed	O
+bilateral	B-Adev
+pulmonary	I-Adev
+infiltrates	I-Adev
+without	I-Adev
+evidence	I-Adev
+of	I-Adev
+peripheral	I-Adev
+blood	I-Adev
+eosinophilia	I-Adev
+	O
+
+Clinicians	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+possibility	O
+that	O
+vinorelbine	O
+may	O
+cause	O
+SIADH	B-Adev
+and	I-Adev
+possibly	I-Adev
+hypokalemia	I-Adev
+	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+34-year-old	O
+man	O
+on	O
+carbamazepine	O
+for	O
+complex	O
+partial	O
+seizures	O
+who	O
+developed	O
+acute	B-Adev
+liver	I-Adev
+and	I-Adev
+renal	I-Adev
+failure	I-Adev
+on	O
+less	O
+than	O
+2.5	O
+grams	O
+a	O
+day	O
+of	O
+acetaminophen	O
+
+Fever	B-Adev
+and	I-Adev
+maculopapular	I-Adev
+rashes	I-Adev
+appeared	O
+at	O
+10	O
+days	O
+after	O
+phenytoin	O
+initiation	O
+and	O
+then	O
+the	O
+drug	O
+was	O
+discontinued	O
+
+We	O
+report	O
+AZA-induced	O
+drug	B-Adev
+eruption	I-Adev
+that	O
+developed	O
+in	O
+two	O
+cases	O
+of	O
+systemic	O
+scleroderma	O
+with	O
+polymyositis	O
+
+Safety	O
+aspects	O
+of	O
+a	O
+coumarin-troxerutin	O
+combination	O
+regarding	O
+liver	B-Adev
+function	I-Adev
+in	O
+a	O
+double-blind	O
+placebo-controlled	O
+study	O
+
+Vogt-Koyanagi-Harada	B-Adev
+disease	I-Adev
+occurring	O
+during	O
+interferon	O
+alpha	O
+therapy	O
+for	O
+chronic	O
+hepatitis	O
+C	O
+
+Glucose	O
+and	O
+insulin	O
+exert	O
+additive	B-Adev
+ocular	I-Adev
+and	I-Adev
+renal	I-Adev
+vasodilator	I-Adev
+effects	I-Adev
+on	O
+healthy	O
+humans	O
+
+Two	O
+patients	O
+with	O
+osteomyelitis	O
+who	O
+developed	O
+reversible	B-Adev
+cholestatic	I-Adev
+jaundice	I-Adev
+during	O
+treatment	O
+with	O
+oxacillin	O
+derivatives	O
+are	O
+described	O
+
+DATA	O
+SYNTHESIS	O
+A	O
+49-year-old	O
+man	O
+developed	O
+symptoms	O
+of	O
+severe	O
+psychosis	B-Adev
+concomitant	O
+with	O
+ciprofloxacin	O
+(250	O
+mg	O
+bid)	O
+treatment	O
+
+Beneficial	O
+effect	O
+of	O
+low-dose	O
+mianserin	O
+on	O
+fluvoxamine-induced	O
+akathisia	B-Adev
+in	O
+an	O
+obsessive-compulsive	O
+patient	O
+
+Beneficial	O
+effect	O
+of	O
+low-dose	O
+mianserin	O
+on	O
+fluvoxamine-induced	O
+akathisia	O
+in	O
+an	O
+obsessive-compulsive	O
+patient	O
+
+Potential	O
+causes	O
+of	O
+methamphetamine-related	O
+keratitis	B-Adev
+can	O
+be	O
+divided	O
+into	O
+four	O
+categories	O
+resulting	O
+from	O
+(a)	O
+direct	O
+pharmacologic	O
+and	O
+physical	O
+effects	O
+of	O
+methamphetamine	O
+(b)	O
+the	O
+toxic	O
+effects	O
+of	O
+diluting	O
+or	O
+"cutting"	O
+agents	O
+such	O
+as	O
+lidocaine	O
+and	O
+quinine	O
+(c)	O
+effects	O
+related	O
+to	O
+the	O
+route	O
+of	O
+drug	O
+administration	O
+(intravenous	O
+inhalation	O
+smoking)	O
+and	O
+(d)	O
+manufacture-related	O
+effects	O
+of	O
+exposure	O
+to	O
+unintentional	O
+caustic	O
+contaminants	O
+in	O
+the	O
+final	O
+product	O
+
+Pulmonary	B-Adev
+oedema	I-Adev
+after	O
+hexoprenaline	O
+administration	O
+in	O
+preterm	O
+labour	O
+
+Venlafaxine-associated	O
+seizures	B-Adev
+at	O
+therapeutic	O
+doses	O
+have	O
+not	O
+been	O
+reported	O
+in	O
+the	O
+literature	O
+
+Methotrexate-induced	O
+pneumonitis	B-Adev
+in	O
+patients	O
+with	O
+rheumatoid	O
+arthritis	O
+and	O
+psoriatic	O
+arthritis	O
+report	O
+of	O
+five	O
+cases	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+She	O
+was	O
+receiving	O
+phenytoin	O
+sodium	O
+300	O
+mg/day	O
+carbamazepine	O
+200	O
+mg	O
+four	O
+times	O
+daily	O
+had	O
+been	O
+discontinued	O
+four	O
+days	O
+before	O
+admission	O
+because	O
+of	O
+leukopenia	B-Adev
+	O
+
+Thoracoscopic	O
+biopsy	O
+to	O
+confirm	O
+metastasis	O
+revealed	O
+instead	O
+fibrotic	B-Adev
+lesions	I-Adev
+apparently	O
+attributable	O
+to	O
+bleomycin	O
+or	O
+cyclophosphamide	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+hemolytic-uremic	B-Adev
+syndrome	I-Adev
+that	O
+developed	O
+during	O
+the	O
+4th	O
+cycle	O
+of	O
+combination	O
+chemotherapy	O
+with	O
+oxaliplatin	O
+5-fluorouracil	O
+and	O
+leucovorin	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+lung	O
+cancer	O
+patient	O
+with	O
+bronquiloalveolar	O
+carcinoma	O
+(BAC)	O
+presenting	O
+with	O
+BOOP	O
+after	O
+chemotherapy	O
+with	O
+docetaxel	O
+and	O
+gemcitabine	O
+producing	B-Adev
+severe	I-Adev
+respiratory	I-Adev
+insufficiency	I-Adev
+and	I-Adev
+simulating	I-Adev
+a	I-Adev
+progression	I-Adev
+of	I-Adev
+the	I-Adev
+tumor	I-Adev
+	O
+
+Relapse	B-Adev
+in	I-Adev
+the	I-Adev
+external	I-Adev
+auditory	I-Adev
+canal	I-Adev
+of	I-Adev
+acute	I-Adev
+promyelocytic	I-Adev
+leukemia	I-Adev
+after	O
+treatment	O
+with	O
+all-trans	O
+retinoic	O
+acid	O
+
+Acute	B-Adev
+neutrophilic	I-Adev
+dermatosis	I-Adev
+induced	O
+by	O
+all-trans-retinoic	O
+acid	O
+treatment	O
+for	O
+acute	O
+promyelocytic	O
+leukemia	O
+
+Fluphenazine-induced	O
+neuroleptic	B-Adev
+malignant	I-Adev
+syndrome	I-Adev
+in	O
+a	O
+schizophrenic	O
+patient	O
+
+Biopsy-proven	O
+acute	B-Adev
+interstitial	I-Adev
+nephritis	I-Adev
+associated	O
+with	O
+the	O
+tyrosine	O
+kinase	O
+inhibitor	O
+sunitinib	O
+a	O
+class	O
+effect?	O
+
+We	O
+describe	O
+two	O
+women	O
+who	O
+developed	O
+HUS	B-Adev
+after	O
+MMC	O
+therapy	O
+and	O
+presented	O
+massive	O
+pulmonary	O
+bleeding	O
+
+Alternating	B-Adev
+sinus	I-Adev
+rhythm	I-Adev
+and	I-Adev
+intermittent	I-Adev
+sinoatrial	I-Adev
+(S-A)	I-Adev
+block	I-Adev
+was	O
+observed	O
+in	O
+a	O
+57-year-old	O
+woman	O
+under	O
+treatment	O
+for	O
+angina	O
+with	O
+80	O
+mg	O
+propranolol	O
+daily	O
+
+These	O
+case	O
+reports	O
+provide	O
+evidence	O
+that	O
+5-aminosalicylic	O
+acid	O
+may	O
+induce	O
+acute	B-Adev
+pancreatitis	I-Adev
+after	O
+long	O
+term	O
+treatment	O
+
+During	O
+that	O
+time	O
+he	O
+had	O
+also	O
+been	O
+taking	O
+amphetamine-dextroamphetamine	O
+(Adderall)	O
+on	O
+work	O
+days	O
+for	O
+his	O
+ADHD	O
+
+Therefore	O
+we	O
+diagnosed	O
+he	O
+r	B-Adev
+eruption	I-Adev
+as	I-Adev
+contact	I-Adev
+dermatitis	I-Adev
+due	O
+to	O
+sodium	O
+bisulfite	O
+
+Macular	B-Adev
+infarction	I-Adev
+after	O
+endophthalmitis	O
+treated	O
+with	O
+vitrectomy	O
+and	O
+intravitreal	O
+gentamicin	O
+
+Since	O
+tamoxifen	O
+therapy	O
+can	O
+induce	O
+endometrial	B-Adev
+disorders	I-Adev
+	O
+surveillance	O
+schemes	O
+of	O
+women	O
+taking	O
+tamoxifen	O
+have	O
+been	O
+recommended	O
+
+Warfarin-associated	O
+bleeding	B-Adev
+complication	I-Adev
+saved	I-Adev
+life	I-Adev
+	O
+
+METHODS/RESULTS	O
+This	O
+paper	O
+presents	O
+a	O
+new	O
+case	O
+of	O
+rifabutin	O
+uveitis	B-Adev
+and	O
+a	O
+review	O
+of	O
+the	O
+various	O
+published	O
+reports	O
+to	O
+date	O
+
+Acute	B-Adev
+abdomen	I-Adev
+due	I-Adev
+to	I-Adev
+endometriosis	I-Adev
+in	O
+a	O
+premenopausal	O
+woman	O
+taking	O
+tamoxifen	O
+
+DISCUSSION	O
+Methotrexate-induced	O
+papular	B-Adev
+eruption	I-Adev
+is	O
+rarely	O
+reported	O
+shortly	O
+after	O
+beginning	O
+methotrexate	O
+therapy	O
+in	O
+patients	O
+with	O
+acute	O
+exacerbation	O
+of	O
+collagen	O
+vascular	O
+diseases	O
+
+We	O
+describe	O
+3	O
+patients	O
+on	O
+concomitant	O
+amiodarone	O
+and	O
+warfarin	O
+who	O
+developed	O
+amiodarone-induced	B-Adev
+thyrotoxicosis	I-Adev
+heralded	O
+by	O
+a	O
+significant	O
+decrease	O
+in	O
+warfarin	O
+requirements	O
+
+We	O
+describe	O
+3	O
+patients	O
+on	O
+concomitant	O
+amiodarone	O
+and	O
+warfarin	O
+who	O
+developed	O
+amiodarone-induced	O
+thyrotoxicosis	B-Adev
+heralded	O
+by	O
+a	O
+significant	O
+decrease	O
+in	O
+warfarin	O
+requirements	O
+
+The	O
+aim	O
+of	O
+this	O
+post-hoc	O
+analysis	O
+of	O
+data	O
+from	O
+a	O
+Phase	O
+III	O
+clinical	O
+trial	O
+(VISTA	O
+NCT00298831)	O
+was	O
+to	O
+investigate	O
+the	O
+impact	O
+of	O
+antibiotics	O
+on	O
+recovery	O
+from	O
+rocuronium-induced	O
+NMB	B-Adev
+after	O
+administration	O
+of	O
+sugammadex	O
+for	O
+reversal	O
+and	O
+compared	O
+the	O
+neuromuscular	O
+recovery	O
+in	O
+patients	O
+who	O
+received	O
+antibiotics	O
+preoperatively	O
+with	O
+those	O
+who	O
+did	O
+not	O
+
+The	O
+aim	O
+of	O
+this	O
+post-hoc	O
+analysis	O
+of	O
+data	O
+from	O
+a	O
+Phase	O
+III	O
+clinical	O
+trial	O
+(VISTA	O
+NCT00298831)	O
+was	O
+to	O
+investigate	O
+the	O
+impact	O
+of	O
+antibiotics	O
+on	O
+recovery	O
+from	O
+rocuronium-induced	O
+NMB	O
+after	O
+administration	O
+of	O
+sugammadex	O
+for	O
+reversal	O
+and	O
+compared	O
+the	O
+neuromuscular	O
+recovery	O
+in	O
+patients	O
+who	O
+received	O
+antibiotics	O
+preoperatively	O
+with	O
+those	O
+who	O
+did	O
+not	O
+
+All	O
+patients	O
+had	O
+taken	O
+phenytoin	O
+for	O
+variable	O
+time	O
+periods	O
+(range	O
+16-80	O
+days	O
+mean	O
+40)	O
+and	O
+were	O
+on	O
+the	O
+medication	O
+when	O
+the	O
+skin	B-Adev
+lesions	I-Adev
+first	O
+appeared	O
+
+One	O
+should	O
+therefore	O
+be	O
+aware	O
+of	O
+possible	O
+extrapyramidal	B-Adev
+side	I-Adev
+effects	I-Adev
+with	O
+olanzapine	O
+that	O
+are	O
+reduced	O
+compared	O
+to	O
+classical	O
+neuroleptic	O
+drugs	O
+but	O
+not	O
+completely	O
+eliminated	O
+
+A	O
+patient	O
+who	O
+had	O
+been	O
+treated	O
+with	O
+large	O
+doses	O
+of	O
+thyroid	O
+hormone	O
+for	O
+several	O
+years	O
+developed	O
+features	O
+of	O
+secondary	B-Adev
+hypothyroidism	I-Adev
+after	O
+thyroid	O
+hormone	O
+withdrawal	O
+
+This	O
+article	O
+discusses	O
+the	O
+possibility	O
+that	O
+simultaneous	O
+use	O
+of	O
+valproic	O
+acid	O
+lamotrigine	O
+and	O
+phenytoin	O
+could	O
+give	O
+this	O
+combination	O
+of	O
+toxicities	B-Adev
+and	O
+that	O
+concurrent	O
+viral	O
+infection	O
+may	O
+increase	O
+this	O
+risk	O
+
+A	O
+second	O
+patient	O
+with	O
+a	O
+similar	O
+glucose	O
+tolerance	O
+test	O
+result	O
+showed	O
+postprandial	B-Adev
+hyperglycemia	I-Adev
+when	O
+treated	O
+similarly	O
+with	O
+betamethasone	O
+valerate	O
+cream	O
+0.1%	O
+
+Phenytoin-induced	O
+hypersensitivity	B-Adev
+reactions	I-Adev
+
+A	O
+54-year-old	O
+man	O
+developed	O
+TEN	B-Adev
+4	O
+weeks	O
+after	O
+beginning	O
+lamotrigine	O
+for	O
+complex	O
+partial	O
+seizures	O
+related	O
+to	O
+a	O
+glioblastoma	O
+multiforme	O
+brain	O
+tumor	O
+
+The	O
+occurrence	O
+of	O
+acute	B-Adev
+hepatitis	I-Adev
+is	O
+best	O
+known	O
+for	O
+ketoconazole	O
+
+Optic	B-Adev
+neuropathy	I-Adev
+developed	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+who	O
+had	O
+been	O
+receiving	O
+D-penicillamine	O
+for	O
+about	O
+1	O
+year	O
+
+Stupor	B-Adev
+and	O
+fast	O
+activity	O
+on	O
+electroencephalography	O
+in	O
+a	O
+child	O
+treated	O
+with	O
+valproate	O
+
+During	O
+her	O
+third	O
+cycle	O
+she	O
+again	O
+received	O
+cisplatin	O
+100	O
+mg/m2	O
+over	O
+30	O
+minutes	O
+and	O
+developed	O
+palmar	B-Adev
+pruritus	I-Adev
+urticaria	I-Adev
+and	I-Adev
+edema	I-Adev
+	O
+
+The	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+infectious	O
+mononucleosis	O
+treated	O
+with	O
+cephalexin	O
+who	O
+later	O
+showed	O
+a	O
+rash	B-Adev
+is	O
+presented	O
+and	O
+the	O
+previous	O
+literature	O
+is	O
+reviewed	O
+
+After	O
+1	O
+week	O
+of	O
+nefazodone	O
+therapy	O
+the	O
+patient	O
+experienced	O
+headache	B-Adev
+confusion	I-Adev
+and	I-Adev
+"gray	I-Adev
+areas"	I-Adev
+in	I-Adev
+her	I-Adev
+vision	I-Adev
+without	I-Adev
+abnormal	I-Adev
+ophthalmologic	I-Adev
+findings	I-Adev
+	O
+
+Nitrofurantoin-induced	O
+pulmonary	B-Adev
+toxicity	I-Adev
+during	O
+pregnancy	O
+a	O
+report	O
+of	O
+a	O
+case	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+Methylphenidate-associated	O
+enuresis	B-Adev
+in	O
+attention	O
+deficit	O
+hyperactivity	O
+disorder	O
+
+To	O
+our	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+case	O
+report	O
+that	O
+demonstrates	O
+the	O
+occurrence	O
+of	O
+fever	B-Adev
+with	O
+low-dose	O
+amifostine	O
+therapy	O
+without	O
+the	O
+manifestation	O
+of	O
+accompanying	O
+rash	O
+or	O
+hypotension	O
+
+Administration	O
+of	O
+excessive	O
+insulin	O
+induced	O
+hypoglycemia	B-Adev
+within	O
+4	O
+to	O
+8	O
+hours	O
+followed	O
+by	O
+rebound	O
+hyperglycemia	O
+
+In	O
+both	O
+cases	O
+symptoms	B-Adev
+of	I-Adev
+autonomic	I-Adev
+instability	I-Adev
+and	I-Adev
+severe	I-Adev
+agitation	I-Adev
+started	O
+within	O
+hours	O
+of	O
+initiation	O
+of	O
+cyclobenzaprine	O
+and	O
+fully	O
+resolved	O
+within	O
+3	O
+days	O
+after	O
+discontinuing	O
+the	O
+proserotoninergic	O
+drugs	O
+
+Secondary	B-Adev
+leukemia	I-Adev
+in	O
+a	O
+child	O
+with	O
+neuroblastoma	O
+while	O
+on	O
+oral	O
+etoposide	O
+what	O
+is	O
+the	O
+cause?	O
+
+Atorvastatin	O
+induced	O
+multiple	B-Adev
+organ	I-Adev
+failure	I-Adev
+	O
+
+While	O
+serotonin	B-Adev
+syndrome	I-Adev
+has	O
+become	O
+more	O
+frequent	O
+in	O
+an	O
+overdose	O
+situation	O
+and	O
+when	O
+an	O
+interacting	O
+drug	O
+is	O
+given	O
+the	O
+toxicity	O
+of	O
+SSIRs	O
+is	O
+less	O
+than	O
+that	O
+of	O
+most	O
+other	O
+psychiatric	O
+drugs	O
+
+A	O
+73-year-old	O
+woman	O
+with	O
+non-Hodgkin's	O
+lymphoma	O
+had	O
+two	B-Adev
+episodes	I-Adev
+of	I-Adev
+severe	I-Adev
+bilateral	I-Adev
+sensori-neural	I-Adev
+hearing	I-Adev
+loss	I-Adev
+after	O
+vincristine	O
+therapy	O
+
+Severe	B-Adev
+hemolytic	I-Adev
+uremic	I-Adev
+syndrome	I-Adev
+in	O
+an	O
+advanced	O
+ovarian	O
+cancer	O
+patient	O
+treated	O
+with	O
+carboplatin	O
+and	O
+gemcitabine	O
+
+Ulcerative	B-Adev
+proctitis	I-Adev
+in	I-Adev
+juvenile	I-Adev
+systemic	I-Adev
+lupus	I-Adev
+erythematosus	I-Adev
+after	O
+ibuprofen	O
+treatment	O
+
+Acute	B-Adev
+asthma	I-Adev
+associated	O
+with	O
+sustained-release	O
+verapamil	O
+
+The	O
+renal	B-Adev
+insufficiency	I-Adev
+of	O
+three	O
+patients	O
+and	O
+the	O
+timing	O
+of	O
+the	O
+seizures	O
+implicate	O
+accumulation	O
+of	O
+ofloxacin	O
+as	O
+a	O
+contributing	O
+factor	O
+
+Hemolytic	B-Adev
+uremic	I-Adev
+syndrome	I-Adev
+in	O
+a	O
+patient	O
+on	O
+cis-platinum	O
+vinblastine	O
+and	O
+bleomycin	O
+
+A	O
+previous	O
+review	O
+described	O
+data	O
+on	O
+15	O
+patients	O
+who	O
+experienced	O
+acute	B-Adev
+hemoglobinemia	I-Adev
+or	I-Adev
+hemoglobinuria	I-Adev
+following	O
+anti-D	O
+IGIV	O
+administration	O
+for	O
+ITP	O
+or	O
+secondary	O
+thrombocytopenia	O
+
+Amiodarone	O
+was	O
+discontinued	O
+and	O
+thyrotoxicosis	O
+gradually	O
+abated	O
+
+De	B-Adev
+novo	I-Adev
+absence	I-Adev
+status	I-Adev
+of	I-Adev
+late	I-Adev
+onset	I-Adev
+following	O
+withdrawal	O
+of	O
+lorazepam	O
+a	O
+case	O
+report	O
+
+Tenofovir-associated	O
+nephrotoxicity	B-Adev
+in	O
+two	O
+HIV-infected	O
+adolescent	O
+males	O
+
+Reports	O
+of	O
+colonic	B-Adev
+perforation	I-Adev
+as	O
+a	O
+result	O
+of	O
+the	O
+administration	O
+of	O
+calcium	O
+polystyrene	O
+sulfonate	O
+and	O
+sorbitol	O
+are	O
+rare	O
+
+Improved	O
+awareness	O
+of	O
+and	O
+further	O
+investigation	O
+into	O
+the	O
+neurotoxic	B-Adev
+effects	I-Adev
+of	O
+ofloxacin	O
+may	O
+enhance	O
+its	O
+safe	O
+use	O
+
+Atypical	B-Adev
+neuroleptic	I-Adev
+malignant	I-Adev
+syndrome	I-Adev
+associated	O
+with	O
+olanzapine	O
+
+OBJECTIVE	O
+The	O
+authors	O
+described	O
+a	O
+case	O
+of	O
+interferon-induced	O
+psychosis	B-Adev
+as	O
+a	O
+framework	O
+to	O
+review	O
+the	O
+literature	O
+and	O
+discuss	O
+the	O
+decision	O
+to	O
+pursue	O
+antiviral	O
+treatment	O
+in	O
+psychiatrically	O
+ill	O
+patients	O
+with	O
+hepatitis	O
+C	O
+
+We	O
+believe	O
+that	O
+methotrexate	O
+represents	O
+a	O
+relatively	O
+effective	O
+alternative	O
+to	O
+surgery	O
+in	O
+patients	O
+with	O
+early	O
+unruptured	O
+tubal	O
+pregnancy	O
+but	O
+suggest	O
+that	O
+it	O
+be	O
+used	O
+with	O
+caution	O
+in	O
+view	O
+of	O
+possible	O
+systemic	B-Adev
+toxicity	I-Adev
+	O
+
+After	O
+intravitreal	O
+injection	O
+of	O
+triamcinolone	O
+acetonide	O
+cataract	B-Adev
+may	O
+rapidly	O
+develop	O
+in	O
+eyes	O
+that	O
+have	O
+been	O
+intensively	O
+treated	O
+topically	O
+and	O
+systemically	O
+by	O
+corticosteroids	O
+for	O
+several	O
+years	O
+
+Acute	B-Adev
+endophthalmitis	I-Adev
+following	O
+intravitreal	O
+bevacizumab	O
+(Avastin)	O
+injection	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+bullous	B-Adev
+eruption	I-Adev
+one	O
+month	O
+after	O
+starting	O
+nicardipine	O
+and	O
+lercanidipine	O
+
+Pulmonary	B-Adev
+fibrosis	I-Adev
+associated	O
+with	O
+nabumetone	O
+
+The	O
+ability	O
+of	O
+tumor	O
+necrosis	O
+factor	O
+(TNF)-alpha	O
+inhibitors	O
+to	O
+impair	O
+pivotal	O
+pro-inflammatory	O
+host	O
+defenses	O
+may	O
+facilitate	O
+the	O
+development	O
+of	O
+disseminated	B-Adev
+cryptococcosis	I-Adev
+	O
+
+This	O
+was	O
+accepted	O
+as	O
+evidence	O
+for	O
+propranolol	O
+being	O
+the	O
+cause	O
+of	O
+this	O
+conduction	B-Adev
+disorder	I-Adev
+	O
+
+We	O
+report	O
+a	O
+third	O
+case	O
+of	O
+a	O
+6-week-old	O
+infant	O
+with	O
+Escherichia	O
+coli	O
+sepsis	O
+who	O
+received	O
+ampicillin	O
+and	O
+other	O
+antibiotics	O
+and	O
+subsequently	O
+developed	O
+TEN	B-Adev
+	O
+
+PURPOSE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+bilateral	B-Adev
+anterior	I-Adev
+uveitis	I-Adev
+associated	O
+with	O
+ovulation	O
+induction	O
+therapy	O
+using	O
+clomiphene	O
+citrate	O
+
+A	O
+57-year-old	O
+woman	O
+presented	O
+with	O
+a	O
+3-week	O
+history	O
+of	O
+dysphagia	B-Adev
+for	I-Adev
+solids	I-Adev
+	O
+6	O
+months	O
+after	O
+starting	O
+treatment	O
+with	O
+nifedipine	O
+
+Although	O
+combinations	O
+of	O
+belladonna	O
+ergotamine	O
+and	O
+phenobarbital	O
+have	O
+been	O
+used	O
+for	O
+medical	O
+treatment	O
+of	O
+menopausal	O
+symptoms	O
+since	O
+the	O
+1960s	O
+this	O
+is	O
+the	O
+first	O
+known	O
+case	O
+report	O
+of	O
+its	O
+association	O
+with	O
+anticonvulsant	B-Adev
+hypersensitivity	I-Adev
+syndrome	I-Adev
+	O
+
+Rifampin	O
+can	O
+be	O
+associated	O
+with	O
+severe	O
+adverse	O
+effects	O
+such	O
+as	O
+hepatitis	B-Adev
+acute	I-Adev
+renal	I-Adev
+failure	I-Adev
+hemolytic	I-Adev
+anemia	I-Adev
+and	I-Adev
+thrombocytopenia	I-Adev
+	O
+
+It	O
+is	O
+believed	O
+that	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+reversible	O
+azathioprine-induced	O
+cholestasis	B-Adev
+associated	O
+with	O
+histological	O
+evidence	O
+of	O
+bile	O
+duct	O
+injury	O
+
+We	O
+present	O
+a	O
+fatal	O
+case	O
+of	O
+subacute	O
+methanol	O
+toxicity	O
+with	O
+associated	O
+diffuse	B-Adev
+brain	I-Adev
+involvement	I-Adev
+including	I-Adev
+bilateral	I-Adev
+putaminal	I-Adev
+necrosis	I-Adev
+and	I-Adev
+cerebral	I-Adev
+edema	I-Adev
+with	I-Adev
+ventricular	I-Adev
+compression	I-Adev
+	O
+
+Patients	O
+with	O
+inoperable	O
+or	O
+metastatic	O
+colorectal	O
+cancer	O
+were	O
+randomized	O
+to	O
+receive	O
+monthly	O
+FU	O
+400	O
+mg/m2/day	O
+plus	O
+LV	O
+20	O
+mg/m2/day	O
+as	O
+intravenous	O
+push	O
+daily	O
+for	O
+five	O
+days	O
+or	O
+FU	O
+alone	O
+
+The	O
+present	O
+report	O
+suggests	O
+that	O
+clarithromycin	O
+coadministration	O
+induces	O
+increased	B-Adev
+plasma	I-Adev
+carbamazepine	I-Adev
+concentrations	I-Adev
+	O
+which	O
+may	O
+result	O
+in	O
+carbamazepine	O
+toxicity	O
+
+In	O
+this	O
+case	O
+interferon	O
+alpha	O
+induced	O
+polymyositis	B-Adev
+and	I-Adev
+cardiomyopathy	I-Adev
+is	O
+diagnosed	O
+in	O
+a	O
+33-yr-old	O
+male	O
+patient	O
+with	O
+history	O
+of	O
+chronic	O
+hepatitis	O
+B	O
+
+To	O
+describe	O
+the	O
+potential	O
+for	O
+interaction	O
+between	O
+opioids	O
+and	O
+serotonergic	O
+antidepressants	O
+leading	O
+to	O
+the	O
+development	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+(SS)	O
+mechanism	O
+of	O
+the	O
+interaction	O
+and	O
+the	O
+spectrum	O
+of	O
+SS	O
+in	O
+elderly	O
+residents	O
+of	O
+a	O
+long-term	O
+care	O
+facility	O
+
+Erythema	B-Adev
+multiforme	I-Adev
+bullosum	I-Adev
+due	O
+to	O
+rifampicin	O
+
+We	O
+describe	O
+a	O
+patient	O
+with	O
+acute	O
+leukemia	O
+who	O
+developed	O
+Horner's	B-Adev
+syndrome	I-Adev
+and	I-Adev
+a	I-Adev
+severe	I-Adev
+demyelinating	I-Adev
+peripheral	I-Adev
+neuropathy	I-Adev
+leading	I-Adev
+to	I-Adev
+death	I-Adev
+after	O
+receiving	O
+high-dose	O
+cytosine	O
+arabinoside	O
+
+This	O
+profile	O
+should	O
+trigger	O
+a	O
+"red	O
+flag"	O
+as	O
+to	O
+the	O
+possibility	O
+of	O
+phenobarbital	O
+behavioral	B-Adev
+side	I-Adev
+effects	I-Adev
+or	I-Adev
+exacerbation	I-Adev
+of	I-Adev
+preexisting	I-Adev
+maladaptive	I-Adev
+behaviors	I-Adev
+	O
+
+Retinal	B-Adev
+abnormalities	I-Adev
+including	I-Adev
+retinal	I-Adev
+hemorrhage	I-Adev
+and	I-Adev
+"cotton-wool"	I-Adev
+spots	I-Adev
+	O
+often	O
+occur	O
+within	O
+the	O
+first	O
+8	O
+weeks	O
+in	O
+the	O
+course	O
+of	O
+interferon	O
+therapy	O
+in	O
+patients	O
+with	O
+chronic	O
+hepatitis	O
+C	O
+
+Rapamycin/sirolimus-induced	O
+pneumonitis	B-Adev
+has	O
+been	O
+described	O
+previously	O
+in	O
+renal	O
+transplant	O
+recipients	O
+and	O
+this	O
+report	O
+describes	O
+a	O
+stable	O
+heart-lung	O
+transplant	O
+recipient	O
+who	O
+developed	O
+a	O
+pulmonary	O
+infiltrate	O
+that	O
+reversed	O
+after	O
+ceasing	O
+SR	O
+therapy	O
+
+IFNalpha-induced	O
+recurrence	B-Adev
+of	I-Adev
+Graves'	I-Adev
+disease	I-Adev
+ten	O
+years	O
+after	O
+thyroidectomy	O
+in	O
+chronic	O
+viral	O
+hepatitis	O
+C	O
+
+Risperidone	O
+withdrawal-related	O
+respiratory	B-Adev
+dyskinesia	I-Adev
+	O
+a	O
+case	O
+diagnosed	O
+by	O
+spirography	O
+and	O
+fibroscopy	O
+
+Paralytic	B-Adev
+ileus	I-Adev
+in	O
+patients	O
+undergoing	O
+bortezomib	O
+treatment	O
+has	O
+been	O
+reported	O
+although	O
+a	O
+definite	O
+attribution	O
+to	O
+bortezomib	O
+administration	O
+has	O
+not	O
+been	O
+established	O
+
+Severe	O
+serotonin	B-Adev
+syndrome	I-Adev
+induced	O
+by	O
+mirtazapine	O
+monotherapy	O
+
+Three	O
+days	O
+after	O
+starting	O
+fluconazole	O
+she	O
+developed	O
+polyuria	B-Adev
+and	I-Adev
+polydipsia	I-Adev
+and	I-Adev
+was	I-Adev
+found	I-Adev
+to	I-Adev
+have	I-Adev
+severe	I-Adev
+hyperglycemia	I-Adev
+which	I-Adev
+led	I-Adev
+to	I-Adev
+the	I-Adev
+diagnosis	I-Adev
+of	I-Adev
+Cushing	I-Adev
+syndrome	I-Adev
+	O
+
+Postoperative	O
+hypocalcemic	B-Adev
+tetany	I-Adev
+caused	O
+by	O
+fleet	O
+phospho-soda	O
+preparation	O
+in	O
+a	O
+patient	O
+taking	O
+alendronate	O
+sodium	O
+report	O
+of	O
+a	O
+case	O
+
+Observations	O
+in	O
+our	O
+patient	O
+suggest	O
+that	O
+the	O
+leukoencephalopathy	B-Adev
+that	O
+developed	O
+in	O
+previously	O
+reported	O
+patients	O
+who	O
+received	O
+5-fluorouracil	O
+and	O
+levamisole	O
+may	O
+have	O
+been	O
+caused	O
+at	O
+least	O
+partly	O
+by	O
+levamisole	O
+
+We	O
+describe	O
+the	O
+clinical	O
+response	O
+as	O
+determined	O
+by	O
+increases	O
+in	O
+total	O
+Hb	O
+and	O
+decreased	O
+transfusion	O
+needs	O
+in	O
+five	O
+patients	O
+with	O
+thalassemia	O
+intermedia	O
+treated	O
+with	O
+HU	O
+alone	O
+or	O
+in	O
+combination	O
+with	O
+SPB	O
+
+According	O
+to	O
+the	O
+Naranjo	O
+et	O
+al	O
+adverse-reaction	O
+probability	O
+scale	O
+enoxaparin	O
+was	O
+the	O
+probable	O
+cause	O
+of	O
+hepatotoxicity	B-Adev
+in	O
+this	O
+patient	O
+
+This	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+hepatolithiasis	B-Adev
+during	O
+octreotide	O
+therapy	O
+
+Treatment	O
+of	O
+amiodarone-induced	O
+thyrotoxicosis	B-Adev
+(AIT)	I-Adev
+with	O
+thionamide	O
+lithium	O
+or	O
+radioactive	O
+iodine	O
+is	O
+ineffective	O
+
+Treatment	O
+of	O
+amiodarone-induced	O
+thyrotoxicosis	O
+(AIT)	O
+with	O
+thionamide	O
+lithium	O
+or	O
+radioactive	O
+iodine	O
+is	O
+ineffective	O
+
+Six	O
+patients	O
+with	O
+no	O
+previous	O
+signs	O
+or	O
+symptoms	O
+suggestive	O
+of	O
+coronary	O
+artery	O
+disease	O
+developed	O
+acute	B-Adev
+coronary	I-Adev
+ischemia/infarction	I-Adev
+shortly	O
+after	O
+cis-diamine-dichloroplatinum	O
+II	O
+(cisplatin)	O
+-based	O
+chemotherapy	O
+
+RESULTS	O
+Replacing	O
+valproate	O
+with	O
+lamotrigine	O
+resulted	O
+in	O
+a	B-Adev
+decrease	I-Adev
+in	I-Adev
+serum	I-Adev
+testosterone	I-Adev
+concentrations	I-Adev
+in	O
+all	O
+3	O
+women	O
+
+A	O
+65-year-old	O
+woman	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+because	O
+of	O
+septic	O
+shock	O
+and	O
+acute	O
+renal	O
+failure	O
+had	O
+a	O
+small-bowel	B-Adev
+obstruction	I-Adev
+due	O
+to	O
+Amphojel	O
+concretions	O
+
+After	O
+the	O
+first	O
+oral	O
+dose	O
+of	O
+propranolol	O
+syncope	B-Adev
+developed	O
+together	O
+with	O
+atrioventricular	O
+block	O
+
+Sorafenib	O
+induced	O
+tumor	B-Adev
+lysis	I-Adev
+syndrome	I-Adev
+in	O
+an	O
+advanced	O
+hepatocellular	O
+carcinoma	O
+patient	O
+
+The	O
+symptoms	O
+did	O
+not	O
+recur	O
+during	O
+the	O
+36	O
+months	O
+of	O
+itraconazole	O
+treatment	O
+after	O
+discharge	O
+and	O
+it	O
+was	O
+concluded	O
+that	O
+ITCZ	O
+was	O
+effective	O
+for	O
+A	O
+flavus	O
+hypertrophic	O
+pachymeningitis	O
+
+A	O
+prospective	O
+randomized	O
+clinical	O
+trial	O
+was	O
+implemented	O
+to	O
+assess	O
+whether	O
+the	O
+concomitant	O
+or	O
+the	O
+sequential	O
+addition	O
+of	O
+tamoxifen	O
+to	O
+chemotherapy	O
+provides	O
+improved	O
+clinical	O
+benefit	O
+in	O
+the	O
+adjuvant	O
+treatment	O
+of	O
+breast	O
+cancer	O
+in	O
+postmenopausal	O
+patients	O
+
+Increased	B-Adev
+libido	I-Adev
+in	O
+a	O
+woman	O
+treated	O
+with	O
+fluvoxamine	O
+a	O
+case	O
+report	O
+
+In	O
+the	O
+following	O
+case	O
+report	O
+a	O
+patient	O
+developed	O
+acute	B-Adev
+interstitial	I-Adev
+nephritis	I-Adev
+with	I-Adev
+renal	I-Adev
+failure	I-Adev
+and	I-Adev
+exfoliative	I-Adev
+dermatitis	I-Adev
+following	O
+ampicillin	O
+therapy	O
+
+Severe	B-Adev
+symptoms	I-Adev
+associated	I-Adev
+with	I-Adev
+serotonin	I-Adev
+toxicity	I-Adev
+were	O
+shown	O
+to	O
+be	O
+uncommon	O
+in	O
+patients	O
+receiving	O
+linezolid	O
+and	O
+selected	O
+serotonin	O
+reuptake	O
+inhibitors	O
+
+We	O
+describe	O
+the	O
+side	B-Adev
+effects	I-Adev
+of	O
+5-FU	O
+in	O
+a	O
+colon	O
+cancer	O
+patient	O
+who	O
+suffered	O
+severe	O
+mucositis	O
+desquamating	O
+dermatitis	O
+prolonged	O
+myelosuppression	O
+and	O
+neurologic	O
+toxicity	O
+that	O
+required	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+
+There	O
+have	O
+been	O
+many	O
+reports	O
+of	O
+probable	O
+lithium-induced	O
+organic	B-Adev
+brain	I-Adev
+syndromes	I-Adev
+occurring	O
+when	O
+serum	O
+lithium	O
+levels	O
+are	O
+within	O
+or	O
+close	O
+to	O
+the	O
+therapeutic	O
+range	O
+
+The	O
+patient	O
+was	O
+enrolled	O
+in	O
+a	O
+weight-loss	O
+clinic	O
+and	O
+his	O
+diabetes	O
+medications	O
+were	O
+adjusted.Subsequently	O
+olanzapine	O
+was	O
+discontinued	O
+because	O
+of	O
+weight	B-Adev
+gain	I-Adev
+and	I-Adev
+uncontrolled	I-Adev
+diabetes	I-Adev
+	O
+
+While	O
+most	O
+physicians	O
+are	O
+aware	O
+of	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+and	I-Adev
+skin	I-Adev
+necrosis	I-Adev
+	O
+the	O
+association	O
+of	O
+heparin	O
+and	O
+hyperkalemia	O
+is	O
+less	O
+well	O
+recognized	O
+
+Gefitinib	O
+(IRESSA	O
+ZD1839)	O
+an	O
+epidermal	O
+growth	O
+factor	O
+receptor	O
+tyrosine	O
+kinase	O
+inhibitor	O
+has	O
+been	O
+approved	O
+in	O
+several	O
+countries	O
+for	O
+the	O
+treatment	O
+of	O
+advanced	O
+non-small-cell	O
+lung	O
+cancer	O
+
+The	O
+case	O
+of	O
+a	O
+4-year-old	O
+girl	O
+with	O
+valproate-induced	O
+stupor	B-Adev
+and	I-Adev
+electroencephalographic	I-Adev
+pattern	I-Adev
+of	I-Adev
+increased	I-Adev
+fast	I-Adev
+activity	I-Adev
+is	O
+reported	O
+
+Prior	O
+to	O
+surgery	O
+levodopa	O
+induced	O
+dyskinesia	O
+had	O
+improved	O
+(<	O
+or	O
+=	O
+50%)	O
+under	O
+treatment	O
+with	O
+amantadine	O
+(400	O
+mg/day	O
+po)	O
+in	O
+all	O
+three	O
+patients	O
+
+Foscarnet-induced	O
+severe	O
+hypomagnesemia	B-Adev
+and	I-Adev
+other	I-Adev
+electrolyte	I-Adev
+disorders	I-Adev
+	O
+
+A	O
+case	O
+is	O
+reported	O
+of	O
+a	O
+child	O
+with	O
+fatal	B-Adev
+pulmonary	I-Adev
+fibrosis	I-Adev
+following	O
+BCNU	O
+therapy	O
+
+A	O
+64-year-old	O
+man	O
+with	O
+schizophrenia	O
+developed	O
+myoclonic	B-Adev
+jerks	I-Adev
+when	O
+given	O
+higher	O
+doses	O
+of	O
+quetiapine	O
+
+The	O
+etiology	O
+of	O
+neurotoxicity	B-Adev
+in	O
+our	O
+two	O
+patients	O
+remains	O
+unclear	O
+however	O
+as	O
+CAP	O
+is	O
+rapidly	O
+metabolized	O
+to	O
+5-FU	O
+in	O
+patients	O
+with	O
+normal	O
+liver	O
+function	O
+it	O
+is	O
+likely	O
+that	O
+5-FU	O
+or	O
+its	O
+active	O
+metabolites	O
+(fluoro-beta-alanine)	O
+were	O
+contributing	O
+factors	O
+
+CONCLUSIONS	O
+Amantadine	O
+can	O
+cause	O
+reversible	B-Adev
+corneal	I-Adev
+edema	I-Adev
+but	O
+can	O
+irreversibly	O
+reduce	O
+the	O
+density	O
+of	O
+endothelial	O
+cells	O
+
+After	O
+gastric-outlet	B-Adev
+obstruction	I-Adev
+was	O
+recognized	O
+in	O
+several	O
+infants	O
+who	O
+received	O
+prostaglandin	O
+E1	O
+we	O
+studied	O
+the	O
+association	O
+between	O
+the	O
+drug	O
+and	O
+this	O
+complication	O
+
+A	O
+wide	O
+variety	O
+of	O
+adverse	B-Adev
+central	I-Adev
+nervous	I-Adev
+system	I-Adev
+effects	I-Adev
+have	O
+been	O
+reported	O
+in	O
+association	O
+with	O
+propafenone	O
+dizziness	O
+is	O
+the	O
+most	O
+common	O
+
+Iatrogenic	B-Adev
+Cushing	I-Adev
+syndrome	I-Adev
+has	O
+been	O
+reported	O
+in	O
+patients	O
+with	O
+CF	O
+treated	O
+concomitantly	O
+and	O
+for	O
+extended	O
+duration	O
+with	O
+inhaled	O
+corticosteroids	O
+and	O
+CYP3A4	O
+inhibitors	O
+
+Red	B-Adev
+blood	I-Adev
+cell	I-Adev
+anemia	I-Adev
+in	O
+a	O
+patient	O
+with	O
+pemphigus	O
+vulgaris	O
+induced	O
+by	O
+the	O
+use	O
+of	O
+mycophenolate	O
+mofetil	O
+and	O
+prednisone	O
+
+Induction	O
+of	O
+systemic	B-Adev
+lupus	I-Adev
+erythematosus	I-Adev
+by	O
+interferon-gamma	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+
+In	O
+this	O
+case	O
+unlike	O
+those	O
+previously	O
+reported	O
+hyponatremia	B-Adev
+recurred	O
+5	O
+months	O
+after	O
+switching	O
+from	O
+citalopram	O
+to	O
+mirtazapine	O
+which	O
+is	O
+believed	O
+to	O
+be	O
+a	O
+safe	O
+antidepressant	O
+
+This	O
+report	O
+describes	O
+a	O
+case	O
+of	O
+acute	B-Adev
+compromise	I-Adev
+of	I-Adev
+renal	I-Adev
+function	I-Adev
+associated	O
+with	O
+hypotension	O
+in	O
+a	O
+7-year-old	O
+boy	O
+treated	O
+with	O
+the	O
+ACE	O
+inhibitor	O
+lisinopril	O
+and	O
+the	O
+ARB	O
+losartan	O
+
+We	O
+report	O
+a	O
+male	O
+patient	O
+with	O
+advanced	O
+AIDS	O
+who	O
+developed	O
+hypercalcemia	B-Adev
+2	O
+weeks	O
+after	O
+institution	O
+of	O
+rhGH	O
+therapy	O
+
+RESULTS	O
+Both	O
+patients	O
+experienced	O
+a	O
+previously	O
+unreported	O
+side	O
+effect--	O
+falling	B-Adev
+backward	I-Adev
+--associated	O
+with	O
+bupropion	O
+use	O
+
+A	O
+second	O
+episode	O
+of	O
+jaundice	B-Adev
+followed	O
+the	O
+intravaginal	O
+administration	O
+of	O
+a	O
+mixture	O
+of	O
+furazolidone	O
+and	O
+nifuroxime	O
+
+Clinicians	O
+should	O
+be	O
+aware	O
+that	O
+an	B-Adev
+erythematous	I-Adev
+and	I-Adev
+exfoliative	I-Adev
+rash	I-Adev
+may	O
+be	O
+induced	O
+by	O
+temozolomide	O
+and	O
+be	O
+familiar	O
+with	O
+the	O
+pharmacologic	O
+and	O
+supportive	O
+measures	O
+necessary	O
+for	O
+its	O
+treatment	O
+
+Captopril-induced	O
+bone	B-Adev
+marrow	I-Adev
+suppression	I-Adev
+in	O
+two	O
+cardiac	O
+patients	O
+with	O
+trisomy	O
+21	O
+
+A	O
+65-year-old	O
+woman	O
+with	O
+angina	O
+pectoris	O
+presented	O
+with	O
+syncope	B-Adev
+after	O
+sublingual	O
+ingestion	O
+of	O
+isosorbide	O
+dinitrate	O
+(5	O
+mg)	O
+
+The	O
+authors	O
+present	O
+a	O
+case	O
+study	O
+of	O
+a	O
+mentally	O
+healthy	O
+man	O
+who	O
+repeatedly	O
+experienced	O
+short-lived	B-Adev
+obsessional-like	I-Adev
+suicidal	I-Adev
+ideas	I-Adev
+and	I-Adev
+images	I-Adev
+after	O
+ingestion	O
+of	O
+the	O
+anti-fungal	O
+drug	O
+ketoconazole	O
+
+Flaccid	B-Adev
+quadriparesis	I-Adev
+was	O
+noted	O
+after	O
+discontinuation	O
+of	O
+vecuronium	O
+
+AIMS	O
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+report	O
+on	O
+the	O
+effectiveness	O
+and	O
+tumor	B-Adev
+side	I-Adev
+effects	I-Adev
+of	O
+topical	O
+interferon	O
+(INF)	O
+alpha	O
+2-beta	O
+in	O
+a	O
+case	O
+of	O
+conjunctiva-cornea	O
+intraepithelial	O
+neoplasia	O
+(CIN)	O
+of	O
+a	O
+patient	O
+that	O
+rejected	O
+any	O
+surgical	O
+procedure	O
+
+Herein	O
+is	O
+reported	O
+an	O
+unusual	O
+case	O
+of	O
+coexistent	O
+warfarin-induced	O
+skin	B-Adev
+necrosis	I-Adev
+and	O
+heparin-induced	O
+thrombocytopenia	O
+following	O
+mitral	O
+valve	O
+replacement	O
+for	O
+thromboembolic	O
+phenomena	O
+associated	O
+with	O
+marantic	O
+endocarditis	O
+and	O
+bronchial	O
+adenocarcinoma	O
+
+Herein	O
+is	O
+reported	O
+an	O
+unusual	O
+case	O
+of	O
+coexistent	O
+warfarin-induced	O
+skin	O
+necrosis	O
+and	O
+heparin-induced	O
+thrombocytopenia	B-Adev
+following	O
+mitral	O
+valve	O
+replacement	O
+for	O
+thromboembolic	O
+phenomena	O
+associated	O
+with	O
+marantic	O
+endocarditis	O
+and	O
+bronchial	O
+adenocarcinoma	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+severe	B-Adev
+unilateral	I-Adev
+posterior	I-Adev
+scleritis	I-Adev
+associated	O
+with	O
+zoledronic	O
+acid	O
+administration	O
+that	O
+was	O
+recognized	O
+and	O
+treated	O
+in	O
+a	O
+timely	O
+manner	O
+
+The	O
+patient's	O
+other	O
+comorbidities	O
+and	O
+medications	O
+have	O
+not	O
+been	O
+suggested	O
+as	O
+possible	O
+interactions	O
+with	O
+sertraline	O
+that	O
+can	O
+cause	O
+rhabdomyolysis	B-Adev
+	O
+
+L-asparaginase-provoked	O
+seizures	B-Adev
+as	I-Adev
+singular	I-Adev
+expression	I-Adev
+of	I-Adev
+central	I-Adev
+nervous	I-Adev
+toxicity	I-Adev
+	O
+
+Acute	B-Adev
+non-lymphocytic	I-Adev
+leukemia	I-Adev
+in	O
+patients	O
+with	O
+ovarian	O
+carcinoma	O
+following	O
+long-term	O
+treatment	O
+with	O
+Treosulfan	O
+(=	O
+dihydroxybusulfan)	O
+
+Children	O
+treated	O
+with	O
+thalidomide	O
+should	O
+undergo	O
+regular	O
+neurophysiologic	O
+studies	O
+in	O
+order	O
+to	O
+detect	O
+presymptomatic	B-Adev
+or	I-Adev
+progressive	I-Adev
+peripheral	I-Adev
+neuropathy	I-Adev
+	O
+
+Nevirapine	O
+is	O
+a	O
+non-nucleoside	O
+reverse	O
+transcriptase	O
+inhibitor	O
+widely	O
+used	O
+in	O
+combination	O
+with	O
+other	O
+antiretroviral	O
+agents	O
+for	O
+the	O
+treatment	O
+of	O
+HIV	O
+infection	O
+
+The	O
+case	O
+is	O
+presented	O
+of	O
+a	O
+72-year-old	O
+man	O
+with	O
+hormone-refractory	O
+prostate	O
+cancer	O
+and	O
+weekly	O
+administration	O
+of	O
+30	O
+mg/m2	O
+docetaxel	O
+who	O
+developed	O
+subacute	B-Adev
+interstitial	I-Adev
+pneumonitis-related	I-Adev
+pulmonary	I-Adev
+fibrosis	I-Adev
+after	O
+seven	O
+doses	O
+and	O
+died	O
+despite	O
+mechanical	O
+ventilation	O
+and	O
+high-dose	O
+corticosteroid	O
+treatment	O
+
+In	O
+this	O
+case	O
+it	O
+was	O
+suspected	O
+that	O
+a	O
+combination	O
+of	O
+cigarette	O
+smoking	O
+pulmonary	O
+fibrosis	O
+and	O
+low-dose	O
+methotrexate	O
+therapy	O
+might	O
+have	O
+promoted	O
+the	B-Adev
+development	I-Adev
+of	I-Adev
+lung	I-Adev
+cancer	I-Adev
+	O
+
+Rapid	O
+onset	O
+of	O
+iatrogenic	B-Adev
+adrenal	I-Adev
+insufficiency	I-Adev
+in	O
+a	O
+patient	O
+with	O
+cystic	O
+fibrosis-related	O
+liver	O
+disease	O
+treated	O
+with	O
+inhaled	O
+corticosteroids	O
+and	O
+a	O
+moderate	O
+CYP3A4	O
+inhibitor	O
+
+Heparin-associated	O
+thrombocytopenia	B-Adev
+and	I-Adev
+thrombosis	I-Adev
+is	O
+a	O
+severe	O
+complication	O
+of	O
+systemic	O
+heparin	O
+therapy	O
+
+The	O
+polycystic	O
+changes	O
+disappeared	O
+from	O
+the	O
+ovaries	O
+in	O
+2	O
+of	O
+the	O
+women	O
+after	O
+valproate	O
+therapy	O
+was	O
+discontinued	O
+and	O
+the	O
+2	O
+women	O
+who	O
+had	O
+gained	O
+weight	O
+and	O
+developed	O
+amenorrhea	O
+while	O
+being	O
+treated	O
+with	O
+valproate	O
+lost	O
+weight	O
+and	O
+resumed	O
+menstruating	O
+after	O
+the	O
+change	O
+in	O
+medication	O
+
+The	O
+polycystic	O
+changes	O
+disappeared	O
+from	O
+the	O
+ovaries	O
+in	O
+2	O
+of	O
+the	O
+women	O
+after	O
+valproate	O
+therapy	O
+was	O
+discontinued	O
+and	O
+the	O
+2	O
+women	O
+who	O
+had	O
+gained	B-Adev
+weight	I-Adev
+and	I-Adev
+developed	I-Adev
+amenorrhea	I-Adev
+while	O
+being	O
+treated	O
+with	O
+valproate	O
+lost	O
+weight	O
+and	O
+resumed	O
+menstruating	O
+after	O
+the	O
+change	O
+in	O
+medication	O
+
+The	O
+cause	O
+of	O
+his	O
+bleeding	O
+was	O
+a	O
+severe	O
+thrombocytopoaenia	B-Adev
+	O
+induced	O
+by	O
+chronic	O
+ingestion	O
+of	O
+quinine	O
+
+The	O
+concomitant	O
+use	O
+of	O
+antidepressant	O
+drugs	O
+associated	O
+with	O
+lithium	O
+as	O
+a	O
+co-adjuvant	O
+seems	O
+to	O
+increase	O
+the	O
+risk	O
+of	O
+this	O
+adverse	B-Adev
+reaction	I-Adev
+	O
+
+Peripheral	B-Adev
+nervous	I-Adev
+system	I-Adev
+disturbances	I-Adev
+caused	O
+by	O
+cytosine	O
+arabinoside	O
+have	O
+rarely	O
+been	O
+reported	O
+
+We	O
+report	O
+an	O
+unusually	O
+short	O
+lived	O
+and	O
+asymptomatic	O
+episode	O
+of	O
+severe	O
+cisplatin-induced	O
+renal	B-Adev
+tubular	I-Adev
+salt	I-Adev
+wasting	I-Adev
+in	O
+a	O
+fit	O
+41-year-old	O
+patient	O
+with	O
+malignant	O
+teratoma	O
+
+This	O
+case	O
+suggests	O
+that	O
+BH-AC	O
+a	O
+derivative	O
+of	O
+cytosine	O
+arabinoside	O
+(1-beta-D-arabinofuranosylcytosine)	O
+could	O
+be	O
+a	O
+cause	O
+of	O
+reversible	B-Adev
+encephalopathy	I-Adev
+syndrome	I-Adev
+	O
+
+She	O
+was	O
+administered	O
+metoclopramide	O
+because	O
+of	O
+nausea	O
+and	O
+within	O
+2	O
+hours	O
+developed	O
+agitation	B-Adev
+dysarthria	I-Adev
+diaphoresis	I-Adev
+and	I-Adev
+a	I-Adev
+movement	I-Adev
+disorder	I-Adev
+	O
+
+This	O
+article	O
+describes	O
+two	O
+cases	O
+of	O
+aplastic	B-Adev
+anemia	I-Adev
+	O
+at	O
+least	O
+one	O
+of	O
+which	O
+was	O
+almost	O
+certainly	O
+induced	O
+by	O
+the	O
+use	O
+of	O
+methazolamide	O
+and	O
+one	O
+case	O
+of	O
+agranulocytosis	O
+related	O
+to	O
+the	O
+use	O
+of	O
+methazolamide	O
+
+This	O
+article	O
+describes	O
+two	O
+cases	O
+of	O
+aplastic	O
+anemia	O
+at	O
+least	O
+one	O
+of	O
+which	O
+was	O
+almost	O
+certainly	O
+induced	O
+by	O
+the	O
+use	O
+of	O
+methazolamide	O
+and	O
+one	O
+case	O
+of	O
+agranulocytosis	B-Adev
+related	O
+to	O
+the	O
+use	O
+of	O
+methazolamide	O
+
+Amprenavir	O
+is	O
+a	O
+human	O
+immunodeficiency	O
+virus-1	O
+(HIV-1)	O
+protease	O
+inhibitor	O
+intended	O
+to	O
+be	O
+used	O
+to	O
+treat	O
+HIV-infected	O
+children	O
+
+Methotrexate-induced	O
+papular	B-Adev
+eruption	I-Adev
+following	O
+treatment	O
+of	O
+psoriasis	O
+has	O
+not	O
+been	O
+previously	O
+reported	O
+
+On	O
+day	O
+7	O
+of	O
+linezolid	O
+treatment	O
+the	O
+patient	O
+developed	O
+severe	O
+pruritus	B-Adev
+macular	I-Adev
+rash	I-Adev
+facial	I-Adev
+edema	I-Adev
+eosinophilia	I-Adev
+marked	I-Adev
+increase	I-Adev
+in	I-Adev
+serum	I-Adev
+creatinine	I-Adev
+level	I-Adev
+	O
+and	O
+mild	O
+hepatitis	O
+
+We	O
+report	O
+a	O
+fatal	O
+case	O
+of	O
+acute	B-Adev
+interstitial	I-Adev
+pneumonitis	I-Adev
+in	O
+a	O
+patient	O
+treated	O
+with	O
+carmustine	O
+(BCNU)	O
+for	O
+a	O
+brain	O
+tumor	O
+
+The	O
+three	O
+reported	O
+cases	O
+demonstrate	O
+that	O
+troglitazone	O
+is	O
+an	O
+idiosyncratic	O
+hepatotoxin	O
+that	O
+can	O
+lead	O
+to	O
+irreversible	B-Adev
+liver	I-Adev
+injury	I-Adev
+	O
+
+High-grade	B-Adev
+atrioventricular	I-Adev
+block	I-Adev
+during	O
+dipyridamole	O
+stress	O
+testing	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+intraoperative	O
+gelatine-induced	O
+anaphylaxis	B-Adev
+whose	O
+diagnosis	O
+was	O
+delayed	O
+as	O
+the	O
+use	O
+of	O
+gelatine	O
+during	O
+surgical	O
+procedures	O
+was	O
+omitted	O
+for	O
+two	O
+times	O
+in	O
+patient's	O
+medical	O
+records	O
+
+The	O
+case	O
+of	O
+a	O
+29-year-old	O
+man	O
+suffering	O
+from	O
+falciparum	O
+malaria	O
+disease	O
+who	O
+got	O
+a	O
+reversible	B-Adev
+hearing	I-Adev
+loss	I-Adev
+from	O
+quinine	O
+therapy	O
+is	O
+presented	O
+
+The	O
+cases	O
+of	O
+two	O
+asthmatic	O
+patients	O
+who	O
+became	O
+hypokalemic	B-Adev
+after	O
+inhalation	O
+of	O
+normal	O
+doses	O
+of	O
+albuterol	O
+are	O
+presented	O
+
+This	O
+article	O
+presents	O
+a	O
+case	O
+of	O
+an	B-Adev
+atypical	I-Adev
+localized	I-Adev
+cutaneous	I-Adev
+eruption	I-Adev
+with	I-Adev
+an	I-Adev
+unusual	I-Adev
+course	I-Adev
+and	I-Adev
+protracted	I-Adev
+resolution	I-Adev
+time	I-Adev
+associated	O
+with	O
+sorafenib	O
+therapy	O
+
+METHOD	O
+We	O
+describe	O
+two	O
+patients	O
+who	O
+presented	O
+with	O
+diabetic	B-Adev
+ketoacidosis	I-Adev
+after	O
+treatment	O
+with	O
+quetiapine	O
+and	O
+risperidone	O
+respectively	O
+
+We	O
+suspect	O
+that	O
+nefazodone	O
+inhibits	O
+metabolism	B-Adev
+of	I-Adev
+tacrolimus	I-Adev
+	O
+
+Our	O
+review	O
+of	O
+194	O
+RA	O
+patients	O
+and	O
+38	O
+PsA	O
+patients	O
+receiving	O
+MTX	O
+has	O
+identified	O
+four	O
+RA	O
+patients	O
+and	O
+one	O
+PsA	O
+patient	O
+with	O
+MTX-induced	O
+pneumonitis	B-Adev
+	O
+giving	O
+a	O
+prevalence	O
+of	O
+2.1%	O
+and	O
+0.03%	O
+respectively	O
+
+A	O
+case	O
+report	O
+of	O
+fatal	O
+dapsone-induced	O
+agranulocytosis	B-Adev
+in	O
+an	O
+Indian	O
+mid-borderline	O
+leprosy	O
+patient	O
+
+Autoimmune	B-Adev
+thyroid	I-Adev
+disease	I-Adev
+is	O
+a	O
+common	O
+side-effect	O
+of	O
+interferon-alpha	O
+(IFN-alpha)	O
+treatment	O
+of	O
+viral	O
+hepatitis	O
+C	O
+
+The	O
+side	O
+effects	O
+of	O
+MMF	O
+such	O
+as	O
+bone	B-Adev
+marrow	I-Adev
+toxicity	I-Adev
+	O
+have	O
+been	O
+reported	O
+
+He	O
+developed	O
+a	O
+late	B-Adev
+secondary	I-Adev
+infection	I-Adev
+in	O
+some	O
+sites	O
+treated	O
+with	O
+imiquimod	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+51-year-old	O
+man	O
+in	O
+whom	O
+IFN-alpha	O
+treatment	O
+was	O
+followed	O
+by	O
+recurrence	B-Adev
+of	I-Adev
+Graves'	I-Adev
+disease	I-Adev
+10	O
+years	O
+after	O
+thyroidectomy	O
+was	O
+performed	O
+and	O
+the	O
+patient	O
+was	O
+declared	O
+cured	O
+
+We	O
+report	O
+2	O
+cases	O
+of	O
+maculopapular	B-Adev
+eruption	I-Adev
+and	I-Adev
+fever	I-Adev
+in	O
+patients	O
+infected	O
+with	O
+human	O
+immunodeficiency	O
+virus	O
+(HIV)	O
+on	O
+the	O
+2nd	O
+day	O
+of	O
+first	O
+administration	O
+of	O
+ritonavir	O
+a	O
+protease	O
+inhibitor	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+woman	O
+who	O
+developed	O
+photo-onycholysis	B-Adev
+on	I-Adev
+multiple	I-Adev
+nails	I-Adev
+after	O
+uptake	O
+of	O
+olanzapine	O
+
+Cimetidine	O
+is	O
+a	O
+rare	O
+cause	O
+of	O
+drug-induced	O
+fever	B-Adev
+	O
+
+Reversible	O
+methotrexate-associated	O
+lymphoproliferative	B-Adev
+disorder	I-Adev
+resembling	O
+advanced	O
+gastric	O
+cancer	O
+in	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+
+The	O
+field	B-Adev
+defects	I-Adev
+and	I-Adev
+some	I-Adev
+electrophysiological	I-Adev
+abnormalities	I-Adev
+persist	I-Adev
+when	O
+vigabatrin	O
+therapy	O
+is	O
+withdrawn	O
+
+A	O
+possible	O
+case	O
+of	O
+carbamazepine	O
+induced	O
+pancreatitis	B-Adev
+	O
+
+Subsequent	O
+to	O
+the	O
+first	O
+dose	O
+of	O
+mirtazapine	O
+the	O
+patient	O
+experienced	O
+seizures	B-Adev
+bradycardia	I-Adev
+and	I-Adev
+prolonged	I-Adev
+QRS	I-Adev
+as	I-Adev
+well	I-Adev
+as	I-Adev
+QTc	I-Adev
+intervals	I-Adev
+on	I-Adev
+EKG	I-Adev
+	O
+
+Stuttering	B-Adev
+priapism	I-Adev
+complicating	O
+warfarin	O
+therapy	O
+in	O
+a	O
+patient	O
+with	O
+protein	O
+C	O
+deficiency	O
+
+She	O
+had	O
+been	O
+on	O
+a	O
+combined	O
+treatment	O
+of	O
+steroid	O
+and	O
+lobenzarit	O
+disodium	O
+for	O
+the	O
+first	O
+3	O
+years	O
+and	O
+then	O
+continued	O
+with	O
+a	O
+combined	O
+treatment	O
+of	O
+steroid	O
+and	O
+bucillamine	O
+for	O
+the	O
+following	O
+years	O
+until	O
+she	O
+was	O
+found	O
+to	O
+have	O
+pulmonary	O
+tuberculosis	O
+at	O
+which	O
+time	O
+the	O
+steroid	O
+was	O
+suspended	O
+10	O
+months	O
+before	O
+she	O
+visited	O
+the	O
+authors'	O
+clinic	O
+
+We	O
+describe	O
+a	O
+rare	O
+case	O
+of	O
+severe	O
+drug-drug	O
+interaction	O
+between	O
+propafenone	O
+and	O
+mirtazapine	O
+leading	O
+to	O
+propafenone	B-Adev
+toxicity	I-Adev
+	O
+
+Because	O
+the	O
+combination	O
+of	O
+bleomycin	O
+and	O
+vinca	O
+alkaloids	O
+is	O
+commonly	O
+used	O
+for	O
+the	O
+treatment	O
+of	O
+AIDS-related	O
+Kaposi's	O
+sarcoma	O
+clinicians	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+risk	O
+of	O
+provoking	O
+acral	B-Adev
+necrosis	I-Adev
+in	O
+patients	O
+who	O
+develop	O
+Raynaud's	O
+phenomenon	O
+under	O
+chemotherapy	O
+
+The	O
+psychotic	O
+behavior	O
+resolved	O
+completely	O
+soon	O
+after	O
+the	O
+discontinuation	O
+of	O
+levetiracetam	O
+
+Male	O
+volunteers	O
+(	O
+n=12)	O
+participated	O
+in	O
+a	O
+randomised	O
+two-period	O
+crossover	O
+trial	O
+evaluating	O
+the	O
+effect	O
+of	O
+multiple	O
+doses	O
+of	O
+600	O
+mg	O
+rifampicin	O
+once	O
+daily	O
+for	O
+7	O
+days	O
+on	O
+repaglinide	B-Adev
+metabolism	I-Adev
+	O
+
+This	O
+report	O
+suggests	O
+that	O
+anemia	B-Adev
+can	O
+occur	O
+due	O
+to	O
+MMF	O
+in	O
+particular	O
+when	O
+it	O
+is	O
+given	O
+with	O
+prednisone	O
+a	O
+side	O
+effect	O
+well	O
+documented	O
+in	O
+the	O
+transplantation	O
+literature	O
+when	O
+the	O
+triple	O
+combination	O
+of	O
+MMF	O
+cyclosporine	O
+and	O
+prednisone	O
+is	O
+used	O
+
+Warfarin	O
+was	O
+initiated	O
+for	O
+deep	O
+vein	O
+thrombosis	O
+prophylaxis	O
+due	O
+to	O
+the	O
+patient's	O
+inability	O
+to	O
+ambulate	O
+
+We	O
+report	O
+a	O
+case	O
+with	O
+chronic	O
+hepatitis	O
+C	O
+(CHC)	O
+who	O
+developed	O
+sarcoidosis	B-Adev
+after	O
+the	O
+treatment	O
+by	O
+interferon	O
+alpha	O
+and	O
+ribavirin	O
+
+The	O
+relation	O
+between	O
+tacrolimus	O
+treatment	O
+and	O
+staining	O
+was	O
+suggested	O
+by	O
+the	O
+appearance	B-Adev
+of	I-Adev
+pigmentation	I-Adev
+during	O
+topical	O
+tacrolimus	O
+treatment	O
+and	O
+its	O
+clinical	O
+disappearance	O
+when	O
+treatment	O
+was	O
+stopped	O
+
+Though	O
+hypotension	O
+dry	O
+mouth	O
+and	O
+constipation	O
+are	O
+well-documented	O
+possible	O
+adverse	O
+effects	O
+the	O
+possibility	O
+of	O
+clonidine-induced	O
+bradycardia	B-Adev
+is	O
+less	O
+well	O
+recognized	O
+and	O
+is	O
+rare	O
+
+Several	O
+hypersensitivity	B-Adev
+reactions	O
+to	O
+cloxacillin	O
+have	O
+been	O
+reported	O
+although	O
+IgE-mediated	O
+allergic	O
+reactions	O
+to	O
+the	O
+drug	O
+are	O
+rare	O
+and	O
+there	O
+is	O
+little	O
+information	O
+about	O
+possible	O
+tolerance	O
+to	O
+other	O
+semisynthetic	O
+penicillins	O
+or	O
+cephalosporins	O
+in	O
+patients	O
+with	O
+cloxacillin	O
+allergy	O
+
+Brugada	B-Adev
+type	I-Adev
+electrocardiographic	I-Adev
+changes	I-Adev
+induced	O
+by	O
+concomitant	O
+use	O
+of	O
+lithium	O
+and	O
+propafenone	O
+in	O
+patient	O
+with	O
+Wolff-Parkinson-White	O
+syndrome	O
+
+Docetaxel-induced	O
+Meibomian	B-Adev
+duct	I-Adev
+inflammation	I-Adev
+and	I-Adev
+blockage	I-Adev
+leading	I-Adev
+to	I-Adev
+chalazion	I-Adev
+formation	I-Adev
+	O
+
+Allergic	O
+side	O
+effects	O
+of	O
+AZA	O
+are	O
+rare	O
+and	O
+reported	O
+allergic	B-Adev
+skin	I-Adev
+eruptions	I-Adev
+from	O
+AZA	O
+are	O
+very	O
+limited	O
+in	O
+Japan	O
+
+Quetiapine	O
+and	O
+[['obsessive-compulsive	B-Adev
+symptoms	I-Adev
+(OCS)']	I-Adev
+['OCS']]	I-Adev
+sessive-compulsive	O
+symptoms	O
+(OCS)	O
+case	O
+report	O
+and	O
+review	O
+of	O
+atypical	O
+antipsychotic-induced	O
+OCS	O
+
+Outcome	O
+of	O
+pregnancy	O
+in	O
+women	O
+treated	O
+with	O
+all-trans	O
+retinoic	O
+acid	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+literature	O
+
+The	O
+potential	O
+development	O
+of	O
+SJS/TEN	B-Adev
+a	I-Adev
+severe	I-Adev
+life-threatening	I-Adev
+illness	I-Adev
+	O
+emphasizes	O
+the	O
+need	O
+for	O
+judicious	O
+use	O
+of	O
+TMP-Sx	O
+and	O
+close	O
+monitoring	O
+and	O
+follow-up	O
+for	O
+patients	O
+who	O
+were	O
+given	O
+TMP-Sx	O
+for	O
+SSTIs	O
+
+A	O
+case	O
+history	O
+of	O
+a	O
+15-year-old	O
+boy	O
+who	O
+developed	O
+incapacitating	O
+tardive	O
+dyskinesia	O
+that	O
+resolved	O
+during	O
+treatment	O
+with	O
+deanol	O
+is	O
+presented	O
+
+Drug-induced	O
+mammary	B-Adev
+hyperplasias	I-Adev
+have	O
+been	O
+reported	O
+as	O
+rare	O
+complications	O
+of	O
+D-penicillamine	O
+and	O
+Neothetazone	O
+
+The	O
+purpose	O
+of	O
+this	O
+report	O
+is	O
+to	O
+document	O
+a	O
+new	O
+case	O
+of	O
+in	O
+utero	O
+CP	O
+exposure	O
+with	O
+multiple	B-Adev
+congenital	I-Adev
+anomalies	I-Adev
+and	O
+to	O
+establish	O
+an	O
+apparent	O
+CP	O
+embryopathy	O
+phenotype	O
+
+AIM	O
+The	O
+aim	O
+of	O
+this	O
+article	O
+is	O
+to	O
+present	O
+the	O
+clinical	O
+characteristics	O
+and	O
+management	O
+of	O
+an	O
+oral	O
+adverse	B-Adev
+effect	I-Adev
+stemming	O
+from	O
+the	O
+use	O
+of	O
+the	O
+antiretroviral	O
+medication	O
+Nevirapine	O
+(NVP)	O
+
+A	O
+27-year-old	O
+man	O
+who	O
+had	O
+a	O
+history	O
+of	O
+bronchial	O
+asthma	O
+eosinophilic	O
+enteritis	O
+and	O
+eosinophilic	O
+pneumonia	O
+presented	O
+with	O
+fever	B-Adev
+skin	I-Adev
+eruptions	I-Adev
+cervical	I-Adev
+lymphadenopathy	I-Adev
+hepatosplenomegaly	I-Adev
+atypical	I-Adev
+lymphocytosis	I-Adev
+and	I-Adev
+eosinophilia	I-Adev
+two	O
+weeks	O
+after	O
+receiving	O
+trimethoprim	O
+(TMP)-sulfamethoxazole	O
+(SMX)	O
+treatment	O
+
+Treatment	O
+with	O
+infliximab	O
+is	O
+known	O
+to	O
+produce	O
+an	O
+increase	B-Adev
+of	I-Adev
+autoantibodies	I-Adev
+(antinuclear	I-Adev
+antibodies	I-Adev
+anti-double-stranded	I-Adev
+DNA)	I-Adev
+but	I-Adev
+not	I-Adev
+clinical	I-Adev
+disease	I-Adev
+	O
+
+Serotonin	B-Adev
+syndrome	I-Adev
+which	O
+occurs	O
+as	O
+a	O
+result	O
+of	O
+enhanced	O
+serotonin	O
+concentration	O
+in	O
+the	O
+central	O
+nervous	O
+system	O
+is	O
+a	O
+well-known	O
+adverse	O
+effect	O
+of	O
+serotonin-active	O
+medications	O
+
+Despite	O
+the	O
+risk	O
+of	O
+needle-track	O
+seeding	O
+PEI	O
+remains	O
+useful	O
+in	O
+the	O
+treatment	O
+of	O
+HCC	O
+
+Trimethoprim-sulfamethoxazole-induced	O
+hepatotoxicity	B-Adev
+in	O
+a	O
+pediatric	O
+patient	O
+
+Prolonged	O
+responses	O
+were	O
+achieved	O
+with	O
+low	O
+doses	O
+of	O
+HU	O
+(3-10	O
+mg/kg/day)	O
+and	O
+higher	O
+doses	O
+were	O
+associated	O
+with	O
+mild	B-Adev
+reversible	I-Adev
+hematologic	I-Adev
+or	I-Adev
+hepatic	I-Adev
+toxicity	I-Adev
+and	I-Adev
+no	I-Adev
+further	I-Adev
+increases	I-Adev
+in	I-Adev
+Hb	I-Adev
+	O
+
+Prolonged	B-Adev
+responses	I-Adev
+were	O
+achieved	O
+with	O
+low	O
+doses	O
+of	O
+HU	O
+(3-10	O
+mg/kg/day)	O
+and	O
+higher	O
+doses	O
+were	O
+associated	O
+with	O
+mild	O
+reversible	O
+hematologic	O
+or	O
+hepatic	O
+toxicity	O
+and	O
+no	O
+further	O
+increases	O
+in	O
+Hb	O
+
+Imidazoline	B-Adev
+intoxication	I-Adev
+in	O
+children	O
+
+Concomitant	O
+administration	O
+of	O
+cytarabine	O
+might	O
+have	O
+affected	O
+his	O
+liver	B-Adev
+function	I-Adev
+and	O
+there	O
+might	O
+have	O
+been	O
+interaction	O
+between	O
+the	O
+drugs	O
+
+The	O
+probability	O
+of	O
+developing	O
+acute	B-Adev
+leukemia	I-Adev
+in	O
+this	O
+study	O
+was	O
+not	O
+significantly	O
+correlated	O
+to	O
+the	O
+total	O
+cumulative	O
+dosage	O
+of	O
+Treosulfan	O
+
+Intraventricular	O
+vancomycin-induced	O
+cerebrospinal	B-Adev
+fluid	I-Adev
+eosinophilia	I-Adev
+	O
+report	O
+of	O
+two	O
+patients	O
+
+This	O
+case	O
+supports	O
+the	O
+view	O
+that	O
+in	O
+gold-induced	O
+pneumonitis	O
+a	O
+prolonged	O
+treatment	O
+with	O
+corticosteroids	O
+may	O
+be	O
+necessary	O
+as	O
+lung	O
+function	O
+continued	O
+to	O
+improve	O
+
+Massive	O
+plasmocytosis	O
+due	O
+to	O
+methimazole-induced	O
+bone	B-Adev
+marrow	I-Adev
+toxicity	I-Adev
+	O
+
+RESULTS	O
+After	O
+4-	O
+to	O
+14-month	O
+period	O
+of	O
+therapy	O
+with	O
+the	O
+combination	O
+of	O
+indapamide	O
+(2.5	O
+mg/day)	O
+and	O
+fosinopril	O
+(10	O
+mg/day)	O
+in	O
+three	O
+patients	O
+and	O
+6-month	O
+period	O
+of	O
+monotherapy	O
+with	O
+indapamide	O
+(2.5	O
+mg/day)	O
+in	O
+one	O
+patient	O
+glucose	B-Adev
+levels	I-Adev
+of	I-Adev
+all	I-Adev
+patients	I-Adev
+increased	I-Adev
+and	I-Adev
+achieve	I-Adev
+criteria	I-Adev
+of	I-Adev
+diabetes	I-Adev
+diagnoses	I-Adev
+	O
+
+RESULTS	O
+After	O
+4-	O
+to	O
+14-month	O
+period	O
+of	O
+therapy	O
+with	O
+the	O
+combination	O
+of	O
+indapamide	O
+(2.5	O
+mg/day)	O
+and	O
+fosinopril	O
+(10	O
+mg/day)	O
+in	O
+three	O
+patients	O
+and	O
+6-month	O
+period	O
+of	O
+monotherapy	O
+with	O
+indapamide	O
+(2.5	O
+mg/day)	O
+in	O
+one	O
+patient	O
+glucose	B-Adev
+levels	I-Adev
+of	I-Adev
+all	I-Adev
+patients	I-Adev
+increased	I-Adev
+and	I-Adev
+achieve	I-Adev
+criteria	I-Adev
+of	I-Adev
+diabetes	I-Adev
+diagnoses	I-Adev
+	O
+
+A	O
+reversible	B-Adev
+toxic	I-Adev
+liver	I-Adev
+damage	I-Adev
+was	O
+observed	O
+in	O
+a	O
+non-alcoholic	O
+woman	O
+treated	O
+with	O
+disulfiram	O
+
+A	O
+60	O
+year-old	O
+woman	O
+with	O
+chronic	O
+renal	O
+failure	O
+developed	O
+acute	B-Adev
+proximal	I-Adev
+muscle	I-Adev
+weakness	I-Adev
+after	O
+receiving	O
+a	O
+regular	O
+dosage	O
+of	O
+colchicine	O
+
+The	O
+cause	O
+of	O
+these	O
+previously	O
+unreported	O
+side	O
+effects	O
+of	O
+niacin	O
+therapy	O
+is	O
+uncertain	O
+but	O
+may	O
+be	O
+related	O
+to	O
+prostaglandin-mediated	B-Adev
+vasodilatation	I-Adev
+hyperalgesia	I-Adev
+of	I-Adev
+sensory	I-Adev
+nerve	I-Adev
+receptors	I-Adev
+and	I-Adev
+potentiation	I-Adev
+of	I-Adev
+inflammation	I-Adev
+in	I-Adev
+the	I-Adev
+gingiva	I-Adev
+with	I-Adev
+referral	I-Adev
+of	I-Adev
+pain	I-Adev
+to	I-Adev
+the	I-Adev
+teeth	I-Adev
+	O
+
+Nocardia	B-Adev
+is	O
+an	O
+important	O
+opportunistic	O
+infectious	O
+agent	O
+in	O
+immunocompromised	O
+hosts	O
+i.e	O
+in	O
+patients	O
+taking	O
+corticosteroids	O
+
+Hepatobiliary	B-Adev
+disorders	I-Adev
+associated	O
+with	O
+orally	O
+administered	O
+terbinafine	O
+have	O
+rarely	O
+been	O
+reported	O
+
+We	O
+report	O
+a	O
+patient	O
+in	O
+whom	O
+the	O
+anti-depressant	O
+trazodone	O
+hydrochloride	O
+(Molipaxin	O
+Roussel)	O
+a	O
+serotonin	O
+antagonist	O
+provoked	O
+generalized	B-Adev
+pustular	I-Adev
+psoriasis	I-Adev
+(GPP)	I-Adev
+	O
+
+Early	O
+recognition	O
+of	O
+hereditary	O
+motor	O
+and	O
+sensory	O
+neuropathy	O
+type	O
+1	O
+can	O
+avoid	O
+life-threatening	O
+vincristine	O
+neurotoxicity	O
+
+Probable	O
+enoxaparin-induced	O
+hepatotoxicity	B-Adev
+	O
+
+Interstitial	B-Adev
+pneumonitis	I-Adev
+associated	O
+with	O
+sirolimus	O
+a	O
+dilemma	O
+for	O
+lung	O
+transplantation	O
+
+He	O
+had	O
+also	O
+developed	O
+elevated	B-Adev
+serum	I-Adev
+ammonia	I-Adev
+levels	I-Adev
+while	O
+on	O
+valproic	O
+acid	O
+
+Cutaneous	B-Adev
+rashes	I-Adev
+and	I-Adev
+eruptions	I-Adev
+can	O
+be	O
+caused	O
+by	O
+many	O
+medications	O
+including	O
+carbamazepine	O
+
+In	O
+this	O
+case	O
+the	B-Adev
+increase	I-Adev
+in	I-Adev
+the	I-Adev
+INR	I-Adev
+value	I-Adev
+with	I-Adev
+associated	I-Adev
+bruising	I-Adev
+after	O
+the	O
+addition	O
+of	O
+amoxycillin	O
+suggests	O
+a	O
+drug	O
+interaction	O
+between	O
+acenocoumarol	O
+and	O
+amoxycillin	O
+other	O
+possible	O
+causes	O
+having	O
+been	O
+eliminated	O
+
+Oncologists	O
+supervising	O
+future	O
+clinical	O
+trials	O
+for	O
+lung	O
+cancer	O
+should	O
+be	O
+alert	O
+to	O
+the	O
+fact	O
+that	O
+sorafenib	O
+can	O
+potentially	O
+induce	O
+serious	B-Adev
+interstitial	I-Adev
+lung	I-Adev
+disease	I-Adev
+	O
+although	O
+this	O
+might	O
+depend	O
+on	O
+racial	O
+differences	O
+
+SUMMARY	O
+A	O
+26-year-old	O
+man	O
+with	O
+bipolar	O
+disorder	O
+seizures	O
+and	O
+mild	O
+mental	O
+retardation	O
+secondary	O
+to	O
+a	O
+traumatic	O
+brain	O
+injury	O
+began	O
+treatment	O
+with	O
+carbamazepine	O
+for	O
+aggression	O
+and	O
+seizure	O
+control	O
+
+Serotonin	B-Adev
+toxicity	I-Adev
+precipitated	O
+by	O
+fentanyl	O
+is	O
+unusual	O
+and	O
+has	O
+not	O
+previously	O
+been	O
+described	O
+in	O
+combination	O
+with	O
+SSRIs	O
+in	O
+the	O
+perioperative	O
+setting	O
+
+It	O
+may	O
+cause	O
+a	O
+severe	O
+adverse	O
+drug	O
+reaction	O
+with	O
+multiorgan	O
+involvement	O
+known	O
+as	O
+dapsone	O
+[['hypersensitivity	B-Adev
+syndrome']	I-Adev
+['a	I-Adev
+severe	I-Adev
+adverse	I-Adev
+drug	I-Adev
+reaction']]	I-Adev
+persensitivity	O
+syndrome	O
+
+Visual	B-Adev
+system	I-Adev
+side	I-Adev
+effects	I-Adev
+caused	I-Adev
+by	I-Adev
+parasympathetic	I-Adev
+dysfunction	I-Adev
+after	O
+botulinum	O
+toxin	O
+type	O
+B	O
+injections	O
+
+Renal	B-Adev
+failure	I-Adev
+associated	O
+with	O
+acetazolamide	O
+therapy	O
+for	O
+glaucoma	O
+
+Acute	B-Adev
+onset	I-Adev
+of	I-Adev
+nephrotic	I-Adev
+syndrome	I-Adev
+during	O
+interferon-alpha	O
+retreatment	O
+for	O
+chronic	O
+active	O
+hepatitis	O
+C	O
+
+A	O
+16-year-old	O
+boy	O
+developed	O
+fever	B-Adev
+generalized	I-Adev
+rigidity	I-Adev
+leukocytosis	I-Adev
+and	I-Adev
+increased	I-Adev
+serum	I-Adev
+transaminase	I-Adev
+and	I-Adev
+creatine	I-Adev
+kinase	I-Adev
+levels	I-Adev
+while	O
+receiving	O
+treatment	O
+with	O
+olanzapine	O
+and	O
+lithium	O
+
+The	O
+hyperpigmentation	B-Adev
+was	I-Adev
+diffuse	I-Adev
+scattered	I-Adev
+flagellate	I-Adev
+like	I-Adev
+and	I-Adev
+linear	I-Adev
+streaking	I-Adev
+which	O
+was	O
+thought	O
+to	O
+be	O
+mainly	O
+related	O
+to	O
+the	O
+skin	O
+toxicity	O
+of	O
+bleomycin	O
+
+Exacerbation	O
+of	O
+5-FU	O
+dermatologic	B-Adev
+toxicities	I-Adev
+in	O
+patients	O
+with	O
+preexisting	O
+conditions	O
+suggests	O
+the	O
+importance	O
+of	O
+aggressive	O
+ocular	O
+prophylaxis	O
+using	O
+frequent	O
+ocular	O
+lubrication	O
+and	O
+topical	O
+steroid	O
+preparations	O
+with	O
+concurrent	O
+medical	O
+management	O
+of	O
+pre-existing	O
+dermatologic	O
+conditions	O
+
+Bowel	B-Adev
+perforation	I-Adev
+associated	O
+with	O
+intraperitoneal	O
+chromic	O
+phosphate	O
+instillation	O
+
+A	O
+62-year-old	O
+woman	O
+who	O
+was	O
+being	O
+treated	O
+for	O
+squamous	O
+cell	O
+carcinoma	O
+of	O
+the	O
+head	O
+and	O
+neck	O
+developed	O
+a	B-Adev
+chemotherapy-related	I-Adev
+hemolytic-uremic	I-Adev
+syndrome	I-Adev
+during	O
+the	O
+second	O
+cycle	O
+of	O
+neoadjuvant	O
+chemotherapy	O
+consisting	O
+of	O
+cisplatin	O
+bleomycin	O
+and	O
+methotrexate	O
+
+These	O
+data	O
+confirm	O
+the	O
+therapeutic	O
+value	O
+of	O
+arsenic	O
+trioxide	O
+in	O
+relapsed/resistant	O
+APL	O
+
+Avascular	B-Adev
+necrosis	I-Adev
+of	I-Adev
+the	I-Adev
+femoral	I-Adev
+head	I-Adev
+in	O
+patients	O
+with	O
+prostate	O
+cancer	O
+treated	O
+with	O
+cyproterone	O
+acetate	O
+and	O
+radiotherapy	O
+
+Ectropion	B-Adev
+secondary	O
+to	O
+bolus	O
+injection	O
+of	O
+5-fluorouracil	O
+
+Metoclopramide-induced	O
+parkinsonism	B-Adev
+is	O
+not	O
+rare	O
+and	O
+appropriate	O
+dose	O
+reduction	O
+in	O
+patients	O
+with	O
+renal	O
+failure	O
+will	O
+help	O
+reduce	O
+the	O
+incidence	O
+of	O
+this	O
+morbidity	O
+
+Posterior	B-Adev
+reversible	I-Adev
+encephalopathy	I-Adev
+syndrome	I-Adev
+associated	O
+with	O
+methotrexate	O
+neurotoxicity	O
+conventional	O
+magnetic	O
+resonance	O
+and	O
+diffusion-weighted	O
+imaging	O
+findings	O
+
+A	O
+6-year-old	O
+boy	O
+(weight	O
+16	O
+kg	O
+at	O
+the	O
+start	O
+of	O
+treatment)	O
+began	O
+sodium	O
+valproate	O
+(valproate	O
+syrup	O
+5%)	O
+treatment	O
+for	O
+epilepsy	O
+in	O
+February	O
+2012	O
+
+Pharmacokinetic	O
+determinants	O
+of	O
+6-mercaptopurine	O
+myelotoxicity	B-Adev
+and	I-Adev
+therapeutic	I-Adev
+failure	I-Adev
+in	O
+children	O
+with	O
+acute	O
+lymphoblastic	O
+leukemia	O
+
+We	O
+report	O
+the	O
+case	O
+histories	O
+of	O
+identical	O
+twin	O
+brothers	O
+who	O
+developed	O
+concordant	O
+acute	O
+lymphoblastic	O
+leukemia	O
+at	O
+the	O
+age	O
+of	O
+4	O
+years	O
+and	O
+who	O
+later	O
+developed	O
+leukoencephalopathy	B-Adev
+and	I-Adev
+hydrocephalus	I-Adev
+related	O
+to	O
+central	O
+nervous	O
+system	O
+prophylaxis	O
+by	O
+in	O
+the	O
+first	O
+case	O
+intrathecally	O
+administered	O
+methotrexate	O
+and	O
+in	O
+the	O
+second	O
+by	O
+intrathecally	O
+administered	O
+methotrexate	O
+and	O
+cranial	O
+irradiation	O
+
+Considering	O
+the	O
+increasing	O
+use	O
+of	O
+TMZ	O
+which	O
+is	O
+regarded	O
+as	O
+a	O
+drug	O
+with	O
+moderate	B-Adev
+toxicity	I-Adev
+	O
+careful	O
+follow-up	O
+with	O
+routine	O
+blood	O
+testing	O
+is	O
+vital	O
+
+While	O
+for	O
+ribavirin	O
+antidepressant	O
+effects	O
+are	O
+not	O
+known	O
+we	O
+suppose	O
+that	O
+antidepressants	O
+may	O
+prevent	O
+changes	O
+in	O
+serotonergic	O
+or	O
+noradrenergic	O
+neurotransmission	O
+caused	O
+by	O
+IFN-alpha	O
+
+While	O
+for	O
+ribavirin	O
+antidepressant	O
+effects	O
+are	O
+not	O
+known	O
+we	O
+suppose	O
+that	O
+antidepressants	O
+may	O
+prevent	O
+changes	B-Adev
+in	I-Adev
+serotonergic	I-Adev
+or	I-Adev
+noradrenergic	I-Adev
+neurotransmission	I-Adev
+caused	O
+by	O
+IFN-alpha	O
+
+To	O
+report	O
+a	O
+case	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+associated	O
+with	O
+interaction	O
+between	O
+fentanyl	O
+and	O
+citalopram	O
+as	O
+evidenced	O
+by	O
+medication	O
+history	O
+clinical	O
+features	O
+and	O
+reversal	O
+following	O
+discontinuation	O
+of	O
+fentanyl	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+ibuprofen-induced	O
+meningitis	B-Adev
+in	O
+an	O
+otherwise	O
+healthy	O
+individual	O
+
+The	O
+reported	O
+cases	O
+of	O
+in	O
+utero	O
+exposure	O
+to	O
+cyclosposphamide	O
+shared	O
+the	O
+following	O
+manifestations	O
+with	O
+our	O
+patient	O
+growth	B-Adev
+deficiency	I-Adev
+developmental	I-Adev
+delay	I-Adev
+craniosynostosis	I-Adev
+blepharophimosis	I-Adev
+flat	I-Adev
+nasal	I-Adev
+bridge	I-Adev
+abnormal	I-Adev
+ears	I-Adev
+and	I-Adev
+distal	I-Adev
+limb	I-Adev
+defects	I-Adev
+including	I-Adev
+hypoplastic	I-Adev
+thumbs	I-Adev
+and	I-Adev
+oligodactyly	I-Adev
+	O
+
+L-Thyroxine-induced	O
+leukopenia	B-Adev
+in	O
+a	O
+patient	O
+with	O
+Hashimoto's	O
+disease	O
+involvement	O
+of	O
+suppressor-cytotoxic	O
+T	O
+cells	O
+
+Carbamazepine-induced	O
+systemic	B-Adev
+lupus	I-Adev
+erythematosus-like	I-Adev
+disease	I-Adev
+	O
+
+CONCLUSIONS	O
+This	O
+case	O
+describes	O
+the	O
+clinically	O
+significant	O
+increase	B-Adev
+of	I-Adev
+INR	I-Adev
+in	O
+an	O
+elderly	O
+patient	O
+after	O
+adding	O
+a	O
+chemotherapy	O
+regimen	O
+of	O
+levamisole	O
+and	O
+5-FU	O
+to	O
+a	O
+previous	O
+regimen	O
+of	O
+warfarin	O
+alone	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+hepatoxicity	B-Adev
+of	O
+ethanol	O
+in	O
+alcoholic	O
+beverages	O
+is	O
+enhanced	O
+by	O
+interaction	O
+with	O
+its	O
+congeners	O
+and	O
+acetaldehyde	O
+they	O
+also	O
+suggest	O
+that	O
+alcoholic	O
+beverages	O
+are	O
+not	O
+equivalent	O
+in	O
+their	O
+potential	O
+to	O
+cause	O
+liver	O
+damage	O
+
+The	O
+dermatology	O
+literature	O
+heretofore	O
+has	O
+not	O
+noted	O
+that	O
+anemia	B-Adev
+is	O
+a	O
+side	O
+effect	O
+of	O
+patients	O
+taking	O
+MMF	O
+to	O
+treat	O
+pemphigus	O
+
+The	O
+9	O
+other	O
+reported	O
+cases	O
+of	O
+D-penicillamine	O
+induced	O
+rapidly	B-Adev
+progressive	I-Adev
+glomerulonephritis	I-Adev
+have	O
+been	O
+reviewed	O
+
+We	O
+describe	O
+a	O
+heroin	O
+abuser	O
+in	O
+whom	O
+clinical	O
+and	O
+laboratory	O
+manifestations	O
+of	O
+acute	B-Adev
+hepatitis	I-Adev
+B	I-Adev
+and	I-Adev
+C	I-Adev
+appeared	O
+a	O
+few	O
+days	O
+after	O
+the	O
+insertion	O
+of	O
+a	O
+subcutaneous	O
+naltrexone	O
+implant	O
+
+Ciprofloxacin-induced	O
+psychosis	B-Adev
+	O
+
+Thalidomide	O
+was	O
+withdrawn	O
+from	O
+world	O
+markets	O
+in	O
+1961	O
+following	O
+recognition	O
+of	O
+its	O
+teratogenic	B-Adev
+effects	I-Adev
+	O
+
+Weekly	O
+AUC2	O
+carboplatin	O
+in	O
+acquired	O
+platinum-resistant	O
+ovarian	O
+cancer	O
+with	O
+or	O
+without	O
+oral	O
+phenoxodiol	O
+a	O
+sensitizer	O
+of	O
+platinum	O
+cytotoxicity	O
+the	O
+phase	O
+III	O
+OVATURE	O
+multicenter	O
+randomized	O
+study	O
+
+We	O
+suggest	O
+the	O
+use	O
+of	O
+esmolol	O
+for	O
+treatment	O
+of	O
+dysrhythmias	O
+secondary	O
+to	O
+caffeine	O
+toxicity	O
+to	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+the	O
+use	O
+of	O
+esmolol	O
+has	O
+not	O
+been	O
+reported	O
+for	O
+this	O
+purpose	O
+
+To	O
+date	O
+there	O
+have	O
+been	O
+few	O
+reports	O
+of	O
+visual	B-Adev
+disturbances	I-Adev
+associated	O
+with	O
+BTX-B	O
+use	O
+
+Gemcitabine	O
+is	O
+a	O
+known	O
+risk	O
+factor	O
+for	O
+hemolytic	B-Adev
+uremic	I-Adev
+syndrome	I-Adev
+(HUS)	O
+which	O
+can	O
+often	O
+have	O
+a	O
+rapidly	O
+fatal	O
+clinical	O
+course	O
+despite	O
+intervention	O
+with	O
+steroids	O
+plasmapheresis	O
+and	O
+hemodialysis	O
+
+Gemcitabine	O
+is	O
+a	O
+known	O
+risk	O
+factor	O
+for	O
+hemolytic	O
+uremic	O
+syndrome	O
+(HUS)	O
+which	O
+can	O
+often	O
+have	O
+a	O
+rapidly	O
+fatal	O
+clinical	O
+course	O
+despite	O
+intervention	O
+with	O
+steroids	O
+plasmapheresis	O
+and	O
+hemodialysis	O
+
+Our	O
+objective	O
+is	O
+to	O
+present	O
+a	O
+retrospective	O
+analysis	O
+of	O
+the	O
+DWI	O
+findings	O
+in	O
+four	O
+patients	O
+who	O
+suffered	O
+subacute	B-Adev
+neurotoxicity	I-Adev
+after	O
+intrathecal	O
+MTX	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+ST	B-Adev
+elevation	I-Adev
+in	I-Adev
+right	I-Adev
+precordial	I-Adev
+leads	I-Adev
+compatible	I-Adev
+with	I-Adev
+type	I-Adev
+1	I-Adev
+Brugada	I-Adev
+syndrome	I-Adev
+following	O
+administration	O
+of	O
+propafenone	O
+in	O
+a	O
+patient	O
+with	O
+Wolff-Parkinson-White	O
+syndrome	O
+who	O
+was	O
+receiving	O
+lithium	O
+at	O
+concentrations	O
+within	O
+therapeutic	O
+levels	O
+
+The	O
+spectrum	O
+of	O
+cutaneous	B-Adev
+eruptions	I-Adev
+associated	O
+with	O
+dihydropyridines	O
+is	O
+extensive	O
+varying	O
+from	O
+exanthemas	O
+to	O
+severe	O
+adverse	O
+events	O
+
+Polymyositis	B-Adev
+after	O
+propylthiouracil	O
+treatment	O
+for	O
+hyperthyroidism	O
+
+Methamphetamine's	O
+extensive	O
+physiologic	O
+effects	O
+inconsistent	O
+street	O
+purity	O
+and	O
+multiple	O
+routes	O
+of	O
+administration	O
+offer	O
+many	O
+possibilities	O
+for	O
+injury	O
+to	O
+the	O
+cornea	O
+
+Since	O
+ethambutol	O
+is	O
+actively	O
+excreted	O
+via	O
+the	O
+renal	O
+system	O
+compromise	O
+of	O
+renal	O
+function	O
+such	O
+as	O
+due	O
+to	O
+renal	O
+tuberculosis	O
+may	O
+lead	O
+to	O
+serum	B-Adev
+concentration	I-Adev
+elevations	I-Adev
+of	I-Adev
+ethambutol	I-Adev
+sufficient	I-Adev
+to	I-Adev
+produce	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+	O
+
+Renal	B-Adev
+failure	I-Adev
+appeared	O
+8	O
+to	O
+17	O
+days	O
+after	O
+beginning	O
+gentamicin	O
+therapy	O
+and	O
+was	O
+characterized	O
+by	O
+creatinine	O
+clearances	O
+4	O
+to	O
+10	O
+ml/min	O
+urine	O
+to	O
+plasma	O
+creatinine	O
+ratios	O
+less	O
+than	O
+20	O
+urinary	O
+sodium	O
+concentrations	O
+16	O
+to	O
+60	O
+mEq/liter	O
+proteinuria	O
+and	O
+cylindruria	O
+
+Seizures	B-Adev
+associated	O
+with	O
+ofloxacin	O
+therapy	O
+
+Cutaneous	B-Adev
+seeding	I-Adev
+after	O
+ultrasound-guided	O
+percutaneous	O
+ethanol	O
+injection	O
+for	O
+treatment	O
+of	O
+hepatocellular	O
+carcinoma	O
+
+Two	O
+patients	O
+who	O
+developed	O
+decreased	B-Adev
+visual	I-Adev
+acuity	I-Adev
+after	O
+several	O
+months	O
+of	O
+ethambutol	O
+treatment	O
+for	O
+Mycobacterium	O
+avium-intracellulare	O
+infection	O
+had	O
+bitemporal	O
+visual	O
+field	O
+defects	O
+that	O
+suggested	O
+optic	O
+chiasm	O
+damage	O
+
+CONCLUSIONS	O
+Metoclopramide	O
+may	O
+cause	O
+reversible	B-Adev
+nonthrombocytopenic	I-Adev
+vascular-type	I-Adev
+palpable	I-Adev
+purpura	I-Adev
+	O
+
+CONCLUSIONS	O
+Life-threatening	O
+adrenal	O
+suppression	O
+requiring	O
+hydrocortisone	O
+supplementation	O
+and	O
+intensive	O
+therapy	O
+was	O
+observed	O
+and	O
+successfully	O
+treated	O
+in	O
+a	O
+newborn	O
+whose	O
+mother	O
+had	O
+received	O
+high-dose	O
+methylprednisolone	O
+in	O
+late	O
+pregnancy	O
+
+A	O
+case	O
+of	O
+extrapyramidal	B-Adev
+symptoms	I-Adev
+(EPS)	I-Adev
+following	O
+administration	O
+of	O
+aripiprazole	O
+to	O
+a	O
+man	O
+with	O
+developmental	O
+disabilities	O
+who	O
+had	O
+never	O
+received	O
+antipsychotic	O
+medications	O
+and	O
+had	O
+no	O
+history	O
+of	O
+movement	O
+disorders	O
+is	O
+presented	O
+
+Although	O
+high-dose	O
+methotrexate	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+useful	O
+in	O
+the	O
+treatment	O
+of	O
+primary	O
+osteogenic	O
+sarcoma	O
+the	O
+tumoricidal	O
+effects	O
+of	O
+therapy	O
+appear	O
+to	O
+have	O
+caused	O
+a	B-Adev
+fatal	I-Adev
+rise	I-Adev
+in	I-Adev
+intracranial	I-Adev
+pressure	I-Adev
+	O
+
+This	O
+case	O
+had	O
+radiation	O
+fibrosis	O
+so	O
+we	O
+suggest	O
+that	O
+radiation	O
+fibrosis	O
+may	O
+be	O
+another	O
+contributor	O
+of	O
+the	O
+occurrence	B-Adev
+of	I-Adev
+ILD	I-Adev
+in	O
+patients	O
+taking	O
+erlotinib	O
+
+Since	O
+recent	O
+studies	O
+have	O
+reported	O
+no	O
+negative	O
+interactions	O
+with	O
+concurrent	O
+use	O
+we	O
+here	O
+report	O
+three	O
+cases	O
+(one	O
+case	O
+of	O
+a	B-Adev
+prolonged	I-Adev
+seizure	I-Adev
+	O
+a	O
+serotonin	O
+syndrome	O
+and	O
+a	O
+focal	O
+seizure)	O
+of	O
+severe	O
+lithium-induced	O
+side	O
+effects	O
+while	O
+patients	O
+underwent	O
+ECT	O
+without	O
+complications	O
+and	O
+lithium	O
+serum	O
+levels	O
+were	O
+still	O
+subtherapeutic	O
+
+Since	O
+recent	O
+studies	O
+have	O
+reported	O
+no	O
+negative	O
+interactions	O
+with	O
+concurrent	O
+use	O
+we	O
+here	O
+report	O
+three	O
+cases	O
+(one	O
+case	O
+of	O
+a	O
+prolonged	O
+seizure	O
+a	B-Adev
+serotonin	I-Adev
+syndrome	I-Adev
+and	O
+a	O
+focal	O
+seizure)	O
+of	O
+severe	O
+lithium-induced	O
+side	O
+effects	O
+while	O
+patients	O
+underwent	O
+ECT	O
+without	O
+complications	O
+and	O
+lithium	O
+serum	O
+levels	O
+were	O
+still	O
+subtherapeutic	O
+
+Since	O
+recent	O
+studies	O
+have	O
+reported	O
+no	O
+negative	O
+interactions	O
+with	O
+concurrent	O
+use	O
+we	O
+here	O
+report	O
+three	O
+cases	O
+(one	O
+case	O
+of	O
+a	O
+prolonged	O
+seizure	O
+a	O
+serotonin	O
+syndrome	O
+and	O
+a	B-Adev
+focal	I-Adev
+seizure	I-Adev
+)	O
+of	O
+severe	O
+lithium-induced	O
+side	O
+effects	O
+while	O
+patients	O
+underwent	O
+ECT	O
+without	O
+complications	O
+and	O
+lithium	O
+serum	O
+levels	O
+were	O
+still	O
+subtherapeutic	O
+
+Since	O
+recent	O
+studies	O
+have	O
+reported	O
+no	O
+negative	O
+interactions	O
+with	O
+concurrent	O
+use	O
+we	O
+here	O
+report	O
+three	O
+cases	O
+(one	O
+case	O
+of	O
+a	O
+prolonged	O
+seizure	O
+a	O
+serotonin	O
+syndrome	O
+and	O
+a	O
+focal	O
+seizure)	O
+of	O
+severe	O
+lithium-induced	O
+side	O
+effects	O
+while	O
+patients	O
+underwent	O
+ECT	O
+without	O
+complications	O
+and	O
+lithium	O
+serum	O
+levels	O
+were	O
+still	O
+subtherapeutic	O
+
+Lithium-associated	O
+transient	B-Adev
+thyrotoxicosis	I-Adev
+in	O
+4	O
+Chinese	O
+women	O
+with	O
+autoimmune	O
+thyroiditis	O
+
+A	O
+patient	O
+while	O
+on	O
+intravenous	O
+ritodrine	O
+therapy	O
+for	O
+preterm	O
+labor	O
+experienced	O
+an	B-Adev
+episode	I-Adev
+of	I-Adev
+acute	I-Adev
+chest	I-Adev
+pain	I-Adev
+	O
+
+Subsequent	O
+in	O
+vivo/vitro	O
+studies	O
+clearly	O
+demonstrated	O
+that	O
+the	O
+neurological	B-Adev
+effects	I-Adev
+were	O
+due	O
+to	O
+a	O
+synergistic	O
+action	O
+of	O
+desferrioxamine	O
+and	O
+prochlorperazine	O
+probably	O
+resulting	O
+in	O
+exceptional	O
+fluxes	O
+of	O
+intra/extra	O
+cellular	O
+iron/copper	O
+disturbing	O
+noradrenergic	O
+and	O
+serotonergic	O
+systems	O
+
+Favorable	O
+outcome	O
+of	O
+de	O
+novo	O
+hepatitis	O
+B	O
+infection	O
+after	O
+liver	O
+transplantation	O
+with	O
+lamivudine	O
+and	O
+adefovir	O
+therapy	O
+
+Pemphigus	B-Adev
+foliaceus	I-Adev
+was	O
+seen	O
+in	O
+a	O
+patient	O
+with	O
+pulmonary	O
+tuberculosis	O
+during	O
+rifampicin	O
+therapy	O
+
+CONCLUSIONS	O
+Clinicians	O
+should	O
+be	O
+aware	O
+of	O
+a	O
+risk	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+with	I-Adev
+serious	I-Adev
+extrapyramidal	I-Adev
+reactions	I-Adev
+in	O
+patients	O
+receiving	O
+sertraline	O
+or	O
+venlafaxine	O
+when	O
+metoclopramide	O
+is	O
+coadministered	O
+even	O
+in	O
+a	O
+single	O
+conventional	O
+dose	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+patient	O
+who	O
+developed	O
+polyserositis	B-Adev
+(pericardial	I-Adev
+effusion	I-Adev
+pleural	I-Adev
+effusion	I-Adev
+and	I-Adev
+pericarditis)	I-Adev
+after	O
+being	O
+started	O
+on	O
+clozapine	O
+and	O
+whose	O
+symptoms	O
+remitted	O
+upon	O
+discontinuation	O
+of	O
+clozapine	O
+
+Three	O
+years	O
+later	O
+treatment	O
+with	O
+ampicillin	O
+caused	O
+another	O
+episode	O
+of	O
+cholestatic	B-Adev
+hepatitis	I-Adev
+with	I-Adev
+cholestasis	I-Adev
+and	I-Adev
+duct	I-Adev
+paucity	I-Adev
+on	I-Adev
+rebiopsy	I-Adev
+	O
+
+METHODS	O
+A	O
+patient	O
+who	O
+developed	O
+dramatic	O
+permanent	B-Adev
+vision	I-Adev
+loss	I-Adev
+after	O
+a	O
+9-month	O
+course	O
+of	O
+treatment	O
+with	O
+ethambutol	O
+and	O
+isoniazid	O
+for	O
+pulmonary	O
+tuberculosis	O
+is	O
+presented	O
+
+The	O
+authors	O
+report	O
+a	O
+case	O
+of	O
+urinary	B-Adev
+incontinence	I-Adev
+(UI)	I-Adev
+that	O
+occurred	O
+in	O
+a	O
+woman	O
+after	O
+administration	O
+of	O
+venlafaxine	O
+
+The	O
+possibility	O
+can	O
+be	O
+raised	O
+that	O
+M-CSF	O
+accelerated	O
+the	O
+underlying	B-Adev
+renal	I-Adev
+disease	I-Adev
+in	I-Adev
+this	I-Adev
+case	I-Adev
+through	I-Adev
+enhancing	I-Adev
+macrophage	I-Adev
+accumulation	I-Adev
+into	I-Adev
+the	I-Adev
+glomerulus	I-Adev
+leading	I-Adev
+to	I-Adev
+the	I-Adev
+development	I-Adev
+of	I-Adev
+nephrotic	I-Adev
+syndrome	I-Adev
+	O
+
+We	O
+describe	O
+two	O
+ELBW	O
+infants	O
+affected	O
+by	O
+hyperkalaemia	O
+treated	O
+with	O
+Kayexalate	O
+who	O
+developed	O
+serious	B-Adev
+hypernatraemia	I-Adev
+	O
+that	O
+has	O
+never	O
+been	O
+reported	O
+before	O
+in	O
+preterm	O
+infants	O
+
+DISCUSSION	O
+Electrolyte	B-Adev
+disorders	I-Adev
+associated	O
+with	O
+foscarnet	O
+are	O
+reviewed	O
+
+We	O
+report	O
+two	O
+cases	O
+that	O
+developed	O
+acute	B-Adev
+myeloid	I-Adev
+leukaemia	I-Adev
+(AML)	I-Adev
+during	O
+tamoxifen	O
+therapy	O
+for	O
+breast	O
+cancer	O
+
+Our	O
+patient	O
+was	O
+a	O
+72-year-old	O
+man	O
+with	O
+advanced	O
+Parkinson's	O
+disease	O
+(PD)	O
+who	O
+received	O
+levodopa	O
+and	O
+anti-cholinergic	O
+drugs	O
+and	O
+whose	O
+head	O
+had	O
+become	O
+almost	O
+completely	B-Adev
+bald	I-Adev
+	O
+
+The	O
+patient	O
+experienced	O
+hallucinations	B-Adev
+agitation	I-Adev
+vomiting	I-Adev
+tachycardia	I-Adev
+and	I-Adev
+seizures	I-Adev
+after	O
+ingestion	O
+of	O
+1050	O
+(48	O
+mg/kg)	O
+of	O
+extended-release	O
+bupropion	O
+
+This	O
+case	O
+report	O
+describes	O
+a	O
+38-year-old	O
+male	O
+in	O
+whom	O
+SIADH	B-Adev
+was	O
+strongly	O
+suspected	O
+secondary	O
+to	O
+Tegretol	O
+therapy	O
+to	O
+control	O
+a	O
+seizure	O
+disorder	O
+
+However	O
+cyclosporine	O
+dependency	O
+is	O
+associated	O
+with	O
+the	O
+risk	O
+of	O
+nephrotoxicity	B-Adev
+	O
+
+The	O
+observations	O
+suggest	O
+that	O
+testicular	B-Adev
+swelling	I-Adev
+and	I-Adev
+pain	I-Adev
+are	O
+side	O
+effects	O
+of	O
+desipramine	O
+
+METHOD	O
+We	O
+describe	O
+three	O
+case-reports	O
+concerning	O
+haematological	B-Adev
+adverse	I-Adev
+effects	I-Adev
+of	O
+quetiapine	O
+
+Typically	O
+drug-induced	B-Adev
+neutropenia	I-Adev
+occurs	O
+in	O
+a	O
+patient	O
+receiving	O
+a	O
+semisynthetic	O
+penicillin	O
+for	O
+two	O
+weeks	O
+or	O
+more	O
+
+Peripheral	B-Adev
+nerve	I-Adev
+dysfunction	I-Adev
+is	O
+a	O
+potentially	O
+serious	O
+complication	O
+of	O
+high-dose	O
+cytosine	O
+arabinoside	O
+
+Tumor-volume	B-Adev
+increase	I-Adev
+at	O
+beginning	O
+of	O
+primary	O
+treatment	O
+with	O
+topical	O
+interferon	O
+alpha	O
+2-beta	O
+in	O
+a	O
+case	O
+of	O
+conjunctiva-cornea	O
+intraepithelial	O
+neoplasia	O
+
+L-asparaginase-induced	O
+posterior	B-Adev
+reversible	I-Adev
+encephalopathy	I-Adev
+syndrome	I-Adev
+during	O
+acute	O
+lymphoblastic	O
+leukemia	O
+treatment	O
+in	O
+children	O
+
+On	O
+the	O
+other	O
+hand	O
+MTX-induced	O
+pneumonitis	B-Adev
+seems	O
+to	O
+be	O
+very	O
+rare	O
+in	O
+psoriatic	O
+arthritis	O
+(PsA)	O
+
+Ototoxicity	B-Adev
+as	O
+a	O
+result	O
+of	O
+cis-platinum	O
+administration	O
+is	O
+well	O
+documented	O
+
+Massive	B-Adev
+subfascial	I-Adev
+hematoma	I-Adev
+after	O
+alteplase	O
+therapy	O
+for	O
+acute	O
+myocardial	O
+infarction	O
+
+We	O
+suggest	O
+that	O
+itraconazole	O
+should	O
+be	O
+added	O
+to	O
+the	O
+list	O
+of	O
+drugs	O
+that	O
+may	O
+be	O
+responsible	O
+for	O
+a	O
+drug-induced	B-Adev
+vanishing	I-Adev
+bile	I-Adev
+duct	I-Adev
+syndrome	I-Adev
+	O
+
+A	O
+67-year-old	O
+man	O
+receiving	O
+a	O
+stable	O
+maintenance	O
+dosage	O
+of	O
+warfarin	O
+experienced	O
+an	O
+increased	B-Adev
+international	I-Adev
+normalized	I-Adev
+ratio	I-Adev
+(INR)	I-Adev
+without	O
+bleeding	O
+when	O
+his	O
+atorvastatin	O
+therapy	O
+was	O
+switched	O
+to	O
+fluvastatin	O
+
+A	O
+67-year-old	O
+man	O
+receiving	O
+a	O
+stable	O
+maintenance	O
+dosage	O
+of	O
+warfarin	O
+experienced	O
+an	O
+increased	O
+international	O
+normalized	O
+ratio	O
+(INR)	O
+without	O
+bleeding	O
+when	O
+his	O
+atorvastatin	O
+therapy	O
+was	O
+switched	O
+to	O
+fluvastatin	O
+
+The	O
+cases	O
+of	O
+CBZ-induced	O
+SLE	B-Adev
+reported	O
+in	O
+the	O
+literature	O
+were	O
+reviewed	O
+
+Ciprofloxacin-induced	O
+hemorrhagic	B-Adev
+vasculitis	I-Adev
+	O
+
+INTERPRETATION	O
+When	O
+high	O
+doses	O
+of	O
+fluticasone	O
+propionate	O
+are	O
+used	O
+growth	B-Adev
+may	I-Adev
+be	I-Adev
+retarded	I-Adev
+and	I-Adev
+adrenal	I-Adev
+suppression	I-Adev
+may	O
+occur	O
+
+To	O
+our	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+significant	O
+hypotension	B-Adev
+associated	O
+with	O
+intravenous	O
+valproate	O
+in	O
+the	O
+treatment	O
+of	O
+status	O
+epilepticus	O
+in	O
+the	O
+pediatric	O
+population	O
+
+While	O
+undergoing	O
+treatment	O
+with	O
+albendazole	O
+he	O
+developed	O
+worsening	B-Adev
+diarrhea	I-Adev
+with	I-Adev
+abdominal	I-Adev
+pain	I-Adev
+and	I-Adev
+fever	I-Adev
+	O
+
+Linezolid-associated	O
+peripheral	B-Adev
+and	I-Adev
+optic	I-Adev
+neuropathy	I-Adev
+lactic	I-Adev
+acidosis	I-Adev
+and	I-Adev
+serotonin	I-Adev
+syndrome	I-Adev
+
+Bone	B-Adev
+marrow	I-Adev
+aplasia	I-Adev
+and	I-Adev
+severe	I-Adev
+skin	I-Adev
+rash	I-Adev
+after	O
+a	O
+single	O
+low	O
+dose	O
+of	O
+methotrexate	O
+
+A	O
+woman	O
+38-year-old	O
+suffering	O
+for	O
+about	O
+ten	O
+years	O
+from	O
+multiple	O
+sclerosis	O
+and	O
+treated	O
+with	O
+repeated	O
+therapy	O
+cycles	O
+of	O
+intrathecal	O
+Depo-Medrol	O
+developed	O
+a	B-Adev
+spastic	I-Adev
+paraparesis	I-Adev
+at	I-Adev
+the	I-Adev
+lower	I-Adev
+limbs	I-Adev
+	O
+
+The	O
+efficacy	O
+of	O
+single-dose	O
+disulfiram	O
+as	O
+an	O
+inhibitor	O
+of	O
+human	O
+P450	O
+2E1	O
+suggests	O
+that	O
+this	O
+modality	O
+for	O
+manipulating	O
+clinical	O
+P450	O
+2E1	O
+activity	O
+may	O
+provide	O
+a	O
+useful	O
+probe	O
+for	O
+delineating	O
+P450	O
+2E1	O
+participation	O
+in	O
+human	O
+drug	O
+biotransformation	O
+or	O
+for	O
+the	O
+treatment	O
+of	O
+poisoning	B-Adev
+by	O
+P450	O
+2E1-activated	O
+toxins	O
+
+To	O
+develop	O
+information	O
+on	O
+the	O
+relative	O
+rarity	O
+or	O
+frequency	O
+of	O
+neurologic	O
+worsening	O
+with	O
+the	O
+initiation	O
+of	O
+penicillamine	O
+therapy	O
+we	O
+conducted	O
+a	O
+retrospective	O
+survey	O
+of	O
+25	O
+additional	O
+patients	O
+with	O
+Wilson's	O
+disease	O
+who	O
+met	O
+the	O
+criteria	O
+of	O
+presenting	O
+with	O
+neurologic	B-Adev
+disease	I-Adev
+and	O
+having	O
+been	O
+treated	O
+with	O
+penicillamine	O
+
+The	O
+authors	O
+present	O
+a	O
+case	O
+of	O
+t-AML	B-Adev
+that	O
+developed	O
+in	O
+a	O
+child	O
+with	O
+metastatic	O
+neuroblastoma	O
+18	O
+months	O
+after	O
+he	O
+received	O
+oral	O
+etoposide	O
+given	O
+for	O
+palliation	O
+purpose	O
+
+Mechanisms	O
+and	O
+triggering	O
+factors	O
+of	O
+hypoglycaemia	B-Adev
+induced	O
+by	O
+mefloquine	O
+and	O
+some	O
+other	O
+anti-malarial	O
+quinine	O
+analogues	O
+are	O
+discussed	O
+
+Only	O
+nondepolarizing	O
+muscle	O
+relaxants	O
+should	O
+be	O
+used	O
+in	O
+patients	O
+who	O
+are	O
+at	O
+risk	O
+for	O
+mucositis	O
+
+CONCLUSION	O
+A	O
+possible	O
+pharmacokinetic	O
+interaction	O
+between	O
+Dantrolene	O
+and	O
+Oxybutynin	O
+should	O
+be	O
+borne	O
+in	O
+mind	O
+when	O
+considering	O
+Carbamazepine	O
+medication	O
+for	O
+a	O
+patient	O
+with	O
+a	O
+spinal	O
+cord	O
+lesion	O
+
+We	O
+describe	O
+a	O
+15-year-old	O
+female	O
+patient	O
+diagnosed	O
+with	O
+acute	O
+lymphoblastic	O
+leukemia	O
+presenting	B-Adev
+with	I-Adev
+status	I-Adev
+epilepticus	I-Adev
+after	O
+receiving	O
+intrathecal	O
+methotrexate	O
+
+Duodenal	B-Adev
+ulceration	I-Adev
+	O
+a	O
+complication	O
+of	O
+tolazoline	O
+therapy	O
+
+Hepatic	B-Adev
+damage	I-Adev
+after	O
+danazol	O
+treatment	O
+
+Hepato-biliary	B-Adev
+abnormalities	I-Adev
+secondary	O
+to	O
+ceftriaxone	O
+use	O
+a	O
+case	O
+report	O
+
+Rhabdomyolysis	B-Adev
+with	O
+concurrent	O
+atorvastatin	O
+and	O
+diltiazem	O
+
+Case	O
+report	O
+mannitol	O
+nephrotoxicity	B-Adev
+syndrome	O
+role	O
+of	O
+hemodialysis	O
+and	O
+postulate	O
+of	O
+mechanisms	O
+
+Uveitis	B-Adev
+during	O
+treatment	O
+of	O
+disseminated	O
+Mycobacterium	O
+avium-intracellulare	O
+complex	O
+infection	O
+with	O
+the	O
+combination	O
+of	O
+rifabutin	O
+clarithromycin	O
+and	O
+ethambutol	O
+
+The	O
+visual	B-Adev
+loss	I-Adev
+in	O
+this	O
+patient	O
+seems	O
+to	O
+result	O
+from	O
+phenol	O
+neurotoxicity	O
+rather	O
+than	O
+mechanical	O
+compression	O
+of	O
+the	O
+intraorbital	O
+optic	O
+nerve	O
+
+Polysomnographic	O
+and	O
+pharmacokinetic	O
+findings	O
+in	O
+levodopa-induced	O
+augmentation	B-Adev
+of	I-Adev
+restless	I-Adev
+legs	I-Adev
+syndrome	I-Adev
+	O
+
+These	O
+cases	O
+highlight	O
+the	O
+occurrence	O
+of	O
+livedo	B-Adev
+reticularis	I-Adev
+as	O
+an	O
+uncommon	O
+side-effect	O
+of	O
+interferon	O
+alpha	O
+treatment	O
+
+So	O
+far	O
+few	O
+cases	O
+of	O
+pulmonary	B-Adev
+side	I-Adev
+effects	I-Adev
+caused	O
+by	O
+ticlopidine	O
+have	O
+been	O
+reported	O
+
+Abnormal	B-Adev
+dexamethasone	I-Adev
+suppression	I-Adev
+tests	I-Adev
+in	O
+a	O
+rifampicin-treated	O
+patient	O
+with	O
+suspected	O
+Cushing's	O
+syndrome	O
+
+Gemcitabine	O
+therapy	O
+has	O
+been	O
+associated	O
+with	O
+radiation	B-Adev
+recall	I-Adev
+reactions	I-Adev
+when	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+carcinoma	O
+
+Increased	B-Adev
+lash	I-Adev
+length	I-Adev
+thickness	I-Adev
+and	I-Adev
+pigmentation	I-Adev
+are	O
+well-documented	O
+side	O
+effects	O
+of	O
+prostaglandin	O
+analog	O
+glaucoma	O
+drops	O
+
+Bullous	B-Adev
+Eruption	I-Adev
+Associated	O
+With	O
+Dihydropyridines	O
+With	O
+Cross	O
+Reactivity	O
+
+Ritonavir	O
+acted	O
+as	O
+a	O
+CYP3A4	B-Adev
+inhibitor	I-Adev
+diminishing	I-Adev
+carbamazepine	I-Adev
+metabolism	I-Adev
+and	I-Adev
+provoking	I-Adev
+an	I-Adev
+increase	I-Adev
+in	I-Adev
+serum	I-Adev
+levels	I-Adev
+and	I-Adev
+clinical	I-Adev
+toxicity	I-Adev
+	O
+
+Acute	B-Adev
+generalized	I-Adev
+exanthematous	I-Adev
+pustulosis	I-Adev
+induced	O
+by	O
+nimesulide	O
+
+Quinine	O
+induced	O
+coagulopathy--a	B-Adev
+near	I-Adev
+fatal	I-Adev
+experience	I-Adev
+	O
+
+A	O
+58-year-old	O
+man	O
+with	O
+rheumatoid	O
+arthritis	O
+developed	O
+lichen	B-Adev
+planus	I-Adev
+during	I-Adev
+treatment	O
+with	O
+gold	O
+
+Atenolol-induced	O
+pseudolymphoma	B-Adev
+	O
+
+First	O
+case	O
+report	O
+of	O
+suspected	O
+onset	O
+of	O
+convulsive	B-Adev
+seizures	I-Adev
+due	O
+to	O
+co-administration	O
+of	O
+valproic	O
+acid	O
+and	O
+tebipenem	O
+
+Fluoxetine-related	O
+death	B-Adev
+in	O
+a	O
+child	O
+with	O
+cytochrome	O
+P-450	O
+2D6	O
+genetic	O
+deficiency	O
+
+Aplastic	B-Adev
+anemia	I-Adev
+and	I-Adev
+agranulocytosis	I-Adev
+in	O
+patients	O
+using	O
+methazolamide	O
+for	O
+glaucoma	O
+
+We	O
+report	O
+a	O
+44-year-old	O
+woman	O
+with	O
+t-MDS	B-Adev
+(refractory	I-Adev
+anemia	I-Adev
+with	I-Adev
+excess	I-Adev
+blasts)	I-Adev
+following	O
+treatment	O
+of	O
+recurrent	O
+anaplastic	O
+astrocytoma	O
+with	O
+temozolomide	O
+(TMZ)	O
+
+An	O
+infant	O
+who	O
+developed	O
+pancreatitis	B-Adev
+during	O
+meglumine	O
+antimoniate	O
+treatment	O
+for	O
+visceral	O
+leishmaniasis	O
+and	O
+who	O
+was	O
+successfully	O
+treated	O
+with	O
+a	O
+combination	O
+of	O
+allopurinol	O
+and	O
+ketoconazole	O
+is	O
+reported	O
+
+L-Carnitine	O
+supplementation	O
+has	O
+been	O
+recommended	O
+to	O
+prevent	O
+the	O
+fatal	O
+hepatotoxic	B-Adev
+effects	I-Adev
+associated	O
+with	O
+valproic	O
+acid	O
+
+L-Carnitine	O
+supplementation	O
+has	O
+been	O
+recommended	O
+to	O
+prevent	O
+the	O
+fatal	O
+hepatotoxic	O
+effects	O
+associated	O
+with	O
+valproic	O
+acid	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+incidence	O
+and	O
+cause	O
+of	O
+Clostridium	B-Adev
+difficile	I-Adev
+colitis	I-Adev
+occurring	O
+after	O
+cisplatin-based	O
+combination	O
+chemotherapy	O
+in	O
+ovarian	O
+cancer	O
+patients	O
+
+Cerebral	B-Adev
+demyelinating	I-Adev
+disease	I-Adev
+developed	O
+in	O
+a	O
+patient	O
+during	O
+adjuvant	O
+therapy	O
+with	O
+levamisole	O
+for	O
+malignant	O
+melanoma	O
+
+Amoxapine-induced	O
+cognitive	B-Adev
+impairment	I-Adev
+in	O
+two	O
+patients	O
+
+Granisetron	O
+hydrochloride	O
+(3	O
+mg	O
+on	O
+days	O
+1	O
+8	O
+and	O
+15)	O
+and	O
+dexamethasone	O
+(13.2	O
+mg	O
+on	O
+day	O
+1	O
+and	O
+6.6	O
+mg	O
+on	O
+days	O
+2	O
+3	O
+8	O
+and	O
+15)	O
+were	O
+used	O
+prior	O
+to	O
+irinotecan	O
+administration	O
+in	O
+both	O
+patients	O
+
+Visceral	B-Adev
+herpesvirus	I-Adev
+infections	I-Adev
+in	O
+leukemic	O
+patients	O
+receiving	O
+cytarabine	O
+
+Although	O
+a	O
+few	O
+case	O
+reports	O
+link	O
+metronidazole	O
+with	O
+the	O
+development	O
+of	O
+pseudomembranous	B-Adev
+colitis	I-Adev
+	O
+albendazole	O
+has	O
+not	O
+been	O
+associated	O
+with	O
+the	O
+development	O
+of	O
+this	O
+condition	O
+
+CONCLUSION	O
+Oral	B-Adev
+mucositis	I-Adev
+is	O
+a	O
+frequent	O
+and	O
+potentially	O
+severe	O
+complication	O
+of	O
+cancer	O
+chemotherapy	O
+
+One	O
+case	O
+of	O
+priapism	B-Adev
+occurred	O
+during	O
+heparin	O
+therapy	O
+for	O
+a	O
+previous	O
+surgical	O
+operation	O
+to	O
+the	O
+knee	O
+is	O
+reported	O
+
+While	O
+both	O
+amiodarone	O
+and	O
+digoxin	O
+can	O
+cause	O
+permanent	B-Adev
+visual	I-Adev
+changes	I-Adev
+	O
+the	O
+ocular	O
+effects	O
+are	O
+often	O
+reversible	O
+
+AIM	O
+Report	O
+of	O
+a	O
+case	O
+of	O
+a	O
+woman	O
+patient	O
+who	O
+developed	O
+celiac	B-Adev
+disease	I-Adev
+after	O
+pegylated	O
+interferon	O
+alpha-2a	O
+and	O
+ribavirin	O
+use	O
+for	O
+chronic	O
+hepatitis	O
+C	O
+
+Differential	O
+diagnoses	O
+included	O
+ocular	O
+rosacea	O
+with	O
+cicatrizing	O
+conjunctivitis	O
+and	O
+5-FU-induced	O
+ectropion	B-Adev
+	O
+
+In	O
+rare	O
+cases	O
+mitomycin	O
+C	O
+(MMC)	O
+may	O
+induce	O
+cancer-associated	B-Adev
+hemolytic	I-Adev
+uremic	I-Adev
+syndrome	I-Adev
+	O
+which	O
+is	O
+characterized	O
+by	O
+hemolytic	O
+anemia	O
+thrombocytopenia	O
+and	O
+progressive	O
+renal	O
+failure	O
+
+Hemolytic	B-Adev
+uremic	I-Adev
+syndrome	I-Adev
+following	O
+the	O
+infusion	O
+of	O
+oxaliplatin	O
+case	O
+report	O
+
+Tacrolimus	O
+(FK506)-induced	O
+mutism	B-Adev
+after	O
+liver	O
+transplant	O
+
+Though	O
+proteinuria	B-Adev
+and	I-Adev
+nephrotic	I-Adev
+syndrome	I-Adev
+is	O
+a	O
+rare	O
+adverse	O
+effect	O
+of	O
+IFN-beta-1b	O
+therapy	O
+physicians	O
+treating	O
+MS	O
+patients	O
+with	O
+this	O
+agent	O
+should	O
+pay	O
+careful	O
+attention	O
+to	O
+new	O
+clinical	O
+symptoms	O
+and	O
+laboratory	O
+findings	O
+
+It	O
+is	O
+suggested	O
+that	O
+the	O
+patient	O
+had	O
+sulfasalazine-induced	O
+lupus	B-Adev
+which	I-Adev
+manifested	I-Adev
+with	I-Adev
+serositis	I-Adev
+and	I-Adev
+pulmonary	I-Adev
+parenchymal	I-Adev
+involvement	I-Adev
+in	I-Adev
+the	I-Adev
+absence	I-Adev
+of	I-Adev
+joint	I-Adev
+symptoms	I-Adev
+	O
+
+By	O
+means	O
+of	O
+the	O
+in	O
+vitro	O
+heparin-induced	O
+platelet	O
+activation	O
+(HIPA)	O
+assay	O
+it	O
+was	O
+shown	O
+that	O
+standard	O
+heparin	O
+and	O
+the	O
+LMW	O
+heparins	O
+Fragmin	O
+and	O
+Fraxiparin	O
+(Sanofi	O
+Labaz	O
+Munich	O
+FRG)	O
+as	O
+well	O
+as	O
+the	O
+enoxaparine	O
+Clexane	O
+(Nattermann	O
+Cologne	O
+FRG)	O
+all	O
+induced	O
+platelet	B-Adev
+activation	I-Adev
+with	O
+the	O
+patient's	O
+serum	O
+
+DISCUSSION	O
+This	O
+case	O
+shows	O
+that	O
+switching	O
+to	O
+zidovudine	O
+potentially	O
+can	O
+lead	O
+to	O
+a	O
+hyperlactatemia	B-Adev
+relapse	I-Adev
+	O
+
+Acute	B-Adev
+leukaemia	I-Adev
+during	O
+tamoxifen	O
+therapy	O
+
+Heparin-associated	O
+thrombocytopenia	B-Adev
+	O
+successful	O
+therapy	O
+with	O
+the	O
+heparinoid	O
+Org	O
+10172	O
+in	O
+a	O
+patient	O
+showing	O
+cross-reaction	O
+to	O
+LMW	O
+heparins	O
+
+A	O
+patient	O
+presented	O
+with	O
+a	O
+painful	B-Adev
+oedematous	I-Adev
+cyanosed	I-Adev
+hand	I-Adev
+having	O
+injected	O
+a	O
+solution	O
+of	O
+diamorphine	O
+and	O
+methylphenidate	O
+into	O
+his	O
+radial	O
+artery	O
+
+We	O
+conclude	O
+that	O
+vincristine	O
+and	O
+actinomycin	O
+D	O
+were	O
+the	O
+cause	O
+of	O
+this	O
+rare	O
+from	O
+of	O
+hepatotoxicity	B-Adev
+and	O
+that	O
+chemotherapy	O
+for	O
+the	O
+underlying	O
+malignant	O
+disease	O
+could	O
+be	O
+given	O
+safely	O
+after	O
+clinical	O
+recovery	O
+
+Pure	B-Adev
+red	I-Adev
+cell	I-Adev
+aplasia	I-Adev
+associated	O
+with	O
+fenoprofen	O
+
+A	O
+56-year-old	O
+white	O
+woman	O
+with	O
+a	O
+diagnosis	O
+of	O
+reactive	O
+depression	O
+developed	O
+severe	B-Adev
+UI	I-Adev
+after	O
+a	O
+30	O
+days'	O
+treatment	O
+with	O
+venlafaxine	O
+75	O
+mg/day	O
+
+PATIENTS	O
+Three	O
+patients	O
+developed	O
+a	O
+reproductive	B-Adev
+endocrine	I-Adev
+disorder	I-Adev
+during	O
+treatment	O
+with	O
+valproate	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+marked	B-Adev
+elevation	I-Adev
+of	I-Adev
+serum	I-Adev
+creatine	I-Adev
+kinase	I-Adev
+(CK)	O
+associated	O
+with	O
+olanzapine	O
+therapy	O
+
+Severe	B-Adev
+C	I-Adev
+difficile	I-Adev
+colitis	I-Adev
+occurred	O
+in	O
+2	O
+patients	O
+(6.1%)	O
+after	O
+receiving	O
+cisplatin-based	O
+combination	O
+chemotherapy	O
+for	O
+ovarian	O
+malignancies	O
+
+A	O
+56-year-old	O
+woman	O
+with	O
+scleroderma	O
+developed	O
+rapidly	B-Adev
+progressive	I-Adev
+glomerulonephritis	I-Adev
+with	I-Adev
+epithelial	I-Adev
+crescents	I-Adev
+associated	I-Adev
+with	I-Adev
+hemoptysis	I-Adev
+after	O
+27	O
+months	O
+of	O
+D-penicillamine	O
+therapy	O
+and	O
+a	O
+cumulative	O
+dose	O
+of	O
+1,200	O
+g	O
+
+High-dose	O
+phosphate	O
+treatment	O
+leads	O
+to	O
+hypokalemia	B-Adev
+in	O
+hypophosphatemic	O
+osteomalacia	O
+
+We	O
+report	O
+a	O
+patient	O
+who	O
+developed	O
+heparin	B-Adev
+associated	I-Adev
+thrombocytopenia	I-Adev
+during	O
+continuous	O
+arteriovenous	O
+haemofiltration	O
+and	O
+discuss	O
+its	O
+implications	O
+and	O
+alternative	O
+anticoagulant	O
+treatment	O
+
+We	O
+describe	O
+a	O
+detailed	O
+case	O
+of	O
+fulminant	B-Adev
+hepatitis	I-Adev
+induced	O
+by	O
+nevirapine	O
+(Viramune)	O
+and	O
+treated	O
+by	O
+liver	O
+transplantation	O
+
+The	O
+literature	O
+is	O
+also	O
+reviewed	O
+for	O
+ARF	B-Adev
+associated	O
+with	O
+mannitol	O
+infusion	O
+in	O
+patients	O
+who	O
+received	O
+dialysis	O
+and	O
+those	O
+who	O
+did	O
+not	O
+receive	O
+dialysis	O
+and	O
+the	O
+possible	O
+mechanism(s)	O
+of	O
+mannitol	O
+nephrotoxicity	O
+are	O
+discussed	O
+
+In	O
+this	O
+case	O
+report	O
+we	O
+present	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+of	O
+a	O
+case	O
+with	O
+chronic	O
+hepatitis	O
+B	O
+that	O
+developed	O
+acute	B-Adev
+dystonia	I-Adev
+soon	O
+after	O
+the	O
+first	O
+dose	O
+of	O
+pegylated	O
+interferon	O
+alpha	O
+
+Trichiasis	B-Adev
+associated	O
+with	O
+prostaglandin	O
+analog	O
+use	O
+
+The	O
+possible	O
+development	O
+of	O
+a	O
+drug-induced	B-Adev
+vasculitis	I-Adev
+or	I-Adev
+lupus-like	I-Adev
+syndrome	I-Adev
+should	O
+be	O
+added	O
+to	O
+the	O
+list	O
+of	O
+rare	O
+toxic	O
+effects	O
+of	O
+vancomycin	O
+
+Healthcare	O
+professionals	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+possible	O
+development	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+as	O
+a	O
+complication	O
+of	O
+initiation	O
+of	O
+fentanyl	O
+and	O
+other	O
+phenylpiperidine	O
+opioids	O
+in	O
+patients	O
+treated	O
+with	O
+SSRIs	O
+
+Acute	B-Adev
+myocardial	I-Adev
+ischemia	I-Adev
+following	O
+accidental	O
+intravenous	O
+administration	O
+of	O
+epinephrine	O
+in	O
+high	O
+concentration	O
+
+Bromide	B-Adev
+intoxication	I-Adev
+secondary	O
+to	O
+pyridostigmine	O
+bromide	O
+therapy	O
+
+We	O
+have	O
+recently	O
+encountered	O
+a	O
+patient	O
+with	O
+acquired	O
+haemophilia	O
+who	O
+developed	O
+a	O
+thrombotic	B-Adev
+left	I-Adev
+middle	I-Adev
+cerebral	I-Adev
+artery	I-Adev
+distribution	I-Adev
+stroke	I-Adev
+while	O
+being	O
+treated	O
+with	O
+pFVIII	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+serotonin	B-Adev
+syndrome	I-Adev
+	O
+which	O
+was	O
+precipitated	O
+by	O
+this	O
+medicine	O
+in	O
+a	O
+patient	O
+who	O
+had	O
+been	O
+predisposed	O
+by	O
+long-term	O
+treatment	O
+with	O
+sertraline	O
+a	O
+selective	O
+serotonin	O
+reuptake	O
+inhibitor	O
+
+Of	O
+the	O
+15	O
+patients	O
+treated	O
+with	O
+tizanidine	O
+and	O
+mexiletine	O
+4	O
+suffered	O
+tizanidine-induced	O
+adverse	O
+effects	O
+such	O
+as	O
+drowsiness	B-Adev
+and	I-Adev
+dry	I-Adev
+mouth	I-Adev
+in	O
+the	O
+retrospective	O
+survey	O
+
+Type	B-Adev
+I	I-Adev
+second-degree	I-Adev
+AV	I-Adev
+block	I-Adev
+(Mobitz	I-Adev
+type	I-Adev
+I	I-Adev
+Wenckebach	I-Adev
+AV	I-Adev
+block)	I-Adev
+during	O
+ritodrine	O
+therapy	O
+for	O
+preterm	O
+labor	O
+
+After	O
+other	O
+potential	O
+causes	O
+of	O
+liver	O
+toxicity	O
+were	O
+excluded	O
+TMP-SMX	O
+was	O
+determined	O
+to	O
+be	O
+the	O
+cause	O
+of	O
+his	O
+acute	B-Adev
+liver	I-Adev
+toxicity	I-Adev
+	O
+
+One	O
+of	O
+the	O
+patients	O
+had	O
+a	O
+dexamethasone	O
+dependent	O
+brain	B-Adev
+metastatic	I-Adev
+condition	I-Adev
+	O
+
+Biomicroscopy	O
+revealed	O
+amiodarone	B-Adev
+corneal	I-Adev
+deposits	I-Adev
+	O
+
+This	O
+case	O
+and	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+show	O
+the	O
+severe	O
+and	O
+unpredictable	O
+nature	O
+of	O
+ethambutol	O
+toxicity	O
+and	O
+its	O
+potential	O
+for	O
+irreversible	B-Adev
+vision	I-Adev
+loss	I-Adev
+despite	O
+careful	O
+ophthalmologic	O
+monitoring	O
+
+Recently	O
+some	O
+studies	O
+have	O
+also	O
+reported	O
+association	O
+between	O
+patients	O
+with	O
+juvenile	O
+rheumatoid	O
+arthritis	O
+(JRA)	O
+treated	O
+with	O
+Methotrexate	O
+(MTX)	O
+and	O
+malignant	B-Adev
+lymphoma	I-Adev
+developing	O
+
+The	O
+two	O
+middle	O
+aged	O
+women	O
+presented	O
+with	O
+respiratory	B-Adev
+symptoms	I-Adev
+after	O
+prolonged	O
+treatment	O
+with	O
+nitrofurantoin	O
+
+OBJECTIVE	O
+1)	O
+To	O
+describe	O
+a	O
+patient	O
+with	O
+rheumatoid	O
+arthritis	O
+receiving	O
+adalimumab	O
+who	O
+developed	O
+fever	B-Adev
+pancytopenia	I-Adev
+splenomegaly	I-Adev
+and	I-Adev
+extreme	I-Adev
+hyperferritinemia	I-Adev
+	O
+
+Visual	B-Adev
+hallucinations	I-Adev
+associated	O
+with	O
+zonisamide	O
+
+Milk-alkali	B-Adev
+syndrome	I-Adev
+induced	O
+by	O
+1,25(OH)2D	O
+in	O
+a	O
+patient	O
+with	O
+hypoparathyroidism	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+female	O
+acromegalic	O
+patient	O
+in	O
+whom	O
+multiple	O
+hepatic	B-Adev
+adenomas	I-Adev
+appeared	O
+soon	O
+after	O
+danazol	O
+treatment	O
+for	O
+uterine	O
+fibromatosis	O
+
+Carbamazepine	B-Adev
+toxicity	I-Adev
+induced	O
+by	O
+clarithromycin	O
+coadministration	O
+in	O
+psychiatric	O
+patients	O
+
+Thrombolytic	O
+therapy	O
+with	O
+tissue	O
+plasminogen	O
+activator	O
+(tPA)	O
+for	O
+acute	O
+myocardial	O
+infarction	O
+may	O
+result	O
+in	O
+major	O
+bleeding	O
+complications	O
+such	O
+as	O
+gastrointestinal	B-Adev
+or	I-Adev
+intracranial	I-Adev
+bleeding	I-Adev
+	O
+
+CONCLUSION	O
+The	O
+hemolytic-uremic	B-Adev
+syndrome	I-Adev
+may	O
+be	O
+a	O
+rare	O
+complication	O
+of	O
+oxaliplatin-based	O
+chemotherapy	O
+
+However	O
+recurrent	O
+staphylococcus	B-Adev
+aureus	I-Adev
+sepsis	I-Adev
+developed	O
+during	O
+CyA	O
+therapy	O
+
+Nabumetone-associated	O
+interstitial	B-Adev
+nephritis	I-Adev
+	O
+
+A	O
+short	O
+review	O
+on	O
+imatinib-related	O
+hepatotoxicity	B-Adev
+is	O
+also	O
+presented	O
+
+Fatal	B-Adev
+interstitial	I-Adev
+pneumonitis	I-Adev
+associated	O
+with	O
+docetaxel	O
+administration	O
+in	O
+a	O
+patient	O
+with	O
+hormone-refractory	O
+prostate	O
+cancer	O
+
+BACKGROUND	O
+Etanercept	O
+is	O
+a	O
+tumor	O
+necrosis	O
+factor	O
+(TNF)	O
+inhibitor	O
+that	O
+has	O
+been	O
+licensed	O
+in	O
+the	O
+United	O
+States	O
+for	O
+the	O
+treatment	O
+of	O
+adult	O
+and	O
+juvenile	O
+rheumatoid	O
+arthritis	O
+as	O
+well	O
+as	O
+psoriatic	O
+arthritis	O
+
+Reye-like	B-Adev
+syndrome	I-Adev
+following	O
+treatment	O
+with	O
+the	O
+pantothenic	O
+acid	O
+antagonist	O
+calcium	O
+hopantenate	O
+
+Sudden	B-Adev
+death	I-Adev
+in	O
+an	O
+infant	O
+from	O
+methemoglobinemia	O
+after	O
+administration	O
+of	O
+"sweet	O
+spirits	O
+of	O
+nitre"	O
+
+FINDINGS	O
+Six	O
+children	O
+with	O
+growth	O
+retardation	O
+noted	O
+after	O
+treatment	O
+with	O
+high-dose	O
+fluticasone	O
+propionate	O
+were	O
+found	O
+to	O
+have	O
+adrenal	B-Adev
+suppression	I-Adev
+	O
+
+Methotrexate-associated	O
+nephropathy	B-Adev
+is	O
+a	O
+rare	O
+complication	O
+in	O
+pediatric	O
+oncology	O
+and	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+suggests	O
+that	O
+exposure	O
+to	O
+nephrotoxic	O
+agents	O
+may	O
+be	O
+a	O
+significant	O
+but	O
+perhaps	O
+underrecognized	O
+risk	O
+factor	O
+for	O
+its	O
+development	O
+
+Four	O
+cases	O
+of	O
+oesophageal	B-Adev
+damage	I-Adev
+associated	O
+with	O
+ingestion	O
+of	O
+the	O
+urinary	O
+anti-spasmodic	O
+agent	O
+emepronium	O
+bromide	O
+are	O
+described	O
+
+A	O
+66-year-old	O
+Japanese	O
+woman	O
+with	O
+severe	O
+scleroderma	O
+developed	O
+anemia	B-Adev
+and	I-Adev
+thrombocytopenia	I-Adev
+due	O
+to	O
+D-penicillamine	O
+(D-Pen)	O
+treatment	O
+although	O
+the	O
+leukopenia	O
+was	O
+not	O
+markedly	O
+severe	O
+
+Corticosteroid	O
+injections	O
+are	O
+commonly	O
+used	O
+as	O
+effective	O
+treatments	O
+for	O
+a	O
+variety	O
+of	O
+pain	O
+disorders	O
+
+We	O
+present	O
+two	O
+cases	O
+of	O
+anaphylaxis	O
+under	O
+anaesthesia	O
+where	O
+return	O
+of	O
+spontaneous	O
+circulation	O
+was	O
+refractory	O
+to	O
+epinephrine	O
+but	O
+occurred	O
+following	O
+the	O
+administration	O
+of	O
+the	O
+alpha-agonist	O
+metaraminol	O
+
+A	O
+51-yr-old	O
+nonsmoking	O
+male	O
+patient	O
+without	O
+any	O
+history	O
+of	O
+previous	O
+allergies	O
+asthma	O
+hay	O
+fever	O
+or	O
+urticaria	O
+developed	O
+attacks	B-Adev
+of	I-Adev
+asthma	I-Adev
+when	O
+captopril	O
+was	O
+added	O
+to	O
+the	O
+nadolol	O
+and	O
+dyazide	O
+treatment	O
+for	O
+his	O
+high	O
+blood	O
+pressure	O
+
+After	O
+ticlopidine	O
+was	O
+discontinued	O
+the	O
+patient	O
+was	O
+rechallenged	O
+with	O
+the	O
+same	O
+dose	O
+of	O
+phenytoin	O
+without	O
+symptoms	O
+of	O
+toxicity	B-Adev
+	O
+
+Rhabdomyolysis	B-Adev
+due	O
+to	O
+an	O
+uncommon	O
+interaction	O
+of	O
+ciprofloxacin	O
+with	O
+simvastatin	O
+
+After	O
+receiving	O
+3	O
+doses	O
+of	O
+ifosfamide/mesna	O
+she	O
+was	O
+found	O
+to	O
+be	O
+unresponsive	O
+
+Symptomatic	B-Adev
+hypoglycemia	I-Adev
+secondary	O
+to	O
+a	O
+glipizide-trimethoprim/sulfamethoxazole	O
+drug	O
+interaction	O
+
+A	O
+51-year-old	O
+man	O
+developed	O
+type	B-Adev
+1	I-Adev
+diabetes	I-Adev
+mellitus	I-Adev
+following	O
+24	O
+weeks	O
+of	O
+treatment	O
+with	O
+recombinant	O
+alpha-2b	O
+peginterferon	O
+plus	O
+ribavirin	O
+for	O
+chronic	O
+hepatitis	O
+C	O
+
+A	O
+noninvasive	O
+method	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+vecuronium-induced	O
+and	O
+magnesium-induced	O
+protracted	B-Adev
+neuromuscular	I-Adev
+block	I-Adev
+in	O
+a	O
+severely	O
+preeclamptic	O
+patient	O
+
+A	O
+noninvasive	O
+method	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+vecuronium-induced	O
+and	O
+magnesium-induced	O
+protracted	B-Adev
+neuromuscular	I-Adev
+block	I-Adev
+in	O
+a	O
+severely	O
+preeclamptic	O
+patient	O
+
+Paroxysmal	B-Adev
+supraventricular	I-Adev
+tachycardia	I-Adev
+during	O
+treatment	O
+with	O
+cisplatin	O
+and	O
+etoposide	O
+combination	O
+
+Conversely	O
+diffuse	B-Adev
+interstitial	I-Adev
+pulmonary	I-Adev
+fibrosis	I-Adev
+should	O
+be	O
+considered	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+patients	O
+receiving	O
+methotrexate	O
+who	O
+develop	O
+bilateral	O
+pulmonary	O
+infiltrates	O
+seen	O
+on	O
+chest	O
+roentgenograms	O
+
+An	O
+83-year-old	O
+man	O
+receiving	O
+glipizide	O
+10	O
+mg	O
+bid	O
+developed	O
+symptomatic	B-Adev
+hypoglycemia	I-Adev
+within	O
+three	O
+days	O
+of	O
+adding	O
+trimethoprim/sulfamethoxazole	O
+(TMP/SMX)	O
+to	O
+his	O
+regimen	O
+
+In	O
+this	O
+case	O
+senna	O
+was	O
+likely	O
+the	O
+cause	O
+of	O
+a	B-Adev
+subacute	I-Adev
+cholestatic	I-Adev
+hepatitis	I-Adev
+exemplifying	O
+again	O
+the	O
+potential	O
+role	O
+of	O
+herbal	O
+related	O
+liver	O
+injury	O
+
+Early	O
+peritoneal	O
+dialysis	O
+has	O
+not	O
+previously	O
+been	O
+reported	O
+for	O
+lisinopril	O
+induced	O
+multiorgan	B-Adev
+failure	I-Adev
+	O
+
+Various	O
+case	O
+reports	O
+concerning	O
+dapsone-induced	O
+agranulocytosis	B-Adev
+are	O
+reviewed	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+a	O
+54-year-old	O
+Turkish	O
+woman	O
+who	O
+presented	O
+with	O
+ceftriaxone-induced	O
+FDE	B-Adev
+	O
+
+In	O
+all	O
+cases	O
+seizures	O
+were	O
+controlled	O
+by	O
+withdrawal	O
+of	O
+phenytoin	O
+and	O
+reduction	O
+of	O
+drug	O
+levels	O
+
+This	O
+case	O
+describes	O
+fulminant	B-Adev
+hepatic	I-Adev
+failure	I-Adev
+in	O
+a	O
+patient	O
+taking	O
+disulfiram	O
+with	O
+no	O
+previous	O
+liver	O
+disease	O
+and	O
+report	O
+of	O
+being	O
+compliant	O
+with	O
+alcohol	O
+abstinence	O
+
+Fungal	O
+infection	O
+is	O
+a	O
+significant	O
+comorbidity	O
+in	O
+patients	O
+with	O
+diabetes	O
+mellitus	O
+and	O
+ketoconazole	O
+an	O
+antifungal	O
+agent	O
+causes	O
+a	B-Adev
+number	I-Adev
+of	I-Adev
+drug	I-Adev
+interactions	I-Adev
+with	I-Adev
+coadministered	I-Adev
+drugs	I-Adev
+	O
+
+Dorzolamide-induced	O
+choroidal	B-Adev
+detachment	I-Adev
+in	O
+a	O
+surgically	O
+untreated	O
+eye	O
+
+Idiosyncratic	O
+factors	O
+involving	O
+vasopressin	O
+receptor	O
+affinity	O
+and	O
+distribution	O
+vasopressin-associated	O
+vasodilation	O
+in	O
+some	O
+vascular	O
+beds	O
+and	O
+the	O
+effect	O
+of	O
+vasopressin	O
+on	O
+the	O
+renin-angiotensin	O
+system	O
+may	O
+further	O
+contribute	O
+to	O
+impaired	B-Adev
+tissue	I-Adev
+perfusion	I-Adev
+	O
+
+Rapid	O
+resolution	O
+of	O
+topiramate-induced	O
+angle-closure	O
+glaucoma	O
+with	O
+methylprednisolone	O
+and	O
+mannitol	O
+
+Rapid	O
+resolution	O
+of	O
+topiramate-induced	O
+angle-closure	B-Adev
+glaucoma	I-Adev
+with	O
+methylprednisolone	O
+and	O
+mannitol	O
+
+A	O
+66-year-old	O
+mand	O
+suffering	O
+from	O
+severe	O
+coronary	O
+heart	O
+disease	O
+took	O
+digoxin	O
+with	O
+suicidal	O
+intent	O
+an	O
+was	O
+treated	O
+for	O
+the	O
+ensuing	O
+complete	B-Adev
+atrioventricular	I-Adev
+block	I-Adev
+with	O
+digoxin-specific	O
+antibody	O
+fragments	O
+
+A	O
+patient	O
+with	O
+generalized	O
+MG	O
+was	O
+effectively	O
+managed	O
+with	O
+MM	O
+but	O
+developed	O
+CNS	O
+lymphoma	O
+after	O
+3	O
+years	O
+of	O
+treatment	O
+
+A	O
+patient	O
+with	O
+generalized	O
+MG	O
+was	O
+effectively	O
+managed	O
+with	O
+MM	O
+but	O
+developed	O
+CNS	B-Adev
+lymphoma	I-Adev
+after	O
+3	O
+years	O
+of	O
+treatment	O
+
+Epoprostenol	O
+may	O
+be	O
+associated	O
+rarely	O
+with	O
+severe	B-Adev
+erythroderma	I-Adev
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+increased	B-Adev
+cerebral	I-Adev
+cortical	I-Adev
+excitability	I-Adev
+following	O
+intoxication	O
+with	O
+flupirtine	O
+a	O
+centrally	O
+acting	O
+analgesic	O
+and	O
+antispastic	O
+drug	O
+
+This	O
+case	O
+represents	O
+the	O
+third	O
+example	O
+of	O
+erythroid	B-Adev
+aplasia	I-Adev
+associated	O
+with	O
+an	O
+anti-inflammatory	O
+agent	O
+and	O
+the	O
+first	O
+instance	O
+due	O
+to	O
+fenoprofen	O
+
+Lichenoid	B-Adev
+drug	I-Adev
+eruption	I-Adev
+to	O
+salsalate	O
+
+Two	O
+pediatric	O
+oncology	O
+patients	O
+with	O
+Ewing's	O
+sarcoma	O
+and	O
+one	O
+with	O
+mixed	O
+germ	O
+cell	O
+tumor	O
+were	O
+treated	O
+with	O
+drug	O
+regimens	O
+that	O
+included	O
+bleomycin	O
+or	O
+cyclophosphamide	O
+
+Although	O
+retinoic	O
+acid	O
+is	O
+well	O
+tolerated	O
+by	O
+the	O
+majority	O
+of	O
+patients	O
+with	O
+this	O
+disease	O
+a	O
+potentially	O
+fatal	B-Adev
+complication	I-Adev
+of	O
+this	O
+kind	O
+of	O
+treatment	O
+has	O
+been	O
+reported	O
+"the	O
+retinoic	O
+acid	O
+syndrome"	O
+
+Three	O
+of	O
+38	O
+children	O
+given	O
+high-dose	O
+cytosine	O
+arabinoside	O
+therapy	O
+developed	O
+a	O
+previously	O
+undescribed	O
+complication	B-Adev
+	O
+
+A	O
+case	O
+of	O
+aseptic	B-Adev
+pleuropericarditis	I-Adev
+in	O
+a	O
+patient	O
+with	O
+chronic	O
+plaque	O
+psoriasis	O
+under	O
+methotrexate	O
+therapy	O
+
+Linezolid-induced	O
+dyserythropoiesis	B-Adev
+	O
+chloramphenicol	O
+toxicity	O
+revisited	O
+
+CONCLUSION	O
+The	O
+present	O
+findings	O
+suggest	O
+that	O
+fluvoxamine	O
+can	O
+cause	O
+increased	B-Adev
+libido	I-Adev
+in	O
+some	O
+patients	O
+
+A	O
+unique	O
+case	O
+of	O
+a	B-Adev
+transient	I-Adev
+nonpigmenting	I-Adev
+fixed	I-Adev
+drug	I-Adev
+eruption	I-Adev
+caused	O
+by	O
+the	O
+radiopaque	O
+contrast	O
+medium	O
+iothalamate	O
+is	O
+reported	O
+
+Mucosal	B-Adev
+pigmentation	I-Adev
+after	O
+oral	O
+lichen	O
+planus	O
+treatment	O
+with	O
+topical	O
+tacrolimus	O
+
+We	O
+now	O
+report	O
+the	O
+first	O
+known	O
+cancer	O
+patient	O
+who	O
+developed	O
+life-threatening	B-Adev
+complications	I-Adev
+after	O
+treatment	O
+with	O
+topical	O
+5-FU	O
+and	O
+was	O
+shown	O
+subsequently	O
+to	O
+have	O
+profound	O
+DPD	O
+deficiency	O
+
+When	O
+the	O
+acute	B-Adev
+manic	I-Adev
+state	I-Adev
+is	I-Adev
+characterized	I-Adev
+by	I-Adev
+marked	I-Adev
+psychotic	I-Adev
+symptoms	I-Adev
+and	I-Adev
+intense	I-Adev
+anxiety	I-Adev
+	O
+it	O
+may	O
+be	O
+associated	O
+with	O
+increased	O
+vulnerability	O
+to	O
+the	O
+development	O
+of	O
+severe	O
+lithium	O
+neurotoxicity	O
+
+Clinicians	O
+who	O
+manage	O
+cachectic	O
+patients	O
+particularly	O
+those	O
+with	O
+protracted	O
+diarrhoea	O
+and/or	O
+receiving	O
+anti-malarial	O
+drugs	O
+including	O
+mefloquine	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+risk	O
+of	O
+severe	B-Adev
+hypoglycaemia	I-Adev
+	O
+
+Arrhythmias	B-Adev
+and	I-Adev
+cardiac	I-Adev
+arrest	I-Adev
+have	O
+been	O
+reported	O
+during	O
+amphotericin	O
+B	O
+administration	O
+but	O
+no	O
+effective	O
+technique	O
+has	O
+been	O
+described	O
+to	O
+prevent	O
+them	O
+
+Based	O
+upon	O
+the	O
+literature	O
+review	O
+the	B-Adev
+hypotension	I-Adev
+in	O
+this	O
+patient	O
+was	O
+possibly	O
+due	O
+to	O
+the	O
+interaction	O
+between	O
+tizanidine	O
+and	O
+lisinopril	O
+
+Baclofen	O
+withdrawal	O
+a	O
+cause	O
+of	O
+prolonged	B-Adev
+fever	I-Adev
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+
+Interstitial	B-Adev
+pneumonitis	I-Adev
+and	I-Adev
+alveolar	I-Adev
+hemorrhage	I-Adev
+complicating	O
+use	O
+of	O
+rituximab	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+
+We	O
+introduce	O
+a	O
+case	O
+of	O
+a	O
+sixty	O
+years	O
+old	O
+woman	O
+with	O
+several	B-Adev
+previous	I-Adev
+episodes	I-Adev
+of	I-Adev
+rhinitis	I-Adev
+conjunctivitis	I-Adev
+and	I-Adev
+perspiration	I-Adev
+immediately	I-Adev
+after	O
+the	O
+administration	O
+of	O
+salmon	O
+calcitonin	O
+with	O
+nasal	O
+spray	O
+or	O
+intramuscular	O
+administration	O
+(Calsynar)	O
+
+In	O
+this	O
+article	O
+we	O
+describe	O
+another	O
+case	O
+of	O
+subcutaneous	B-Adev
+changes	I-Adev
+following	O
+repeated	O
+glatiramer	O
+acetate	O
+injection	O
+presented	O
+as	O
+localized	O
+panniculitis	O
+in	O
+the	O
+area	O
+around	O
+the	O
+injection	O
+sites	O
+in	O
+a	O
+46-year-old	O
+female	O
+patient	O
+who	O
+was	O
+treated	O
+with	O
+glatiramer	O
+acetate	O
+for	O
+18	O
+months	O
+
+In	O
+this	O
+article	O
+we	O
+describe	O
+another	O
+case	O
+of	O
+subcutaneous	O
+changes	O
+following	O
+repeated	O
+glatiramer	O
+acetate	O
+injection	O
+presented	O
+as	O
+localized	O
+panniculitis	O
+in	O
+the	O
+area	O
+around	O
+the	O
+injection	O
+sites	O
+in	O
+a	O
+46-year-old	O
+female	O
+patient	O
+who	O
+was	O
+treated	O
+with	O
+glatiramer	O
+acetate	O
+for	O
+18	O
+months	O
+
+Eighty-two	O
+patients	O
+with	O
+various	O
+malignancies	O
+who	O
+received	O
+imipenem/cilastatin	O
+143	O
+times	O
+for	O
+neutropenic	O
+fever	O
+between	O
+March	O
+1994	O
+and	O
+October	O
+1999	O
+in	O
+Department	O
+of	O
+Pediatric	O
+Oncology	O
+Gazi	O
+University	O
+were	O
+identified	O
+
+The	O
+present	O
+report	O
+first	O
+highlights	O
+the	O
+potentially	B-Adev
+life-threatening	I-Adev
+side	I-Adev
+effects	I-Adev
+associated	O
+with	O
+over-the-counter	O
+NSAIDs	O
+during	O
+DDAVP	O
+replacement	O
+therapy	O
+for	O
+central	O
+DI	O
+
+Case	O
+report	O
+lack	O
+of	O
+control	O
+of	O
+[['diabetes']	B-Adev
+['weight	I-Adev
+gain']]	I-Adev
+abetes	O
+and	O
+weight	O
+gain	O
+in	O
+a	O
+patient	O
+on	O
+initiation	O
+and	O
+rechallenge	O
+of	O
+therapy	O
+with	O
+olanzapine	O
+
+Intravenous	O
+azithromycin-induced	O
+ototoxicity	B-Adev
+	O
+
+Orally	O
+delivered	O
+PXD	O
+showed	O
+no	O
+evidence	O
+of	O
+clinical	O
+activity	O
+when	O
+combined	O
+with	O
+weekly	O
+AUC2-carboplatin	O
+in	O
+PROC	O
+
+We	O
+report	O
+such	O
+a	O
+series	O
+of	O
+patients	O
+who	O
+had	O
+transient	B-Adev
+asymptomatic	I-Adev
+bradycardia	I-Adev
+after	O
+being	O
+treated	O
+with	O
+continuous	O
+infusion	O
+5-FU	O
+
+Consolidation	O
+therapy	O
+with	O
+bortezomib/lenalidomide/	O
+dexamethasone	O
+versus	O
+bortezomib/dexamethasone	O
+after	O
+a	O
+dexamethasone-based	O
+induction	O
+regimen	O
+in	O
+patients	O
+with	O
+multiple	O
+myeloma	O
+a	O
+randomized	O
+phase	O
+III	O
+trial	O
+
+Based	O
+on	O
+prior	O
+data	O
+suggesting	O
+that	O
+scheduling	O
+alterations	O
+of	O
+platinum	O
+would	O
+increase	O
+activity	O
+the	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+potential	O
+therapeutic	O
+benefit	O
+of	O
+phenoxodiol	O
+(PXD)	O
+a	O
+novel	O
+biomodulator	O
+shown	O
+to	O
+have	O
+chemoresistance	O
+reversing	O
+potential	O
+when	O
+combined	O
+with	O
+weekly	O
+AUC2-carboplatin	O
+in	O
+PROC	O
+patients	O
+
+We	O
+also	O
+describe	O
+a	O
+new	O
+noninvasive	O
+method	O
+to	O
+assess	O
+magnesium-induced	O
+neuromuscular	B-Adev
+block	I-Adev
+when	O
+curariform	O
+muscle	O
+relaxant	O
+was	O
+given	O
+simultaneously	O
+
+Our	O
+series	O
+of	O
+3	O
+patients	O
+supports	O
+a	O
+causal	O
+connection	O
+between	O
+bleomycin	O
+and	O
+scleroderma	B-Adev
+	O
+
+In	O
+this	O
+paper	O
+we	O
+report	O
+a	O
+patient	O
+with	O
+primary	O
+anti-phospholipid	O
+syndrome	O
+treated	O
+by	O
+corticosteroid	O
+who	O
+developed	O
+disseminated	B-Adev
+nocardiosis	I-Adev
+	O
+
+Eye	B-Adev
+movement	I-Adev
+disorders	I-Adev
+in	O
+bone	O
+marrow	O
+transplant	O
+patients	O
+on	O
+cyclosporin	O
+and	O
+ganciclovir	O
+
+Prolonged	B-Adev
+severe	I-Adev
+cholestasis	I-Adev
+induced	O
+by	O
+oxacillin	O
+derivatives	O
+
+Cisplatin	O
+was	O
+the	O
+common	O
+drug	O
+in	O
+the	O
+cases	O
+presented	O
+and	O
+therefore	O
+could	O
+be	O
+related	O
+to	O
+the	O
+INR	B-Adev
+elevations	I-Adev
+	O
+
+5-Fluorouracil	O
+cardiotoxicity	B-Adev
+complicating	O
+treatment	O
+of	O
+stage	O
+IIB	O
+cervical	O
+cancer--case	O
+report	O
+
+RESULTS	O
+A	O
+clinical	O
+diagnosis	O
+of	O
+fixed	B-Adev
+drug	I-Adev
+eruption	I-Adev
+owing	O
+to	O
+use	O
+of	O
+the	O
+PDE5	O
+inhibitor	O
+tadalafil	O
+(Cialis)	O
+was	O
+made	O
+
+Pancytopenia	B-Adev
+associated	O
+with	O
+5-aminosalicylic	O
+acid	O
+use	O
+in	O
+a	O
+patient	O
+with	O
+Crohn's	O
+disease	O
+
+Fludarabine	B-Adev
+induced	I-Adev
+lung	I-Adev
+toxicity	I-Adev
+must	O
+be	O
+considered	O
+in	O
+all	O
+patients	O
+who	O
+develop	O
+unexplained	O
+lung	O
+disease	O
+while	O
+receiving	O
+fludarabine	O
+
+Although	O
+other	O
+nitrites	O
+induce	O
+methemoglobinemia	O
+exposure	O
+to	O
+methyl	O
+nitrite	O
+during	O
+phenylpropanolamine	O
+production	O
+appears	O
+to	O
+be	O
+a	O
+new	O
+cause	O
+of	O
+occupational	B-Adev
+methemoglobinemia	I-Adev
+	O
+
+We	O
+report	O
+four	O
+cases	O
+of	O
+sensorimotor	B-Adev
+axonal	I-Adev
+neuropathy	I-Adev
+in	O
+children	O
+aged	O
+10-15	O
+years	O
+treated	O
+with	O
+thalidomide	O
+for	O
+myxopapillary	O
+ependymoma	O
+Crohn's	O
+disease	O
+and	O
+recurrent	O
+giant	O
+aphthous	O
+ulceration	O
+
+The	O
+patient	O
+died	B-Adev
+of	I-Adev
+respiratory	I-Adev
+failure	I-Adev
+after	O
+8	O
+days	O
+of	O
+steroid	O
+infusion	O
+and	O
+erlotinib	O
+discontinuation	O
+
+Hypo-oestrogenic	B-Adev
+and	I-Adev
+anabolic/androgenic	I-Adev
+side-effects	O
+of	O
+danazol	O
+are	O
+well	O
+known	O
+by	O
+the	O
+gynaecologist	O
+and	O
+some	O
+of	O
+them	O
+are	O
+present	O
+in	O
+>	O
+50%	O
+of	O
+patients	O
+being	O
+treated	O
+for	O
+endometriosis	O
+
+We	O
+believe	O
+that	O
+this	O
+is	O
+the	O
+first	O
+description	O
+of	O
+acute	B-Adev
+hepatitis	I-Adev
+caused	O
+by	O
+an	O
+idiosyncratic	O
+adverse	O
+reaction	O
+to	O
+gliclazide	O
+or	O
+to	O
+one	O
+of	O
+its	O
+metabolites	O
+
+In	O
+view	O
+of	O
+our	O
+experience	O
+in	O
+the	O
+present	O
+case	O
+it	O
+should	O
+be	O
+stressed	O
+that	O
+close	O
+monitoring	O
+of	O
+coagulation	O
+capacity	O
+is	O
+necessary	O
+in	O
+critically	O
+ill	O
+patients	O
+in	O
+order	O
+to	O
+avoid	O
+fatal	O
+haemorrhage	B-Adev
+after	O
+initiating	O
+warfarin	O
+therapy	O
+regardless	O
+of	O
+the	O
+dosage	O
+
+We	O
+report	O
+a	O
+patient	O
+who	O
+developed	O
+acute	B-Adev
+pancreatitis	I-Adev
+during	O
+amiodarone	O
+therapy	O
+
+We	O
+report	O
+a	O
+76-year-old	O
+man	O
+who	O
+developed	O
+an	O
+acute	B-Adev
+blistering	I-Adev
+eruption	I-Adev
+following	O
+high-dose	O
+penicillin	O
+treatment	O
+for	O
+pneumococcal	O
+septicaemia	O
+
+OBJECTIVE	O
+To	O
+report	O
+a	O
+case	O
+of	O
+colchicine-induced	O
+myopathy	B-Adev
+in	O
+a	O
+teenager	O
+with	O
+familial	O
+Mediterranean	O
+fever	O
+(FMF)	O
+
+We	O
+believe	O
+that	O
+mucositis	O
+was	O
+a	O
+contributing	O
+factor	O
+to	O
+this	O
+case	O
+of	O
+fatal	B-Adev
+hyperkalemia	I-Adev
+after	O
+administration	O
+of	O
+succinylcholine	O
+with	O
+a	O
+mechanism	O
+similar	O
+to	O
+that	O
+reported	O
+with	O
+thermal	O
+injury	O
+
+Our	O
+experience	O
+supports	O
+hemodialysis	O
+for	O
+ESRF	O
+patients	O
+with	O
+atenolol	O
+toxicity	O
+
+Epirubicin-cyclophosphamide	O
+adjuvant	O
+chemotherapy	O
+plus	O
+tamoxifen	O
+administered	O
+concurrently	O
+versus	O
+sequentially	O
+randomized	O
+phase	O
+III	O
+trial	O
+in	O
+postmenopausal	O
+node-positive	O
+breast	O
+cancer	O
+patients	O
+
+Rupture	B-Adev
+of	I-Adev
+a	I-Adev
+cerebral	I-Adev
+aneurysm	I-Adev
+associated	O
+with	O
+nifedipine	O
+treatment	O
+
+An	O
+immediate	B-Adev
+hemolytic	I-Adev
+reaction	I-Adev
+induced	O
+by	O
+repeated	O
+administration	O
+of	O
+oxaliplatin	O
+
+Patient	O
+B	O
+developed	O
+perioral	B-Adev
+and	I-Adev
+upper	I-Adev
+extremity	I-Adev
+paresthesias	I-Adev
+during	O
+the	O
+fourth	O
+cycle	O
+of	O
+CAP	O
+alone	O
+(2500	O
+mg/m2)	O
+
+We	O
+describe	O
+four	O
+patients	O
+who	O
+had	O
+seizures	B-Adev
+while	O
+receiving	O
+ofloxacin	O
+no	O
+other	O
+causes	O
+were	O
+evident	O
+
+The	O
+case	O
+history	O
+and	O
+toxicological	O
+findings	O
+of	O
+an	O
+infant	B-Adev
+fatality	I-Adev
+involving	O
+pseudoephedrine	O
+brompheniramine	O
+and	O
+dextromethorphan	O
+are	O
+presented	O
+
+A	O
+drug	B-Adev
+interaction	I-Adev
+between	O
+zafirlukast	O
+and	O
+theophylline	O
+
+Dipyrone	O
+also	O
+known	O
+as	O
+metamizole	O
+is	O
+an	O
+analgesic	O
+and	O
+antipyretic	O
+drug	O
+that	O
+was	O
+banned	O
+by	O
+the	O
+United	O
+States	O
+Food	O
+and	O
+Drug	O
+Administration	O
+because	O
+of	O
+its	O
+association	O
+with	O
+agranulocytosis	B-Adev
+	O
+
+A	O
+fatal	O
+case	O
+of	O
+pancytopenia	B-Adev
+due	O
+to	O
+levomepromazine	O
+
+Reversible	B-Adev
+heart	I-Adev
+failure	I-Adev
+in	O
+a	O
+patient	O
+receiving	O
+etanercept	O
+for	O
+ankylosing	O
+spondylitis	O
+
+The	O
+most	O
+likely	O
+cause	O
+of	O
+liver	B-Adev
+failure	I-Adev
+in	O
+this	O
+patient	O
+was	O
+therefore	O
+clarithromycin	O
+which	O
+undergoes	O
+hepatic	O
+metabolism	O
+and	O
+has	O
+been	O
+reported	O
+to	O
+cause	O
+fulminant	O
+hepatic	O
+failure	O
+
+Localized	B-Adev
+panniculitis	I-Adev
+and	I-Adev
+subsequent	I-Adev
+lipoatrophy	I-Adev
+with	O
+subcutaneous	O
+glatiramer	O
+acetate	O
+(Copaxone)	O
+injection	O
+for	O
+the	O
+treatment	O
+of	O
+multiple	O
+sclerosis	O
+
+glycopyrrolate	O
+(5.0	O
+microg/kg)	O
+not	O
+only	O
+resulting	O
+in	O
+resolution	B-Adev
+of	I-Adev
+bradycardia	I-Adev
+but	O
+also	O
+resulting	O
+in	O
+an	O
+exaggerated	O
+increase	O
+of	O
+arterial	O
+blood	O
+pressure	O
+
+This	O
+case	O
+underscores	O
+problems	O
+in	O
+clinical	O
+management	O
+with	O
+sulfadiazine	O
+hypersensitivity	B-Adev
+	O
+potential	O
+immunosuppression	O
+from	O
+corticosteroids	O
+and	O
+selection	O
+of	O
+medications	O
+for	O
+recurrences	O
+of	O
+toxoplasmic	O
+chorioretinitis	O
+
+This	O
+case	O
+underscores	O
+problems	O
+in	O
+clinical	O
+management	O
+with	O
+sulfadiazine	O
+hypersensitivity	O
+potential	O
+immunosuppression	B-Adev
+from	O
+corticosteroids	O
+and	O
+selection	O
+of	O
+medications	O
+for	O
+recurrences	O
+of	O
+toxoplasmic	O
+chorioretinitis	O
+
+CONCLUSION	O
+The	O
+results	O
+suggest	O
+that	O
+olanzapine	O
+may	O
+be	O
+useful	O
+in	O
+treating	O
+patients	O
+with	O
+clozapine-induced	O
+granulocytopenia	O
+without	O
+the	O
+risk	O
+of	O
+recurrence	O
+of	O
+hematologic	O
+side	O
+effects	O
+
+CONCLUSION	O
+The	O
+results	O
+suggest	O
+that	O
+olanzapine	O
+may	O
+be	O
+useful	O
+in	O
+treating	O
+patients	O
+with	O
+clozapine-induced	O
+granulocytopenia	B-Adev
+without	O
+the	O
+risk	O
+of	O
+recurrence	O
+of	O
+hematologic	O
+side	O
+effects	O
+
+CONCLUSION	O
+Patients	O
+with	O
+insulin	O
+allergy	O
+may	O
+not	O
+have	O
+complete	O
+resolution	O
+of	O
+their	O
+symptoms	O
+after	O
+standard	O
+desensitization	O
+particularly	O
+those	O
+patients	O
+with	O
+concomitant	O
+protamine	O
+allergy	O
+
+To	O
+our	O
+knowledge	O
+the	O
+syndrome	O
+of	O
+fever	B-Adev
+pulmonary	I-Adev
+infiltrates	I-Adev
+and	I-Adev
+pleural	I-Adev
+effusion	I-Adev
+following	O
+use	O
+of	O
+acyclovir	O
+has	O
+not	O
+been	O
+previously	O
+reported	O
+
+We	O
+are	O
+concerned	O
+that	O
+the	O
+macular	B-Adev
+lesion	I-Adev
+was	O
+a	O
+retinal	O
+toxic	O
+effect	O
+of	O
+gentamicin	O
+because	O
+of	O
+the	O
+recent	O
+description	O
+of	O
+similar	O
+lesions	O
+occurring	O
+after	O
+the	O
+inadvertent	O
+intraocular	O
+injection	O
+of	O
+massive	O
+doses	O
+of	O
+this	O
+drug	O
+
+Acute	B-Adev
+myocardial	I-Adev
+infarction	I-Adev
+during	O
+high-dose	O
+methylprednisolone	O
+therapy	O
+for	O
+Graves'	O
+ophthalmopathy	O
+
+With	O
+itraconazole	O
+hepatotoxic	B-Adev
+reactions	O
+have	O
+only	O
+very	O
+rarely	O
+been	O
+reported	O
+and	O
+histologic	O
+data	O
+are	O
+lacking	O
+
+We	O
+describe	O
+in	O
+detail	O
+the	O
+first	O
+U.S	O
+case	O
+report	O
+of	O
+a	O
+4(1/2)-year-old	O
+boy	O
+who	O
+experienced	O
+angioedema	B-Adev
+during	O
+treatment	O
+with	O
+oxcarbazepine	O
+
+Caution	B-Adev
+should	O
+be	O
+used	O
+when	O
+coadministering	O
+enfuvirtide	O
+and	O
+niacin	O
+to	O
+HIV-infected	O
+patients	O
+
+Several	O
+case	O
+reports	O
+of	O
+aplastic	B-Adev
+anemia	I-Adev
+with	O
+use	O
+of	O
+acetazolamide	O
+and	O
+two	O
+cases	O
+with	O
+use	O
+of	O
+methazolamide	O
+have	O
+appeared	O
+in	O
+the	O
+literature	O
+
+SSRIs	O
+and	O
+fentanyl	O
+are	O
+commonly	O
+co-administered	O
+especially	O
+in	O
+the	O
+setting	O
+of	O
+chronic	O
+or	O
+malignant	O
+pain	O
+as	O
+underlying	O
+depression	O
+may	O
+contribute	O
+to	O
+the	O
+pathogenesis	O
+of	O
+pain	O
+
+In	O
+this	O
+report	O
+we	O
+present	O
+four	O
+patients	O
+treated	O
+with	O
+a	O
+combination	O
+of	O
+different	O
+psychotropic	O
+drugs	O
+in	O
+whom	O
+asterixis	B-Adev
+was	O
+triggered	O
+either	O
+by	O
+adding	O
+carbamazepine	O
+(CBZ)	O
+to	O
+a	O
+treatment	O
+regimen	O
+or	O
+by	O
+increasing	O
+its	O
+dosage	O
+
+Squamous-cell	B-Adev
+carcinoma	I-Adev
+arising	I-Adev
+in	O
+a	O
+basal-cell	O
+epithelioma	O
+treated	O
+with	O
+5-fluorouracil	O
+
+The	O
+case	O
+of	O
+a	O
+bipolar	O
+patient	O
+who	O
+developed	O
+thyrotoxicosis	B-Adev
+with	I-Adev
+severe	I-Adev
+exophthalmos	I-Adev
+while	O
+on	O
+lithium	O
+therapy	O
+is	O
+described	O
+
+The	O
+patient	O
+received	O
+only	O
+the	O
+ophthalmic	O
+sulfonamide	O
+and	O
+it	O
+was	O
+used	O
+for	O
+one	O
+day	O
+but	O
+he	O
+developed	O
+Stevens-Johnson	B-Adev
+syndrome	I-Adev
+	O
+
+Papillary	B-Adev
+necrosis	I-Adev
+associated	O
+with	O
+the	O
+HIV	O
+protease	O
+inhibitor	O
+indinavir	O
+
+A	O
+case	O
+is	O
+reported	O
+of	O
+a	O
+40	O
+year	O
+old	O
+woman	O
+treated	O
+with	O
+intraventricular	O
+IL-2	O
+for	O
+leptomeningeal	O
+disease	O
+who	O
+developed	O
+progressive	B-Adev
+cognitive	I-Adev
+dysfunction	I-Adev
+	O
+
+We	O
+document	O
+the	O
+abrupt	O
+development	O
+of	O
+an	O
+extensive	B-Adev
+choroidal	I-Adev
+detachment	I-Adev
+after	O
+initiation	O
+of	O
+dorzolamide	O
+therapy	O
+in	O
+a	O
+surgically	O
+untreated	O
+eye	O
+with	O
+primary	O
+open-angle	O
+glaucoma	O
+
+Serotonin	B-Adev
+toxicity	I-Adev
+as	O
+a	O
+consequence	O
+of	O
+linezolid	O
+use	O
+in	O
+revision	O
+hip	O
+arthroplasty	O
+
+Gallstones	B-Adev
+and	I-Adev
+bile	I-Adev
+sludge	I-Adev
+are	O
+common	O
+side	O
+effects	O
+of	O
+octreotide	O
+therapy	O
+but	O
+rarely	O
+become	O
+symptomatic	O
+or	O
+require	O
+treatment	O
+
+The	O
+authors'	O
+results	O
+suggest	O
+that	O
+L-dopa	O
+may	O
+cause	O
+daytime	B-Adev
+somnolence	I-Adev
+in	O
+some	O
+patients	O
+with	O
+Parkinson's	O
+disease	O
+
+Seventy-four	O
+per	O
+cent	O
+of	O
+patients	O
+with	O
+epileptogenic	O
+disorders	O
+seen	O
+at	O
+the	O
+Emergency	O
+Unit	O
+at	O
+Groote	O
+Schuur	O
+Hospital	O
+were	O
+on	O
+phenytoin	O
+and	O
+11.6%	O
+of	O
+these	O
+had	O
+blood	B-Adev
+levels	I-Adev
+in	I-Adev
+the	I-Adev
+toxic	I-Adev
+range	I-Adev
+	O
+
+Based	O
+on	O
+the	O
+history	O
+and	O
+clinical	O
+features	O
+a	O
+diagnosis	O
+of	O
+insulin-induced	O
+lipohypertrophy	B-Adev
+was	O
+made	O
+
+An	O
+unusual	O
+presentation	O
+of	O
+spontaneous	B-Adev
+sub-conjunctival	I-Adev
+haematoma	I-Adev
+in	O
+a	O
+patient	O
+receiving	O
+warfarin	O
+
+He	O
+developed	O
+congestive	B-Adev
+heart	I-Adev
+failure	I-Adev
+5	O
+days	O
+after	O
+administration	O
+of	O
+cyclophosphamide	O
+
+Fulminant	B-Adev
+liver	I-Adev
+failure	I-Adev
+associated	O
+with	O
+clarithromycin	O
+
+Nifedipine	O
+may	O
+induce	O
+or	O
+aggravate	O
+pre-existing	O
+gastro-oesophageal	B-Adev
+reflux	I-Adev
+	O
+
+Rifampin-associated	O
+thrombocytopenia	B-Adev
+secondary	I-Adev
+to	I-Adev
+poor	I-Adev
+compliance	I-Adev
+	O
+
+CONCLUSIONS	O
+There	O
+was	O
+a	O
+temporal	O
+relationship	O
+between	O
+the	O
+onset	B-Adev
+of	I-Adev
+nonconvulsive	I-Adev
+status	I-Adev
+epilepticus	I-Adev
+and	O
+initiation	O
+of	O
+ifosfamide	O
+infusion	O
+
+Gemcitabine-induced	O
+pericardial	B-Adev
+effusion	I-Adev
+and	I-Adev
+tamponade	I-Adev
+after	O
+unblocked	O
+cardiac	O
+irradiation	O
+
+Although	O
+useful	O
+in	O
+the	O
+management	O
+of	O
+chronic	O
+alcoholism	O
+disulfiram	O
+is	O
+being	O
+increasingly	O
+associated	O
+with	O
+a	B-Adev
+wide	I-Adev
+spectrum	I-Adev
+of	I-Adev
+side	I-Adev
+effects	I-Adev
+and	I-Adev
+untoward	I-Adev
+medical	I-Adev
+sequelae	I-Adev
+which	I-Adev
+now	I-Adev
+include	I-Adev
+catatonia	I-Adev
+	O
+
+DISCUSSION	O
+The	O
+Naranjo	O
+probability	O
+scale	O
+indicated	O
+a	O
+probable	O
+relationship	O
+between	O
+sertraline	O
+treatment	O
+and	O
+the	O
+onset	O
+of	O
+rhabdomyolysis	B-Adev
+	O
+
+Severe	O
+Raynaud's	B-Adev
+phenomenon	I-Adev
+with	O
+yohimbine	O
+therapy	O
+for	O
+erectile	O
+dysfunction	O
+
+Possible	O
+theophylline	B-Adev
+toxicity	I-Adev
+during	O
+anesthesia	O
+
+Calcification	B-Adev
+and	I-Adev
+ossification	I-Adev
+of	I-Adev
+the	I-Adev
+spinal	I-Adev
+arachnoid	I-Adev
+after	O
+intrathecal	O
+administration	O
+of	O
+Depo-Medrol	O
+
+Circulating	O
+anticoagulant	O
+in	O
+the	O
+procainamide-induced	O
+lupus	B-Adev
+syndrome	I-Adev
+	O
+
+This	O
+report	O
+describes	O
+a	O
+case	O
+of	O
+bilateral	B-Adev
+ptosis	I-Adev
+induced	O
+by	O
+chloroquine	O
+
+When	O
+the	O
+data	O
+of	O
+the	O
+57	O
+patients	O
+are	O
+evaluated	O
+a	O
+reversible	O
+direct	O
+cytotoxic	B-Adev
+effect	I-Adev
+of	O
+ticlopidine	O
+on	O
+the	O
+pluripotent/bipotent	O
+hematopoietic	O
+progenitor	O
+stem	O
+cell	O
+is	O
+proposed	O
+
+We	O
+report	O
+a	O
+child	O
+with	O
+yolk	O
+sac	O
+tumor	O
+who	O
+developed	O
+localized	B-Adev
+pigmentation	I-Adev
+after	O
+the	O
+first	O
+course	O
+of	O
+chemotherapy	O
+regimen	O
+that	O
+included	O
+cisplatin	O
+etoposide	O
+and	O
+bleomycin	O
+
+Except	O
+hypothyroidism	B-Adev
+after	O
+radioiodine	O
+treatment	O
+(euthyroid	O
+under	O
+substitutional	O
+therapy)	O
+she	O
+suffered	O
+from	O
+no	O
+other	O
+diseases	O
+
+Late	B-Adev
+lethal	I-Adev
+hepatitis	I-Adev
+B	I-Adev
+virus	I-Adev
+reactivation	I-Adev
+after	O
+rituximab	O
+treatment	O
+of	O
+low-grade	O
+cutaneous	O
+B-cell	O
+lymphoma	O
+
+Despite	O
+the	O
+low	O
+dosage	O
+of	O
+warfarin	O
+international	B-Adev
+normalized	I-Adev
+ratio	I-Adev
+(INR)	I-Adev
+was	I-Adev
+markedly	I-Adev
+elevated	I-Adev
+from	O
+1.15	O
+to	O
+11.28	O
+for	O
+only	O
+4	O
+days	O
+and	O
+bleeding	O
+symptoms	O
+concurrently	O
+developed	O
+
+The	O
+possible	O
+role	O
+of	O
+interferon	O
+beta	O
+in	O
+the	O
+pathogenesis	O
+of	O
+sarcoidosis	B-Adev
+in	O
+this	O
+patient	O
+is	O
+discussed	O
+
+We	O
+hypothesize	O
+that	O
+a	O
+pharmacodynamic	O
+or	O
+pharmacokinetic	O
+drug	O
+interaction	O
+between	O
+venlafaxine	O
+and	O
+trimipramine	O
+involving	O
+the	O
+CYP2D6	O
+isoenzyme	O
+may	O
+have	O
+played	O
+a	O
+role	O
+in	O
+inducing	O
+the	O
+seizures	B-Adev
+	O
+
+A	O
+case	O
+is	O
+described	O
+of	O
+severe	B-Adev
+splenic	I-Adev
+hemorrhage	I-Adev
+and	I-Adev
+rupture	I-Adev
+which	O
+developed	O
+3	O
+h	O
+after	O
+completion	O
+of	O
+tPA	O
+infusion	O
+for	O
+suspected	O
+acute	O
+myocardial	O
+infarction	O
+
+Three	O
+weeks	O
+later	O
+the	O
+decerebrate	O
+rigidity	O
+and	O
+high	O
+BP	O
+remained	O
+and	O
+tizanidine	O
+was	O
+initiated	O
+to	O
+see	O
+whether	O
+the	O
+decrease	O
+in	O
+muscle	O
+tone	O
+could	O
+facilitate	O
+hypertension	O
+control	O
+and	O
+motor	O
+recovery	O
+
+CONCLUSIONS	O
+The	O
+administration	O
+of	O
+prostaglandin	O
+E1	O
+to	O
+neonates	O
+can	O
+cause	O
+gastric-outlet	B-Adev
+obstruction	I-Adev
+due	I-Adev
+to	I-Adev
+antral	I-Adev
+hyperplasia	I-Adev
+	O
+
+During	O
+and	O
+after	O
+IFN	O
+therapy	O
+we	O
+should	O
+consider	O
+the	O
+possibility	O
+of	O
+occurrence	O
+of	O
+IDDM	B-Adev
+as	I-Adev
+well	I-Adev
+as	I-Adev
+other	I-Adev
+autoimmune	I-Adev
+diseases	I-Adev
+and	O
+observe	O
+the	O
+clinical	O
+course	O
+carefully	O
+
+In	O
+two	O
+of	O
+these	O
+cases	O
+akathisia	B-Adev
+resolved	O
+after	O
+withdrawal	O
+of	O
+olanzapine	O
+and	O
+substitution	O
+by	O
+a	O
+classical	O
+or	O
+an	O
+atypical	O
+neuroleptic	O
+agent	O
+respectively	O
+
+In	O
+two	O
+of	O
+these	O
+cases	O
+akathisia	B-Adev
+resolved	O
+after	O
+withdrawal	O
+of	O
+olanzapine	O
+and	O
+substitution	O
+by	O
+a	O
+classical	O
+or	O
+an	O
+atypical	O
+neuroleptic	O
+agent	O
+respectively	O
+
+Captopril-related	O
+(and	O
+-induced?)	O
+asthma	B-Adev
+	O
+
+These	O
+findings	O
+suggest	O
+that	O
+clozapine-induced	O
+seizures	B-Adev
+can	O
+be	O
+successfully	O
+treated	O
+that	O
+gradual	O
+dose	O
+titration	O
+can	O
+reduce	O
+the	O
+likelihood	O
+of	O
+further	O
+episodes	O
+of	O
+seizures	O
+and	O
+that	O
+concomitant	O
+use	O
+of	O
+a	O
+suitable	O
+mood	O
+stabilizer/anti-epileptic	O
+medication	O
+can	O
+improve	O
+the	O
+outcome	O
+of	O
+treatment-resistant	O
+schizophrenia	O
+
+These	O
+findings	O
+suggest	O
+that	O
+clozapine-induced	O
+seizures	O
+can	O
+be	O
+successfully	O
+treated	O
+that	O
+gradual	O
+dose	O
+titration	O
+can	O
+reduce	O
+the	O
+likelihood	O
+of	O
+further	O
+episodes	O
+of	O
+seizures	O
+and	O
+that	O
+concomitant	O
+use	O
+of	O
+a	O
+suitable	O
+mood	O
+stabilizer/anti-epileptic	O
+medication	O
+can	O
+improve	O
+the	O
+outcome	O
+of	O
+treatment-resistant	O
+schizophrenia	O
+
+According	O
+to	O
+the	O
+Naranjo	O
+probability	O
+scale	O
+the	O
+papular	B-Adev
+eruption	I-Adev
+was	O
+probably	O
+caused	O
+by	O
+methotrexate	O
+
+The	O
+patient's	O
+defects	O
+may	O
+be	O
+due	O
+to	O
+methimazole	O
+teratogenicity	B-Adev
+or	O
+could	O
+represent	O
+a	O
+previously	O
+undescribed	O
+syndrome	O
+affecting	O
+ectodermal	O
+structures	O
+
+CONCLUSIONS	O
+Itraconazole-induced	O
+liver	B-Adev
+injury	I-Adev
+presents	I-Adev
+with	I-Adev
+a	I-Adev
+cholestatic	I-Adev
+pattern	I-Adev
+of	I-Adev
+injury	I-Adev
+with	I-Adev
+damage	I-Adev
+to	I-Adev
+the	I-Adev
+interlobular	I-Adev
+bile	I-Adev
+ducts	I-Adev
+possibly	I-Adev
+leading	I-Adev
+to	I-Adev
+ductopenia	I-Adev
+	O
+
+Rhabdomyolysis	B-Adev
+resulting	O
+from	O
+the	O
+drug	O
+interaction	O
+between	O
+diltiazem	O
+and	O
+other	O
+HMG-CoA	O
+reductase	O
+inhibitors	O
+has	O
+been	O
+described	O
+in	O
+the	O
+literature	O
+
+Acute	O
+angioedema	B-Adev
+response	O
+to	O
+topical	O
+5-fluorouracil	O
+therapy	O
+
+Hypersensitivity	B-Adev
+reactions	I-Adev
+due	O
+to	O
+chloramphenicol	O
+are	O
+rarely	O
+reported	O
+in	O
+the	O
+literature	O
+
+Diagnosis	O
+of	O
+sclerosing	B-Adev
+glomerulonephritis	I-Adev
+occurred	O
+in	O
+this	O
+patient	O
+during	O
+anastrozole	O
+use	O
+suggesting	O
+a	O
+newly	O
+defined	O
+side	O
+effect	O
+of	O
+anastrozole	O
+
+A	O
+patient	O
+with	O
+coccidioidal	O
+meningitis	O
+was	O
+treated	O
+with	O
+intrathecally	O
+administered	O
+amphotericin	O
+B	O
+and	O
+an	B-Adev
+acute	I-Adev
+toxic	I-Adev
+delirium	I-Adev
+with	I-Adev
+EEG	I-Adev
+abnormalities	I-Adev
+developed	O
+
+This	O
+case	O
+raises	O
+important	O
+questions	O
+about	O
+non-ketotic	B-Adev
+hyperosmolar	I-Adev
+diabetic	I-Adev
+coma	I-Adev
+with	O
+antipsychotics	O
+the	O
+possible	O
+association	O
+between	O
+hyperglycaemia	O
+and	O
+hyperthermia	O
+and	O
+the	O
+direction	O
+of	O
+causality	O
+in	O
+this	O
+the	O
+recognition	O
+of	O
+either	O
+syndrome	O
+when	O
+they	O
+co-exist	O
+and	O
+management	O
+issues	O
+in	O
+such	O
+patients	O
+
+CONCLUSIONS	O
+Reversible	B-Adev
+lupus-like	I-Adev
+syndrome	I-Adev
+appears	O
+to	O
+be	O
+a	O
+rare	O
+but	O
+significant	O
+side	O
+effect	O
+of	O
+5-ASA	O
+compounds	O
+
+A	O
+patient	O
+with	O
+chronic	O
+myeloid	O
+leukaemia	O
+treated	O
+with	O
+busulphan	O
+for	O
+4-5	O
+years	O
+developed	O
+signs	O
+of	O
+busulphan	B-Adev
+toxicity	I-Adev
+and	I-Adev
+portal	I-Adev
+hypertension	I-Adev
+with	I-Adev
+ascites	I-Adev
+oesophageal	I-Adev
+varices	I-Adev
+and	I-Adev
+jaundice	I-Adev
+	O
+
+Several	O
+cases	O
+of	O
+lithium-induced	O
+Creutzfeldt-Jakob	B-Adev
+syndrome	I-Adev
+have	O
+been	O
+reported	O
+to	O
+date	O
+all	O
+of	O
+them	O
+were	O
+elderly	O
+patients	O
+and	O
+a	O
+half	O
+had	O
+"therapeutic"	O
+lithium	O
+serum	O
+levels	O
+
+There	O
+is	O
+however	O
+currently	O
+no	O
+data	O
+on	O
+the	O
+effect	O
+of	O
+combined	O
+hyperglycaemia	O
+and	O
+hyperinsulinaemia	O
+on	O
+the	O
+renal	B-Adev
+and	I-Adev
+ocular	I-Adev
+blood	I-Adev
+flow	I-Adev
+seen	O
+in	O
+diabetic	O
+patients	O
+on	O
+insulin	O
+therapy	O
+
+Pemphigus	B-Adev
+vulgaris	I-Adev
+precipitated	O
+by	O
+glibenclamide	O
+therapy	O
+
+Methimazole-associated	O
+cholestatic	B-Adev
+liver	I-Adev
+injury	I-Adev
+	O
+case	O
+report	O
+and	O
+brief	O
+literature	O
+review	O
+
+The	O
+most	O
+likely	O
+cause	O
+of	O
+such	O
+hyponatremic	B-Adev
+episode	I-Adev
+is	O
+vinblastine	O
+
+Anti-tuberculous	O
+drugs	O
+had	O
+been	O
+stopped	O
+on	O
+the	O
+2nd	O
+day	O
+of	O
+therapy	O
+due	O
+to	O
+development	O
+of	O
+optic	B-Adev
+neuritis	I-Adev
+secondary	I-Adev
+to	O
+ethambutol	O
+administration	O
+at	O
+another	O
+hospital	O
+
+Based	O
+on	O
+this	O
+experience	O
+we	O
+suggest	O
+that	O
+low-dose	O
+ketamine	O
+added	O
+to	O
+propofol	O
+may	O
+be	O
+associated	O
+with	O
+prevention	O
+of	O
+EA	O
+in	O
+children	O
+with	O
+a	O
+history	O
+of	O
+EA	O
+with	O
+propofol	O
+TIVA	O
+
+Tetany	B-Adev
+in	O
+a	O
+child	O
+with	O
+AIDS	O
+receiving	O
+intravenous	O
+tobramycin	O
+
+Sideroblastic	B-Adev
+anemia	I-Adev
+due	O
+to	O
+linezolid	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+left	O
+ventricular	O
+assist	O
+device	O
+
+Oral	O
+dapsone	O
+has	O
+been	O
+available	O
+for	O
+over	O
+60	O
+years	O
+and	O
+has	O
+been	O
+used	O
+to	O
+treat	O
+severe	O
+acne	O
+vulgaris	O
+however	O
+the	O
+oral	O
+formulation	O
+is	O
+known	O
+to	O
+cause	O
+dose-dependent	B-Adev
+haematological	I-Adev
+reactions	I-Adev
+and	O
+is	O
+currently	O
+indicated	O
+only	O
+for	O
+diseases	O
+such	O
+as	O
+dermatitis	O
+herpetiformis	O
+and	O
+Hansen's	O
+disease	O
+
+Enalapril-induced	O
+anemia	B-Adev
+in	O
+two	O
+kidney	O
+transplant	O
+recipients	O
+
+PURPOSE	O
+To	O
+report	O
+two	O
+cases	O
+in	O
+which	O
+topical	O
+brimonidine	O
+resulted	O
+in	O
+apparent	B-Adev
+central	I-Adev
+nervous	I-Adev
+system	I-Adev
+depression	I-Adev
+and	I-Adev
+unresponsiveness	I-Adev
+in	O
+an	O
+infant	O
+
+BACKGROUND	O
+Interferon	O
+beta	O
+has	O
+become	O
+standard	O
+therapy	O
+for	O
+reducing	O
+relapse	O
+frequency	O
+in	O
+relapsing/remitting	O
+Multiple	O
+Sclerosis	O
+(RRMS)	O
+
+In	O
+this	O
+article	O
+lithium	O
+is	O
+not	O
+discussed	O
+although	O
+there	O
+are	O
+a	O
+number	O
+of	O
+concerns	O
+about	O
+lithium's	O
+potential	O
+teratogenicity	O
+and	O
+it	O
+has	O
+been	O
+implicated	O
+in	O
+Epstein's	B-Adev
+anomaly	I-Adev
+	O
+a	O
+congenital	O
+heart	O
+defect	O
+among	O
+infants	O
+born	O
+to	O
+women	O
+taking	O
+lithium	O
+as	O
+with	O
+other	O
+medications	O
+however	O
+the	O
+data	O
+have	O
+specific	O
+limitations	O
+
+The	O
+risk	O
+of	O
+gastrointestinal	B-Adev
+bleeding	I-Adev
+during	O
+the	O
+treatment	O
+with	O
+antiagregants	O
+and	O
+anticoagulants	O
+the	O
+risk	O
+of	O
+bradycardia	O
+in	O
+beta-blockade	O
+possible	O
+interactions	O
+with	O
+other	O
+medications	O
+lowering	O
+the	O
+heart	O
+rate	O
+are	O
+discussed	O
+
+The	O
+risk	O
+of	O
+gastrointestinal	O
+bleeding	O
+during	O
+the	O
+treatment	O
+with	O
+antiagregants	O
+and	O
+anticoagulants	O
+the	O
+risk	O
+of	O
+bradycardia	B-Adev
+in	O
+beta-blockade	O
+possible	O
+interactions	O
+with	O
+other	O
+medications	O
+lowering	O
+the	O
+heart	O
+rate	O
+are	O
+discussed	O
+
+Hepatotoxicity	B-Adev
+of	O
+paracetamol	O
+enhanced	O
+by	O
+ingestion	O
+of	O
+alcohol	O
+report	O
+of	O
+two	O
+cases	O
+
+Cancer	O
+patients	O
+who	O
+are	O
+receiving	O
+5-FU	O
+treatment	O
+and	O
+are	O
+DPD	O
+deficient	O
+can	O
+develop	O
+severe	B-Adev
+side	I-Adev
+effects	I-Adev
+	O
+
+A	O
+patient	O
+is	O
+described	O
+who	O
+developed	O
+a	O
+poorly	B-Adev
+differentiated	I-Adev
+sarcoma	I-Adev
+after	O
+cyclophosphamide	O
+was	O
+used	O
+to	O
+treat	O
+his	O
+rheumatoid	O
+arthritis	O
+
+Photo-onycholysis	B-Adev
+caused	O
+by	O
+olanzapine	O
+and	O
+aripiprazole	O
+
+We	O
+observed	O
+5	O
+reactions	O
+in	O
+3	O
+patients	O
+that	O
+appear	O
+to	O
+be	O
+related	O
+to	O
+a	O
+high	O
+dose-infusion	O
+time	O
+ratio	O
+indicating	O
+that	O
+dose	O
+and	O
+rate	O
+of	O
+infusion	O
+may	O
+be	O
+important	O
+factors	O
+in	O
+precipitating	O
+anaphylactoid	B-Adev
+reactions	I-Adev
+with	O
+cisplatin	O
+
+CONCLUSION	O
+Fixed	B-Adev
+drug	I-Adev
+eruption	I-Adev
+is	O
+associated	O
+with	O
+many	O
+drugs	O
+but	O
+this	O
+is	O
+the	O
+first	O
+such	O
+report	O
+with	O
+omeprazole	O
+
+One	O
+type	O
+of	O
+SMON	B-Adev
+is	O
+associated	O
+with	O
+acrodermatitis	O
+enteropathica	O
+which	O
+has	O
+a	O
+very	O
+high	O
+frequency	O
+of	O
+occurrence	O
+in	O
+association	O
+with	O
+administration	O
+of	O
+clioquinol	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+amiodarone-induced	O
+thyrotoxicosis	B-Adev
+of	O
+protracted	O
+duration	O
+unresponsive	O
+to	O
+conventional	O
+thionamide	O
+therapy	O
+with	O
+therapy	O
+limited	O
+by	O
+severe	O
+adverse	O
+drug	O
+reactions	O